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ABSTRACT 
Bartonella, a group of Gram negative facultative intracellular bacteria, are known 
to cause diseases, such as Cat Scratch Disease, Trench Fever and Carrion’s Disease, that 
involve angiogenesis during the infective cycle.  B. bacilliformis, the etiological agent of 
Carrion’s Disease, causes a bi-phasic infection resulting in the formation of blood-filled 
angiogenic proliferative cutaneous nodules called verruga peruana.  The work presented 
here was undertaken to characterize the mechanism by which these nodules are produced. 
Previous work in our laboratory suggested that the Bartonella henselae genome 
contains a homologue to the virB operon, a set of genes coding for a Type IV Secretion 
System (TFSS) that has been implicated in the pathogenesis of other !-2-proteobacteria.  
We identified virB operons in two additional Bartonella pathogens, B. quintana and B. 
clarridgeiae.  No corresponding operon sequences were detected in B. bacilliformis 
DNA, however.  This finding suggests that virB gene products are not required for 
verruga peruana formation.  To continue our search for factors involved in B. 
bacilliformis-induced angiogenesis, we conducted a microarray analysis of differential 
 gene expression in infected and uninfected endothelial cells.  The results suggest 
similarities between later stage (36 hours) B. bacilliformis infection and that of HHV-8, 
the causative agent of Kaposi’s Sarcoma, particularly in relation to the host immune 
response.  Finally, our research focused on the secreted factors that B. bacilliformis 
produces during its host infective cycle.  Our data suggest that the B. bacilliformis 
homologue to the molecular chaperone GroEL not only induces angiogenesis in 
endothelial cells, but also protects endothelial cell tubule from the degradation seen when 
these cells are in the presence of live B. bacilliformis.  In summary, the induction of 
verruga peruana nodules via B. bacilliformis may be the result of multiple factors over 
the course of persistent infection.  Early infection may cause vascular damage, which 
induces VEGF and hypoxia factors.  As infection persists, bacterial secretion of a unique 
GroEL may result in continued angiogenesis and the ensuing activation of immune cells, 
producing a localized environment of continual incomplete angiogenesis in areas of 
cutaneous infection. 
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General Introduction 
Bartonella Species – Microbiological Aspects, Identification & Epidemiology 
 
As emerging pathogens, Bartonella species show a wide variety of infective abilities 
and potential hosts.  Bartonella are Gram-negative bacilli, many of which possess polar 
flagella and are highly motile.  Clinical growth of Bartonella species requires incubation 
between 25 and 37°C in 5% CO2 on a blood rich media, such as BHI (Brain Heart Infusion) 
containing 5-10% sheep’s blood.  Bartonella are extremely slow growing in vitro, typically 
requiring 14 days for primary isolate culture growth.  Although growth in liquid media is 
possible, Bartonella species tend to be grown on solid media due to their fastidious nature 
and lack of turbidity.  Bartonella colonies tend to be sticky, irregular, raised, whitish, self-
adherent and very small.  Biochemically, Bartonella species tend to be carbohydrate-
metabolism inert, and catalase and oxidase reaction negative (Anderson, 1997; Maurin et al., 
1997).  Bartonella species contain relatively small genomes, with sizes ranging from 1.5 – 
2.0 Mbp, and a G+C content of approximately 40% (Schmidt, 1998).  Diagnostic 
identification of  intraspecies differentiation has relied heavily on the use of  16S rRNA and 
the gene for citrate synthesis (gltA) (Birtles et al., 1996; Ehrenborg et al., 2000).  
Comparative sequence analysis places Bartonella in the !-2 subgroup of Proteobacteria, a 
class that also contains Afipia, Agrobacterium and Brucella.   
 The first identified Bartonella species, Bartonella bacilliformis, was originally 
described in 1909.  This strain remained the only member of the Bartonella genus for more 
than 80 years.  In the early 1990s, however, detailed 16S rRNA analysis of several species 
belonging to Rochalimaea, a genus previously classified as Rickettsiaceae, showed such a 
close similarity to Bartonella bacilliformis that the decision was made to combine these two 
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genera into a single genus (O'Connor et al., 1991).  The taxonomic unification of 
Rochalimaea and Bartonella added four more strains, B. quintana, B. henselae, B. 
clarridgeiae and B. elizabethae, to the Bartonella genus (Brenner et al., 1993).  Since that 
time, numerous new Bartonella species have been identified, bringing the current total to 
more than 20 (Birtles et al., 1995). 
Of the many Bartonella species known, only a few have been identified as human 
pathogens.  The best characterized of these are B. henselae, and B. quintana.  B. henselae, the 
causative agent of Cat Scratch Disease (CSD), is the most widely-studied of all Bartonella 
species. Initially identified as a member of the genus Rochalimaea, B. henselae causes the 
highest number of infections of any of the human Bartonella pathogens.  The bacterium is 
transmitted to humans through the bite or scratch from a cat or other small mammal.  
Symptoms begin with the formation of localized erythematous papules, followed by a mild 
fever and lymphadenitis.  Normally, the course of the infection is self-limiting in an 
immunocompetent host (Brenner et al., 1993), with the localized swelling at the site of 
infection being cleared quickly, and the fever and lymphadenitis disappearing over the course 
of several weeks. (Dehio et al., 1997; Kordick et al., 1995; Maurin et al., 1997).  In patients 
with damaged or compromised immune function, however, infection by B. henselae can 
result in bacillary angiomatosis (BA) and/or peliosis hepatitis (Koehler et al., 2003; Maurin 
et al., 1997; Schmidt, 1998), two conditions characterized by the appearance of angiogenic 
lesions on the skin and internal organs, respectively (Dehio, 2003).  Several studies have 
correlated the production of these lesions directly with B. henselae infection, and have 
highlighted the role played by invading macrophages in the vascular proliferative process 
(Kirby, 2004; McCord et al., 2005; McCord et al., 2006; Resto-Ruiz et al., 2002).   
3 
 
B. quintana is transmitted via the body louse and is found predominantly among 
homeless and immunocompromised individuals (Foucault et al., 2002; Jackson, 1996; Rolain 
et al., 2003).  Infection by B. quintana, which results in a condition known as Urban Trench 
Fever, is often accompanied by recurring high fevers and severe pain in the back and shins 
(Ohl et al., 2000).  This repeating cycle of clinical symptoms is thought to be caused by the 
process of B. quintana invasion and release from host cells, and can result in bacteremia and 
BA. Studies have shown that both B. henselae and B. quintana are able to attach to and 
invade multiple cell types, including erythrocytes, epithelial and endothelial cells (Batterman 
et al., 1995).  Once they have successfully invaded the cell, these bacteria are able to alter 
normal cell cycle pathways.  Apoptosis is turned off during the initial stages of infection and 
vascular proliferation is induced, with both processes acting in concert to increase the 
numbers of infected cells (Liberto et al., 2004; Liberto et al., 2003).  
B. henselae and B. quintana are more closely related to each other than they are to 
either of two other human pathogens, B. clarridgeiae and B. bacilliformis (Anderson, 1997). 
Clinical manifestations of B. clarridgeiae infection are similar to those of CSD.  Like B. 
henselae and B. quintana, B. clarridgeiae can induce BA formation in an 
immunocompromised host (Berger et al., 1993; Maurin et al., 1997). Little research has been 
done regarding the molecular mechanisms underlying B. clarridgeiae infection or the role 
host cells play during the process of infection. 
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Bartonella bacilliformis – History & Epidemiology 
 
In 1909, Dr. A.L. Barton described an erythrocyte-adherent bacillus-shaped 
bacterium that he named Bartonella bacilliformis.  This bacterium was later determined to be 
the causative agent of Oroya fever, a disease characterized by severe hemolytic anemia and 
an untreated mortality rate of 85% (Anderson, 1997; Chomel et al., 2003).  The vector 
responsible for host-to-host transmission of B. bacilliformis is Lutzomyia verriformis 
(formerly known as Phlebotomus), a sandfly that inhabits the high-altitude valleys of the 
Andes mountains (Anderson, 1997; Schultz, 1968b). Transmission of the bacterium takes 
place when the female sandfly infects its human host during nocturnal blood-feeding; the 
source of the bacterium in the sandfly is the previous human host on which it fed (Schmidt, 
1998).  Replication of B. bacilliformis is not known to occur in the sandfly nor does B. 
bacilliformis infect the sandfly itself.  Unlike other Bartonella species, B. bacilliformis has 
not been conclusively shown to infect any host other than humans, although there have been 
anecdotal reports of infection of farm animals as well (Anderson, 1997).  The requirement for 
the sandfly as a vector is very specific, and normally limits the infective range of B. 
bacilliformis to the sandfly’s natural habitat in the inter-Andean mountains of Peru, 
Columbia and Ecuador. 
Bartonella bacilliformis is the causative agent of Carrion’s disease, a biphasic disease 
consisting of the initial acute phase, Oroya fever, and a second, chronic phase, called verruga 
peruana.  During the Oroya fever phase (so named for a Peruvian valley where it has often 
been reported), the bacteria invade nearly 100% of the host erythrocytes, causing a life-
threatening sepsis and hemolysis.  Oroya fever epidemics have been recorded since pre-Incan 
times.  A particularly devastating outbreak occurred between 1869 and 1873, killing nearly 
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10,000 railroad workers (Hertig, 1942; Schultz, 1968a).  Survivors of Oroya fever may 
subsequently develop verruga peruana, a condition characterized by the eruption of blood-
filled nodules on the skin of infected patients.  The link between Oroya fever and nodule 
formation was established by a Peruvian medical student, Daniel Carrion, who injected 
himself with the bloody material from a patient suffering from verruga peruana, and carefully 
documented the appearance of Oroya fever symptoms.  Carrion died from the resulting 
illness, and the disease that killed him was subsequently named Carrion’s disease in 
acknowledgement of his sacrifice. 
Bartonella bacilliformis – Known Virulence Factors 
Invasion-related Factors 
 
Bartonella bacilliformis is known to code for several virulence factors that help the 
bacterium survive in both its arthropod and human host. Studies have shown that the 
bacterium is able to invade a wide variety of cells, including red blood cells (RBCs), 
endothelial and epithelial cells. The majority of research has focused on the invasion of B. 
bacilliformis into host RBCs during the Oroya fever stage of the infection (Benson et al., 
1986).  Red blood cells, which are nonendocytocic and unnucleated, are the first host cells to 
be invaded (Dehio, 2001).  During RBC infection, B. bacilliformis is known to use at least 
three bacterial-encoded virulence factors: flagella, deformin and the invasion-associated 
locus gene products IalA and IalB (Buckles et al., 2000; Cartwright et al., 1999; Coleman et 
al., 2001; Mernaugh et al., 1992; Mitchell et al., 1995). The first, and most intensely studied, 
virulence factor is the flagellum. B. bacilliformis contains several polar flagella and is highly 
motile.  The flagella are composed of multiple 42-kDa flagellin subunits and are highly 
resistant to both protease K and trypsin treatment (Anderson, 1997; Scherer et al., 1993).  
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Pre-incubation of B. bacilliformis with anti-flagella antibodies significantly reduces the 
efficiency of invasion (Scherer et al., 1993).  Moreover, a mutant lacking flagella exhibits a 
75% reduction in its ability to bind to erythrocytes (Battisti et al., 1999).   At the present 
time, it is not known whether flagella play a direct role in binding to erythrocytes, or whether 
the motility they provide simply increases the likelihood that the bacterium will collide with 
a host cell, although studies with inhibitors of respiration and motive force support the latter 
interpretation (Benson et al., 1986; Scherer et al., 1993). B. henselae and B. quintana do not 
show the presence of flagella, thus leading some investigators to suggest that the motive-
force provided by the B. bacilliformis flagella is not necessary for invasion (Anderson, 1997).  
Deformin, a second well-studied B. bacilliformis virulence factor, produces deep 
invaginations within the RBC cell membrane. The secretion of deformin and the resulting 
formation of membrane invaginations are believed to enhance the ability of the flagellated B. 
bacilliformis to “push” itself into host RBCs (Mernaugh et al., 1992; Xu et al., 1995).  
Studies of purified deformin show that it is able to achieve these invaginations even in the 
absence of bacteria (Iwaki-Egawa et al., 1997).  Deformin activity has been reported to 
reside in a complex of several 36-kDa proteins with a small (1.4 kDa) hydrophobic molecule 
(Hendrix and Kiss, 2003).  The exact composition of the hydrophobic molecule has not yet 
been determined.  The role(s) of IalA and IalB in invasion by B. bacilliformis show genetic 
similarities to invasion-associated genes products found in Yersinia species (Anderson, 1997; 
Mecsas et al., 1995; Wachtel et al., 1995). The ialA gene is 510 bp and codes for a putative 
NTPase core protein, while ialB is 558 bp and codes for a homologue of the Yersinia ail 
(adhesion and invasion locus) protein (Cartwright et al., 1999; Coleman et al., 2001).  B. 
bacilliformis IalA acts as a (di)nucleoside polyphosphate hydrolase, and has distinct 
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homology to the nudix class of nucleotide pyrophosphatases produced by A. tumefaciens (Xu 
et al., 2003).  The function of IalB has not been determined, but it is known to be an inner 
membrane protein that is also required for B. bacilliformis RBC invasion (Coleman et al., 
2003; Mitchell et al., 1995).  Studies with E. coli harboring recombinant plasmids carrying 
the ialAB locus have shown that both ialA and ialB are required for invasiveness in vitro, as 
indicated by a 6- to 39-fold increase in invasion in the presence of both genes.  Moreover, 
expression of ialAB enhances the efficiency of invasion even in the absence of flagella 
(Coleman et al., 2003).  
B. bacilliformis is known to continue replication inside both the endosomal vacuole 
and the cytoplasm of RBCs without lysing either cell type. While the purpose of RBC 
colonization is still unknown, it is generally considered to increase the potential for 
successful invasion, since it provides B. bacilliformis with direct access to host iron and any 
other blood-supplied host growth factor(s) the bacterium might require.  Colonization of 
RBCs would also give B. bacilliformis a safe haven in which to replicate where it could 
effectively evade the host immune response.  
Investigations are ongoing to determine the mechanism(s) by which B. bacilliformis 
invades host endothelial and epithelial cells (Dehio, 2001; Garcia et al., 1992), a process that 
results in the verruga stage of the infection.  Cellular invasion is known to require the activity 
of B. bacilliformis flagella, as shown by a 50-90% decrease in invasion when cells are 
incubated with anti-B. bacilliformis flagella antibodies (Scherer et al., 1993).  The process is 
also reported to be Rho-GTPase dependent, as indicated by a decrease in B. bacilliformis 
invasion when endothelial cells are pre-incubated with C3 exoenzyme, a protein known to 
inactivate Rho-GTPase (Verma et al., 2000; Verma et al., 2002).  These data suggest that B. 
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bacilliformis invasion is dependent upon actin rearrangement in host cells. This hypothesis is 
supported further by the observation that uptake of the bacteria is significantly reduced in the 
presence of cytochalasin D, which inhibits host actin rearrangement (Hoang et al., 2004).  
Additional studies indicate that B. bacilliformis outer membrane proteins play a direct role in 
invasion, as the presence of anti-Bartonella anti-sera causes a marked decrease in bacteria 
uptake (Minnick, 1994).  Within one hour of invasion, B. bacilliformis-induced actin 
rearrangement leads to the formation of filamentous actin extensions called filopodia.  
Filopodia formation is accompanied by host cell membrane ruffling, a phenomenon that may 
implicate the activation of Rac and Cdc42 and other host signaling pathways (Verma et al., 
2002).  Invasion is most often seen in the endothelial cells which line the capillary beds of 
the host skin and related subcutaneous tissues. Host endothelial and epithelial cells contain 
the invaded B. bacilliformis within a vacuole called the invasome, a term coined specifically 
for B. bacilliformis (Dehio et al., 1997).  The invasome has been shown to migrate from the 
cell membrane to a position near the host nucleus, although the mechanism and effect of this 
translocation are unknown.  Bacterial invasion into these cells is characterized by two distinct 
histological manifestations of verruga peruana.  The first consists of spindle-form lesions that 
contain fusiform cells with T cell and monocyte/macrophage infiltration.  The second is 
described as a pyogenic granulomatous hemangioma characterized by a hyperplastic 
endothelium and extensive vascularization (Anderson, 1997; Maurin et al., 1997).  When 
examined histologically, the spindle-form lesions are strikingly similar to Kaposi’s sarcoma, 
while the granulomatous forms tend to resemble the bacillary angiomatosis seen during 
infection by B. henselae (Berger et al., 1993; Caceres-Rios et al., 1995; Cockerell, 1992).  
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The invasion of epithelial cells has been shown to cause the up-regulation of 
numerous growth factors, cytokines and interleukins, some of which are known to be 
involved in angiogenesis (Claesson-Welsh, 1999; Fox, 2001).  Previous work has indicated 
that the invasion of B. bacilliformis into epithelial cells produces a transient up-regulation of 
TNF-!, which is in turn known to up-regulate the production of various angiogenic factors. 
Studies exposing cultured endothelial cells to B. bacilliformis extracts have led to the 
suggestion that the bacterium itself produces a possible mitotic and/or angiogenic factor 
(Garcia et al., 1990; Garcia et al., 1992).   A B. bacilliformis heat shock protein, Bb65, 
strongly activates T cells which in turn produce Eta-1/osteopotin, an inducer of vascular cell 
proliferation (Knobloch et al., 1990).   
Adherence-Related Factors 
 
Several laboratories are involved in the characterization of factors responsible for 
promoting adherence of B. bacilliformis to the host cell. Initially, work by Walker and 
Winkler (1981) suggested that “fiber-like projections” on the polar surface of the bacterium 
were responsible for contact with the RBC surface (Anderson, 1997; Walker et al., 1981).  
These “projections” have been studied further and show a resemblance to the Bundle-
forming pili (BFP) found in E. coli and S. enteritidis.  The bundles range in size from 50 to 
600 nm and have been shown to be resistant to solubilization by SDS and formic acid.   
 The aforementioned flagella may also play a role in the adhesion of B. bacilliformis 
to host cells (Krueger et al., 1995).  Studies have shown that cultures of B. bacilliformis that 
have been highly-passaged or have had their flagella removed bind poorly to host RBCs, 
although this may be due less to a direct role of flagella in adhesion than to a requirement for 
flagellar-motive force in promoting collisions between the bacterium and the host cell.   
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 Infection with B. bacilliformis begins a rapid and energy-dependent adhesion to and 
invasion of RBCs.  In vitro studies show a 15-30 minute lag time between introduction and 
adhesion, with maximal adhesion at six hours post infection (Verma et al., 2001; Verma et 
al., 2000; Verma et al., 2002).  The treatment of B. bacilliformis with agents that inactivate 
bacterial proton-motive force (N-ethylmaleimide) or respiration (KCN) results in a 
significant decrease in their binding to RBCs.  However, exposure of the RBCs to glycolysis 
(NaF) or proton-motive force (N-ethylmaleimide) inhibitors has no affect on bacterial 
adherence, suggesting that the RBC itself is passive in the adhesion process and does not 
contribute energy (Verma et al., 2002).  The host receptor for B. bacilliformis has not been 
identified but the bacterium shows a definite predilection for rabbit or sheep RBCs.  
Research in the Baumstark lab has shown that B. bacilliformis is able to invade both 
enucleated (sheep) and nucleated (goose) RBCs (McCormick, personal communication).   
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The virB Operon 
 
Previous studies on the infectious process of the plant pathogen A. tumefaciens 
identified a set of genes, termed the virB operon, that are required for the infection of plant 
cells (Chen et al., 2002; Krall et al., 2002).  In A. tumefaciens, the virB operon was found to 
contain 11 genes, designated virB1 through virB11 depending on their location downstream 
of the vir Box, a regulatory element found directly upstream of virB1.  It was subsequently 
proposed that the virB operon acts to form a Type IV secretion system (TFSS) that provides a 
conduit for A. tumefaciens to transfer a single stranded copy of T DNA, or T strand, into 
plant host cells (Boschiroli et al., 2002; Escudero et al., 1995; Ohashi et al., 2002).  
Originally, Type IV secretion systems were identified in mating-pair formation systems (Mpf 
systems) required for the conjugal transfer of plasmid DNA.  They are thought primarily to 
form pilus structures for DNA transfer to recipient cells.  A. tumefaciens and E. coli have 
been the only bacteria positively identified as having these systems (Chen et al., 2002).  The 
functions of all the virB proteins composing the A. tumefaciens virB operon have not yet been 
elucidated.  However, several virB proteins have been characterized and a model outlining 
the structure and assembly of the secretion machinery has been developed (Figure GI.1) 
(Baron et al., 2001; Sagulenko et al., 2001),.  The best characterized virB gene products in A. 
tumefaciens are VirB2, forming the transfer pilus, VirB4, a putative ATPase, and VirB9, 10 
and 11, which interact to form a protein complex that anchors the TFSS to the cell membrane 
(Figure GI.1) (Boschiroli et al., 2002; Krall et al., 2002; Sagulenko et al., 2001; Stephens, 
Kathryn et al., 1995).   
Previous work in our laboratory revealed the presence of a homologue to the A. 
tumefaciens virB operon in B. henselae (Anderson, 1997; Padmalayam et al., 2000b; 
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Schmiederer et al., 2001).  The B. henselae virB operon is composed of 10 genes that exhibit 
homology to the A. tumefaciens virB genes, as shown in Table GI.1, and are positioned in a 
similar order within the operon.  While mutagenesis studies and deletions of the virB operon 
have not been conducted in B. henselae, it has been noted that continued passage of the cells 
leads to a decrease in virulence, which may be related to the loss of VirB2 pilus formation 
(personal communication, Padmalayam).  Interaction studies with virB-encoded proteins 
suggest that TFSS formation of the B. henselae virB operon is similar to that of A. 
tumefaciens (Shamaei-Tousi et al., 2004).  These studies indicate that the VirB2 protein acts 
as the primary subunit of the TFSS pilus, with VirB3, VirB9, the 17kDa antigen (encoded by 
virB5) and the15kDa antigen (encoded by virB7) serving as pore-forming anchors in the 
periplasm.  The inner member anchor proteins VirB4, VirB8, VirB10 and VirB11 are 
proposed to interact to form a pore into the cytoplasm.  Recently, identification of virB 
protein homologues in S. meliloti, Brucella suis, Brucella  abortus, Bordatella  pertussis and 
additional Bartonella species has been reported, with functional studies suggesting that they 
play a role as TFSS transport machinery (Boschiroli et al., 2002; Gorvel et al., 2002; Ohashi 
et al., 2002; Weiss et al., 1993). 
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Figure GI.1 – Assembly of the virB gene products in A. tumefaciens.   
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above.  
According to this model, A. tumefaciens VirB2 (in yellow) forms the pilus for cell-to-cell 
contact, with VirB9 (dark red) as an outer membrane-bound anchor.  VirB4, in dark blue, is 
predicted to act as an ATPase and provide energy into the process for Ti DNA translocation.  
The associated VirB9/10/11 protein complex (light blue and purple) forms the inner 
membrane-bound anchor (Christie, 1997).    
 
 
 
 
Figure GI.2 – Proposed Assembly of virB gene products in B. henselae. 
The proposed assembly of the virB operon proteins, functioning as a TFSS, is shown above.  
B. henselae VirB2 (in yellow) forms the pilus, interacting with the 17kDa antigen (VirB5, 
shown in dark purple).  VirB3 (orange), VirB9 (red) and the 15kDa antigen (purple) form a 
periplasmic pore. The VirB4 (green) and VirB11 (blue) are membrane-bound and predicted 
to act as ATPases.  The associated VirB8/10/11 protein complex (yellow and blue) form the 
inner membrane-bound anchor (Shamaei-Tousi et al., 2004). 
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Table GI.1  – Homology of selected Bartonella virB operon genes compared to the A. 
tumefaciens virB Operon.   
The following table indicates the DNA sequence identity within the open reading frames 
coding for virB proteins of A. tumefaciens and the Bartonella species. 
 
 (% DNA Sequence Identity) 
 
 
 
 
Brucella 
 Suis 
Sinorhizobium  
meliloti 
Bartonella 
henselae 
Bartonella 
tribocorum 
virB2-homologue 47 45 34 36 
virB3-homologue 43 39 44 41 
virB4-homologue 47 45 50 49 
17kDa Antigen N/A N/A N/A N/A 
virB6-homologue 46 46 40 38 
15kDa Antigen N/A N/A N/A N/A 
virB8-homologue 48 48 38 43 
virB9-homologue 46 46 41 42 
virB10-homologue 48 48 44 43 
virB11-homologue 42 42 48 48 
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Angiogenesis  
 
The verruga peruana stage of Carrion’s disease is marked by blood-filled skin 
nodules, resulting from the uncontrolled up-regulation of angiogenesis in localized 
endothelial cells (Caceres-Rios et al., 1995; Garcia et al., 1992).  Up-regulation of 
angiogenesis is initiated by the invasion of B. bacilliformis into host cells.  The activation 
and suppression of angiogenesis is normally tightly controlled by the balanced production of 
both angiogenic stimulators and angiogenic suppressors in multiple cell types.  In general, 
however, angiogenesis is regulated by Vascular Endothelial Growth Factor (VEGF) and "-
Fibroblast Growth Factor ("FGF), and the presence of their respective receptors on 
endothelial cells.  VEGF, and its alternative splicing protein VPF, activate angiogenesis by 
specifically increasing the microvascular permeability of endothelial cells to other plasma 
proteins and by phosphorylating VEGFR-1 and 2 (VEGF receptors 1 and 2).  This 
phosophorylation causes the activation of phosopholipase C# and an increase in cytoplasmic 
Ca+2 levels, resulting in the generation of inositol 1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG).  Production of these intracellular messengers along with the activation of VEGFR-1 
and -2 results in a strong cell proliferation response and the generation of matrix-degrading 
proteases (Claesson-Welsh, 1999; Dong et al., 2001).    "FGF also functions as a mitogenic 
protein, specifically stimulating endothelial cells to migrate and form tubules while also 
increasing the production of proteases (Folkman et al., 1992).   However, VEGF and "FGF 
are not the only angiogenesis effecting factors, as shown in Table GI.2 (Bamias et al., 2003; 
Conway et al., 2001; Sottile, 2004).  The factors listed are all able to upset the natural 
balance of angiogenesis, driving it in a specific direction, and can be produced by a variety of 
cell types, including epithelial cells.  The process of angiogenesis begins with the 
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vasodilation and increased permeability of existing blood vessels, along with increased 
permeability and degradation of the surrounding extracellular matrix.  This allows for the 
activated endothelial cells to migrate and form new lumen walls; generating a “pathway” for 
returning to a larger blood vessel (Carmeliet, 2000; Neufeld et al., 1999).  These endothelial 
cells mature by remodeling themselves to supply the surrounding area with their specific 
requirements, and are functional once a stable matrix and musculature are established 
(Neufeld et al., 1999).  In the verruga peruana stage of B. bacilliformis infection, the blood 
vessels produced are not seen in a mature form; instead, they are open-ended and allow blood 
to leak into the cutaneous and interstitial spaces around them.  The invasion of epithelial cells 
is known to cause the up-regulation of numerous growth factors, cytokines and interleukins, 
some of which (Table GI.2) are known to be involved in angiogenesis (Claesson-Welsh, 
1999; Folkman et al., 1992).  Previous work has indicated that the invasion of endothelial 
cells by B. bacilliformis produces a transient up-regulation of TNF-!, which in turn is known 
to up-regulate VEGF production.  BB65, a heat shock and highly immunogenic B. 
bacilliformis protein, strongly activates T cells which in turn produce host Eta-1/osteopotin, a 
protein that is then transiently able to induce vascular cell proliferation.  Interestingly, almost 
all skin disorders, such as psoriasis, show an increase of VEGF and VEGF-related proteins in 
epithelial cells as well as an increase in VEGF receptors in endothelial cells (Carmeliet, 
2000; Hudlick et al., 1986; Knobloch et al., 1990; Takahashi et al., 2002). 
17 
 
Table GI.2 – Factors produced by host cells involved with angiogenesis.   
The table below shows the wide variety of host cell products which are involved in 
angiogenesis. 
 
Protein Function  Protein Function 
Activators   Inhibitors  
Angiopoietin-1  
Stabilization of vessels 
via tightening 
endothelial-smooth 
muscle interactions 
 
Angiopoietin-2 
Induction of vessel 
regression without 
further 
angiogenesis 
signals 
Angiotropin 
Endothelial growth 
factor 
 
Angiostatin 
Inhibition of 
growth and 
migration 
avb3 Integrin 
Receptor of matrix 
macromolecules  
Endostatin Inhibition of 
growth and survival 
avb5 Integrin 
Receptor of matrix 
macromolecules  
IP-10 Inhibition of 
endothelial growth 
COX2 
Essential for tumor 
angiogenesis 
 
Thrombospondin-
1 
Inhibition of 
endothelial 
migration, growth 
and differentiation 
Endoglin 
Stimulation of 
extracellular matrix 
production  
Vasostatin Endothelial cell 
growth inhibitor 
Ephrins 
Regulation of 
artery/vein phenotype    
FGF 
Stimulates angiogenesis 
& arteriogenesis    
Fibronectin 
Promotion of endothelial 
adhesion, growth and 
survival    
HIF1a 
Hypoxia-induced 
endothelial growth 
factor    
IL-6 
Endothelial growth 
factor    
IL-8 
Endothelial growth 
factor    
Laminin 1 
Promotion of 
Endothelial tube 
formation    
Matrix 
Metalloproteinase 
Cellular migration and 
matrix remodeling    
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Protein (con’t) Function    
Activators     
MCP-1 
Stimulation of  
arterogenesis    
NO Synthase 
Stimulation of 
angiogenesis and 
vasodilation    
PDGF and receptors 
Recruitment of smooth 
muscle cells    
PECAM 
Endothelial junction 
molecule, essential for 
cell survival    
Perlecan 
Enhancement of FGF 
Signaling    
Ras 
Pro-angiogenic 
oncogene    
TGF-B & B1 
Stimulation of 
extracellular matrix 
production    
VEGF Receptors 
Angiogenic signaling 
receptor    
VEGF, VEGF-C, 
PIGF and various 
homologues 
Stimulation of 
angiogenesis 
   
Vitronectin 
Promotion of endothelial 
survival and migration    
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The goal of this study is to gain insights into the molecular mechanism by which B. 
bacilliformis induces the formation of verruga peruana during Carrion’s disease.  Our 
research has revealed that B. bacilliformis does not contain any homologues to the virB 
operon found in several other Bartonella species and has led us to conclude that this operon 
does not play a role in verruga peruana formation.  Interestingly, using microarray-based 
analysis of infected HMEC-1 cells, we have determined that several hypoxia and angiogenic 
factors are up-regulated or significantly altered, which may aid in the induction of 
angiogenesis.  We also show that infected HMEC-1 cells produce high levels of immune 
response genes, corresponding to an interferon-based immune response; this would likely 
result in the recruitment of immune effector cells which could in turn produce more 
angiogenic up-regulatory factors.  Finally, we have found the secretion, by B. bacilliformis, 
of a unique GroEL protein.  Motif analysis indicates that this GroEL contains a 
staphylocoagulase binding site, which may interact with host integrins up-regulate multiple 
pathways, including angiogenesis.  While this GroEL may be angiogenic, it may also 
function to protect HMEC-1 cells from the tubule degradation effects seen in the presence of 
live B. bacilliformis.  Taken together, these results suggest to us that the infection of host 
endothelial cells by B. bacilliformis induces a strong interferon-based immune response that 
is coupled with host cell hypoxia in a microenvironment containing high concentrations of an 
angiogenic GroEL protein, and that this series of events results in the localized formation of 
verruga peruana. 
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GroEL 
 
The cellular environment is often inhospitable to the folding and unfolding of proteins 
in their biologically active confirmation.  Therefore, both prokaryotes and eukaryotes contain 
proteins, called molecular chaperones, that allow this confirmation to occur on a 
physiological timescale (Fenton et al., 2003). Chaperones are classified into two groups 
according to their sequence homologies:  Type I, represented by GroEL; and Type II, 
represented by eukaryotic CCT (cytosolic chaperonin containing TCP-1) and archaebacterial 
chaperones (Carrascosa et al., 2001).  GroEL and the CCT chaperones differ in several ways.  
Firstly, GroEL is considered nonspecific with respect to its substrate binding while CCT is 
more specialized. Secondly, GroEL is a homeric-protein whereas CCT is a heteromeric 
complex built of eight different polypeptides (Carrascosa et al., 2001).  Finally, GroEL 
requires a cofactor while CCT does not (Carrascosa et al., 2001).  The main Type I 
cytoplasmic chaperones identified to date include HtpG, the Clp system, trigger factor, the 
DnaK system, and the GroE system.  Little is known about the role of the HtpG system in 
promoting proper folding, although the chaperone is highly expressed during heat shock.  
Bacterial strains that do not contain the HtpG system behave like wild-type strains and show 
no distinctive phenotype associated with the loss of the chaperone  (Wong et al., 2004).  The 
Clp family of chaperones consists of a group of ATP-binding proteins that were originally 
isolated based on their association with the serine protease ClpP.  ClpA, ClpX and HslU all 
exhibit ATP hydrolytic activity, which provides the energy required for ClpP-mediated 
proteolysis.  ClpB also binds to the serine protease, but does not hydrolyze ATP.  Clp 
proteins can be further divided into two classes according to the number of nucleotide 
binding domains in each protein. ClpA and ClpB contain two nucleotide binding domains 
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while ClpX and HslU contain only one nucleotide binding domain (Wong et al., 2004).  
These ATP binding proteins not only target misfolded or foreign proteins for degradation, but 
can also act as chaperones to promote refolding of improperly folded proteins.  
 Trigger factor is a chaperone that is common to all eubacteria.  In E. coli, it has been 
shown to interact with nascent chains and to bind closely to the nascent chain exit site of the 
ribosomal complex (Wong et al., 2004).  Trigger factor is involved in the prevention of 
misfolding and the aggregation of nascent chains as they are translated by the ribosome.  
DnaK is an ATP-dependent chaperone that functions in concert with the co-chaperone DnaJ.  
DnaK recognizes hydrophobic sequences in extended polypeptide chains.  Like trigger 
factor, it binds to nascent chains (Wong et al., 2004).  In eukaryotes, DnaK is present in the 
cytosol, endoplasmic reticulum, mitochondria and chloroplasts,  and acts in concert with 
DnaJ and GrpE (Ranson et al., 1998).  GroEL often acts in concert with a second protein, 
GroES.  The GroESL system promotes protein refolding in two stages. First, it prevents the 
aggregation of non-native nascent peptides by forming complexes with them and thus 
lowering the concentration of aggregation-prone peptides in solution.  Second, it releases the 
bound substrates into the central cavity of the GroEL complex, allowing folding in a 
protected environment without intramolecular interactions.  It has been suggested that 
GroESL has the ability to unfold kinetically-trapped folding intermediates, thereby giving 
them a new chance to fold correctly (Wong et al., 2004). 
GroEL is an oligomeric complex of 14 identical 57-kilodalton subunits arranged in 7-
member rings sticking back to back.  The crystal structure of GroEL shows a hollow 
cylindrical complex 135Å in diameter with a height of 145 Å (Grallert et al., 2001).  The 
openings at each end of the cylinder form the entrance to a cavity with a diameter of 45 Å 
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(Grallert et al., 2001).  The GroEL monomer consists of 547 amino acids arranged in three 
distinct domains: equatorial, intermediate and apical.  The equatorial domain, which contains 
a nucleotide binding site, is also used for the inter-and intra-ring interactions of a protein 
complex.  This domain also contains the ATP binding site, which is located on the inner sides 
of the GroEL cylinder (Gomez-Puertas et al., 2004; Grallert et al., 2001; Wong et al., 2004).  
The apical domain binds to both the substrate and GroES (Gomez-Puertas et al., 2004; 
Grallert et al., 2001).  The intermediate domain of each subunit transfers the ATP-induced 
conformational changes from the equatorial domain to the apical domain (Grallert et al., 
2001; Wong et al., 2004).  GroES, a seven-member ring structure composed of 10- kilodalton 
subunits, binds ATP on one or both ends of the GroEL cylinder.  GroES exhibits a dome-
shaped structure with outside dimensions of 80 Å in diameter and 30 Å in height, and inside 
dimensions of 30 Å in diameter and 20 Å in height (Grallert et al., 2001).  Transcription of 
the E. coli GroESL system is positively controlled by the product of rpoH, the heat shock 
promoter-specific $32 subunit of RNA polymerase (Arsene et al., 2000).  The heat shock 
response is induced as a consequence of a rapid increase in $32 levels and the stimulation of 
$32 activity.  Down-regulation of the GroESL response occurs as a consequence of declining 
$32 levels as heat stress signaling decreases (Arsene et al., 2000). 
 GroEL activity requires communication between the three ring domains, which is 
accomplished by the interaction of GroES and ATP at specific times during the nascent 
protein binding cycle (Amir et al., 2004).  In the ATP-free conformation, the GroEL 
chaperone has an open structure and a high affinity for unfolded substrates.  In contrast, in 
the ATP-bound conformation the cavity structure is closed and has a low affinity for 
substrates (Gomez-Puertas et al., 2004; Ranson et al., 1998). Substrate recognition is 
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achieved by the presence of hydrophobic residues on the unfolded polypeptide, which are 
exposed to the surface and are recognized by interaction with hydrophobic residues of the 
chaperone-binding site (Gomez-Puertas et al., 2004).   Functional protein folding in the 
presence of the whole GroESL chaperone system proceeds by a reaction cycle that begins 
with the binding of protein substrate to the intermediate domain.  This then allows for the 
binding of GroES.  Binding of ATP subsequently produces a conformational change that 
leads to the closure of the inner GroEL cavity (Amir et al., 2004; Poso et al., 2004; Wong et 
al., 2004).  In the folding cavity, the substrate binds to the apical domain in the top cylinder 
of GroEL (Gomez-Puertas et al., 2004; Poso et al., 2004; Wong et al., 2004).  The folding of 
the nascent protein is thought to be accomplished, in part, by the binding of both GroES and 
ATP, which provides a physical stress on the GroEL ring subunits, thereby constraining the 
hydrophobic interactions and allowing for different conformational structures to be achieved 
(Keskin et al., 2002; Poso et al., 2004; Sot et al., 2003; van der Vaart et al., 2004; Walter, 
2002).  Following the conformational changes in the nascent protein, the hydrophobic 
binding site is altered and the now-folded protein is ejected into the bulk solution (Sot et al., 
2003; Walter, 2002).  Since each GroEL subunit acts as a protein-binding unit, a full cycle 
involves binding of both substrate and GroES to one ring of the complex followed by the 
same steps on the opposite ring (Poso et al., 2004).  Inner ring communication is of pivotal 
importance as it mediates a structural symmetry that imposes alternating functions (Poso et 
al., 2004).  It is been shown that while positive cooperativity governs the binding of ATP, it 
is negative cooperativity that regulates the communication between rings (Poso et al., 2004).  
GroEL homologues are found in nearly all prokaryotic and eukaryotic organisms. In many 
organisms, they were originally isolated as heat shock proteins.  This observation, coupled 
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with their monomeric migration pattern on denaturing gels, led to their early general 
designation as “hsp60 proteins.”  More recently, they have also been called “cpn60” 
(chaperonin60) proteins.    
Recent research has given scientists insight into possible immunological aspects of 
the presence of GroEL in bacterial-host disease interactions. Chaperones are known to be 
potent immunogens in both humans and rodents.  Given the high degree of sequence 
similarity between bacterial and the mammalian molecular chaperones, it is surprising that 
bacterial chaperones elicit such a strong immune response (Ranford et al., 2000).  It can often 
be difficult to extract purified GroEL, as many other bacterial contaminants are often found 
in GroEL preparations, including LPS (lipopolysaccharide), LAM (lipoarabinomannan), 
peptidoglycan, or other bacterial exotoxins (Ranford et al., 2000). However, studies that have 
been done using GroEL homologues from other bacteria have shown that even with the 
complete removal of these contaminants GroEL is able to induce cytokine activity and is 
therefore able to elicit an immune response (Ranford et al., 2000).  In mice infected with M. 
tuberculosis, up to 20% of the reactive T cells are responsive toward the chaperonin 60.2 (the 
GroEL homologue in this organism); moreover, leukocytes, fibroblasts and epithelial cells 
are also induced to produce pro-inflammatory cytokines in the presence of chaperone 60.2 
proteins (Ranford et al., 2000).  GroEL homologues from several different Mycobacteria 
species and from E. coli have been shown to stimulate cytokine-dependent up-regulation of 
vascular endothelial cell adhesion molecules and are potent inducers of human monocyte IL-
1b and IL-6 production (Retzlaff et al., 1994). GroEL from E. coli has also been tested for its 
ability to induce the expression of various cytokines in HUVEC cells cultures.  Incubation of 
purified GroEL with these endothelial cells resulted in increased GM-CSF, IL-6, E-Selectin, 
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ICAM-1 and VCAM-1 release in a dose-dependent fashion (Galdiero et al., 1997; Ranford et 
al., 2000; Retzlaff et al., 1994).  The induction of the latter three proteins is controlled by the 
production of cytokines IL-1 and TNF-alpha (Ranford et al., 2000).  Not surprisingly, 
Mycobacterium and E. coli are not the only bacteria that produce GroEL proteins with 
immunological activity.  Cpn60 proteins from several bacteria have been reported to localize 
to the bacterial cell surface, where they can serve as potential antigens.  These include 
proteins from Helicobacter, which play a role in preventing bacterial aggregation, from 
Legionella, which increase host intracellular uptake, and Actinobacillus, which act as 
adhesion molecules (Garduno et al., 1998; Ranford et al., 2000). Studies have shown a wide 
variety of extra-chaperone functions for GroEL as well, including roles in cellular adherence 
of Clostridium difficle, endocarditis in S. aureus, and the infection cycle in Chlamydia 
trachomatis and Rhizobium leguminosarum (George et al., 2004; Hennequin et al., 2001; 
Karunakaran et al., 2003; Qoronfleh et al., 1998).  Interestingly, a study using Actinobacillus 
actinomycetemcomitans Cpn60 with epithelial cells shows strongly induced 
phosophorylation and activation of ERK1/2 which inhibits caspase 3 activity in UV-radiation 
exposed cells, thereby avoiding apoptosis-induced cell death (Zhang et al., 2004).   
Several studies have reported the use of GroEL comparisons to establish phylogenetic 
relationships among the !-2 proteobacteria, and for bacterial identification during infection 
(Haake et al., 1997; Lee et al., 2003; Paddock et al., 1997).  Work with Rickettsial GroEL 
has shown it to be up-regulated early during the infection cycle, where it may act to enhance 
intracellular survival (Gaywee et al., 2002).  Based on their investigation of factors in B. 
bacilliformis lysates that induce proliferation in HUVEC cells cultures, Minnick et al. (2003)  
proposed that GroEL is a mitogen, and as such may play a direct role in the production of the 
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vasculoproliferative nodules seen during the verruga peruana stage of B. bacilliformis 
infection (Minnick et al., 2003).  Their conclusion was based on:  1) the identification of a 
mitogen that is heat and trypsin sensitive; 2) a correlation between mitogenicity and the 
levels of GroEL in B. bacilliformis lysates; and 3) the inhibition of mitogen activity in the 
presence of anti-GroEL antibodies.   Subsequent experiments by these authors involving 
infection of HUVEC cells with GroEL-overproducing strains of B. bacilliformis showed a 
correlation between high levels of GroEL and the acceleration of apoptosis, however.  These 
observations led to the proposal that intracellular B. bacilliformis GroEL functions as an 
ortholog to eukaryotic hsp60 proteins, which are known to accelerate pro-caspase3 activation 
by enhancing its vulnerability to upstream activator caspase.   Since both cell proliferation 
and the inhibition of apoptosis are believed to be involved in the induction of verruga 
peruana, the finding that GroEL increases the rate of apoptosis would appear to compromise 
its role in the angiogenic process.   This issue remains unresolved.  
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Chapter I – Search for virB operon homologues in selected Bartonella species 
 
Introduction 
 
Bartonella species have been assigned to the alpha-2 proteobacterium subgroup, a 
category that also includes Brucella abortus, Sinorhizobium meliloti and Agrobacterium 
tumefaciens.  Although they are diverse in terms of their host range and growth conditions, 
alpha-2 proteobacteria all interact directly with the cells of the organisms they infect.  The 
mechanism of interaction has been particularly well-characterized in the plant pathogen A. 
tumefaciens (Chen et al., 2002; Christie, 1997; de Paz et al., 2005; Krall et al., 2002).  
Direction interaction by A. tumefaciens with host cells results in the production of tumors 
called Gall Tumors.  The cellular proliferation leading to the formation of Gall Tumors is 
induced by the expression of genes located on a segment of bacterial DNA, called the Ti 
DNA, that is transferred to the host cells during the process of infection.  Transfer is 
mediated by the products of the virB operon, a set of 11 genes encoded on the A. tumefaciens 
chromosome (Christie, 1997; Escudero et al., 1995; Loubens et al., 1997).  The virB operon 
of A. tumefaciens has been shown to code for a Type 4 Secretion System (TFSS), a complex 
of proteins that uses ATP hydrolysis to promote the movement of the Ti DNA through the 
VirB pilus and into the host cell (Baron et al., 2001; Baron et al., 1997; Berger et al., 1994; 
Dang et al., 1997; Das et al., 1997; Finberg et al., 1995; Rashkova et al., 1997; Stephens, 
Kathryn et al., 1995; Thorstenson et al., 1993). 
In 2000, a set of genes was reported in Bartonella henselae that exhibits a high degree 
of sequence similarity to those encoded by the A. tumefaciens virB operon (Padmalayam et 
al., 2000a; Schmiederer et al., 2000).  The B. henselae operon consists of 10 genes, eight of 
which have homologues in the A. tumefaciens virB operon.  Expression of B. henselae virB 
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genes is induced following uptake of the bacterium by the host cell (Schmiederer et al., 
2001).  The virB gene products play essential roles in the processes used by B. henselae to 
colonize the host cell, including the rearrangement of the host cytoskeleton and the inhibition 
of apoptosis (Batterman et al., 1995; Dehio et al., 1997; Kordick et al., 1995; Schmid et al., 
2004).  To date, the virB operon has been identified in three Bartonella species (de Paz et al., 
2005; Padmalayam et al., 2000a; Seubert et al., 2003b; Woestyn et al., 2004).  
The biphasic infection caused by B. bacilliformis, like the infections produced by 
other members of the alpha-2 proteobacteria subgroup, involves direct interaction with the 
cells of the host.  During the initial phase, B. bacilliformis invades red blood cells, 
successfully infecting up to 100% of erythrocytes (Benson et al., 1986; Dehio, 2001; 
Schulein et al., 2002).  The second phase, or verruga phase, is marked by the colonization of 
epithelial and endothelial cells, which induces the vascular proliferation that is responsible 
for the cutaneous and subcutaneous vascular lesions that are a hallmark of this phase (Dehio, 
2001; Dehio, 1999; Dehio et al., 1997; Kirby, 2004; Verma et al., 2000). While genetically 
similar to other Bartonella species, B. bacilliformis is unique among Bartonella species for 
its relatively small genome (1.5 Mbp) and more severe clinical presentation.  Its interactions 
with host cells are also distinct:  unlike that of B. henselae and B. quintana, induction of 
vascular proliferation in B. bacilliformis can occur in an immunocompetent host (Battisti et 
al., 1999; Krueger et al., 1995). 
Given the role the virB operon plays in both A. tumefaciens and B. henselae 
pathogenesis, we sought to determine whether a homologous operon is present in the genome 
of B. bacilliformis and other Bartonella species.  This study reports the identification of a 
virB operon in B. quintana, the causative agent of trench fever, and in B. clarridgeiae, a 
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species that, like B. henselae, has been associated with Cat Scratch Disease (CSD).  In 
contrast to the results obtained with these Bartonella species, our work with B. bacilliformis 
produced no evidence of virB homologues.  Based on our results, we propose that B. 
bacilliformis, unlike other clinically significant Bartonella, does not make use of a virB-
encoded Type 4 Secretion System to invade cells and induce cellular proliferation. 
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Materials and Methods 
 
Bacterial Growth and Culture.  The following Bartonella species were obtained from the 
American Type Culture Collection (ATCC):  B. henselae Houston-1, B. quintana subspecies 
Fuller, B. clarridgeiae, and B. bacilliformis KC584.  All Bartonella species were grown on 
Brain Heart Infusion (BHI) agar supplemented with 10% sheep’s blood.  Bartonella 
henselae, B. quintana and B. clarridgeiae were incubated at 37°C, while B. bacilliformis was 
incubated at 25°C for 5-7 days.  Growth was monitored by visual inspection. Once confluent 
colonies were visible, the Bartonella was harvested by the addition of 15 ml of sterile 
Phosphate Buffered Saline (PBS), pH 7.4, and the plate was gently scraped using a cell 
scraper (Fisher).  The PBS-Bartonella mixture was removed by aspiration and placed in a 
sterile 15 ml tube (Falcon).  Bartonella to be used for genomic DNA extraction was then 
centrifuged at 2000xg for 10 minutes at 4°C, and then the PBS was decanted.  Unused 
Bartonella was stored at -80°C in 50% PBS/50% glycerol until needed. 
Genomic Isolation of Bartonella DNA.  Harvested Bartonella were resuspended in 300 µL 
of sterile PBS, pH 7.4.  To this mixture, 30 µL of 10% Sodium dodecyl sulfate (SDS) and 3 
µL of Proteinase K (10mg/ml) was added.  The mixture was then incubated at 55°C for 2 
hours while shaking at 600 rpm.  The Bartonella DNA was subsequently extracted three 
times with a 25:24:1 mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim). 
After each extraction the phases were separated by centrifugation at 14,000xg at 4°C.  The 
DNA in the aqueous phase was precipitated with 1/10 volume of 3M sodium acetate (pH 4.8) 
and 3 volumes of ice-cold 100% ethanol.  This mixture was then incubated overnight at -
80°C.  The mixture was centrifuged at 14,000xg for 15 minutes at 4°C then decanted and 
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allowed to air dry.  The precipitated DNA was dissolved in the appropriate volume of Tris-
EDTA pH 8.0 (TE) buffer, containing RNase A (10mg/ml) and stored at 4°C until needed. 
Design of Consensus Primers and virB Gene Sequencing via PCR.  Sequences of A. 
tumefaciens, B. henselae, and other members of the alpha-2 proteobacterium family were 
compiled and placed into a Clustal alignment for each respective virB gene.  From these 
analyses, regions of similar sequence were identified and used to make PCR primers (Table 
1.1).  PCR products were purified on Qiagen columns according to the manufacturer’s 
instructions and sequenced using capillary sequencing techniques (ABI).  These products 
were then analyzed using Vector NTI Sequence Analysis software (Invitrogen) for restriction 
sites; open reading frames and the formation of any contiguous regions of DNA.  The Vector 
NTI software was then used to prepare new Bartonella-specific PCR primers which were 
used in a low-stringency cycle of PCR.  This process continued until entire open reading 
frames were identified.  All completed sequences were submitted to GenBank. 
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Table 1.1 – Consensus and Bartonella-specific virB Operon Primers.   
A.  Consensus PCR primers were prepared by Clustal alignment of DNA sequences from 
alpha-2-proteobacteria bacteria known to contain homologue virB operon genes.  B.  
Bartonella-specific primers were generated using Vector NTI (Invitrogen) software from 
DNA sequence data garnered from the use of consensus primers on B. quintana and B. 
clarridgeiae. 
 
A.  Consensus Primers 
Locus Primer Name Primer Sequence (5’ – 3’) 
virB2-homologue CVirB2Fwd 
CVirB2Rvc 
GCTGTTGCGCGTGATATCGG 
CGCCAAATACGATGGCAACG 
virB3-homologue CVirB3Fwd 
CVirB3Rvc 
AGCTTATGGACGACGATCCC 
GTGCAGCCAAGGGGGATATG 
virB4-homologue CVirB4Fwd 
CVirB4Rvc 
GCACATCAGCCAGCATGTCG 
AAAACGGCGCCCATCGATAA 
virB6-homologue CVirB6Fwd 
CVirB6Rvc 
TTAGTTTTCTGTTGCGTTTAACGGC 
ATTGCCACCAATCGGACGAT 
virB8-homologue CVirB8Fwd 
CVirB8Rvc 
CCTTGGCTGTTGCGGTGGTT 
CGTGACATCAAAACCAAGCG 
virB9-homologue CVirB9Fwd 
CVirB9Rvc 
GCACTCTTCATTGCTTGCAT 
ATACAAAGCACGTCGTTGCC 
virB10-homologue CVirB10Fwd 
CVirB10Rvc 
TCAACGGGATGAAAACCGGA 
AAGCGGGTGATGAGCGTCCT 
virB11-homologue CVirB11Fwd 
CVirB11Rvc 
GTGAACTTCCATCTGGAACC 
ATCGATCACCAGATACAGCA 
 
B.  Bartonella-specific virB Primers 
Locus Primer Name Primer Sequence (5’ – 3’) 
virB2-homologue VirB2Fwd 
VirB2Rvc 
ATGACAGAGACTATATCCAGAAATATT 
TGATGAGCCCATTAATGTACTAACA 
virB3-homologue VirB3Fwd 
VirB3Rvc 
ATGAATGAAGATACTCTTTTTCTTG 
TAATTGACATCTGTTCAGTTCCTTA 
virB4-homologue VirB4Fwd 
VirB4Rvc 
ATGTCAATTATGAAACGGGAGTCTT 
TTGATTTTCTCTCCTTTGGTGAAAT 
17kDa Antigen 17kdaFwd 
17kdaRvc 
ATGGCTGCCTATATTTCACCAAAGG 
AAGTCGGACATCAGAATTCCCAAGT 
virB6-homologue VirB6Fwd 
VirB6Rvc 
ATGAATACGACAGTGAGTGGGTTGTCT 
AAATCGACCACGGCCTCTATCTCCA 
15kDa Antigen 15kdaFwd 
15kdaRvc 
ATGAAACGAAAAATAACTTTTTTTA 
CTTTTCACGAGCGATTTCCGTATTT 
virB8-homologue VirB8Fwd 
VirB8Rvc 
ATGAAAAATTCTCTGATCAAAATACGG 
TTTTATCACCTCTGGATCAGATCGAT 
virB9-homologue VirB9Fwd 
VirB9Rvc 
ATGATGAGATTTTCAAAAATAATCTTT 
TCCTTCATGACCATTTCCTATGTTC 
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Locus (con’t) Primer Name Primer Sequence (5’ – 3’) 
virB10-homologue VirB10Fwd 
VirB10Rvc 
ATGGTCATGAAGGATGAAATGGATGAA 
TTTCAAAATCACCGCAGAATTTTTA 
virB11-homologue VirB11Fwd 
VirB11Rvc 
ATGAACAAAACCTGCATAAAT 
TAAGCTCCCGACAACTAAATC 
 
Design and Synthesis of virB probes for Phage Library Construction and Southern Blot 
Analysis.  Using Bartonella-specific sequence data, probes were prepared as follows for % 
phage library construction and Southern blot analysis.  A PCR amplification was carried out 
using the PCR DIG Probe Synthesis kit (Roche) to produce digoxigenin (DIG)-labeled PCR 
products.  These products were analyzed on a 1% agarose gel to verify that they were of the 
predicted size.  Following verification, probes were denatured by heating at 95°C for 10 
minutes and were then added to 45 ml of hybridization solution (Roche).  The probes were 
stored at -20°C until needed. 
Southern Blot Analysis of the B. bacilliformis Genome.   
Digestion of Bartonella Genomic DNA.  Genomic DNA samples from B. quintana, B. 
clarridgeiae and B. bacilliformis were probed using previously prepared virB gene-specific 
DIG-labeled probes as follows (Southern, 1975).  Briefly, previously purified genomic DNA 
was incubated with EcoRI  at 37°C for approximately 16 hours in an Eppendorf variable 
shaker.  To the digested genomic DNA, 10µL of 3M sodium acetate and 1ml of ice-cold 
100% ethanol were added, and the samples were incubated for one hour at -80°C.  The 
precipitated DNA was then collected by centrifugation at 14,000xg for 20 minutes at room 
temperature.  The supernatant was decanted and the digested genomic DNA was dried at 
room temperature.  The digestion products were separated by 0.8% agarose gel 
electrophoresis.  The agarose gel was then soaked in 0.25N HCl for 10 minutes and 
subsequently transferred to 0.5M NaOH and 1.5M NaCl for soaking twice (15 minutes per 
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soak).  An apparatus was then set up to allow the transfer of DNA from the agarose gel to a 
nitrocellulose membrane that had been rinsed with deionized water.  This transfer was 
completed by placement in a reservoir containing of 20x Standard Saline Citrate (SSC) 
overnight.  The nitrocellulose membrane containing the DNA was rinsed in 5X SSC for five 
minutes, then UV cross-linked (FisherBiotech) using “Optimal cross-link” settings with the 
cross-linking step being repeated three times.  Cross-linked membranes were stored in 
airtight bags at -80°C until needed. 
Hybridization and Development of Southern Blot Membranes.  Prepared nitrocellulose 
membranes were thawed at room temperature as needed, and pre-hybridized with DIG Easy 
Hyb solution (Roche) at 42°C for two hours with rotation.  The appropriate probe (Table 1.2) 
was removed from storage at -20°C, thawed in a hybridization oven at 80°C for one hour and 
then denatured at 99°C for 20 minutes before use.  After decanting the DIG Easy Hyb 
solution, the probe was added to the nitrocellulose membrane and the membrane was 
hybridized at 42°C overnight with rotation.  After incubation overnight, the probe solution 
was removed and stored at -20°C while the membrane was washed twice with 2X SSC 
containing 0.1% SDS for five minutes per wash at room temperature.  The wash solution was 
decanted and the membrane was washed twice with 2X SSC containing 0.1% SDS at 60°C.  
This solution was decanted and the membrane was washed by incubating for two minutes 
with constant shaking at room temperature in the Washing Buffer (Roche) supplemented 
with 1X malic acid solution (Roche) containing 0.3% Tween-20 (Sigma).  The Wash Buffer 
was decanted and replaced with Blocking Buffer (Roche), consisting of Wash Buffer 
supplemented with 1:10 Blocking Buffer concentrate for 30 minutes with constant shaking, 
at room temperature.  The Blocking Buffer was decanted, and 100 ml of anti-DIG antibodies 
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(Roche) diluted 1:5000 in Blocking Buffer was added to membrane.  The membrane was 
incubated with the antibody mixture for one (1) hour, with shaking at room temperature.  The 
Anti-DIG antibody mixture was decanted and saved at -20°C for further use, and the 
membrane was again washed twice in Washing Buffer for 15 minutes at room temperature.  
Finally, the membrane was equilibrated in Detection Buffer (Roche), containing 0.1M Tris-
HCl, 0.1M NaCl, pH 9.5, for three minutes at room temperature.  The Detection Buffer was 
decanted and the membrane was developed using Nitro-blue tetrazolium chloride/5-bromo-4-
chloro-3’-indolyphosphate (NBT/BCIP; Roche) to visualize the banding pattern.  After the 
bands were clear, the membranes were washed with deionized H2O followed by TE buffer, 
and allowed to air dry. 
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Table 1.2 – DIG-Labeled Probes for Southern Blot Analysis.   
The following table shows the DNA primer sequences for Southern Blot probes, designed 
from B. bacilliformis, B. quintana and B. clarridgeiae DNA sequences as noted below. 
 
Bartonella 
Species 
Probe Target Primer 
Name 
Primer Sequence (5’ – 3’) 
B. 
bacilliformis 
18.5kDa 
Antigen 
B. 
bacilliformis-
specific 
Control 
SB18.5 Fwd 
SB18.5 Rvc 
CTATGCCCTTAAGCAGTTAACAC 
AATGCAGAGTATAGTTATGGG 
 
B. 
clarridgeiae 
Internal 
Fragment of 
virB4 
SBV4IntFwd 
SBV4IntRvc 
CTCTTCGTTTCACTGCTGTGGAATC 
CCAGCTTGTGTTTTCAGGAATGCCAC  
 
B. quintana virA 
Fragment 
SBVirAFwd 
SBVirARvc 
CTTGCAGGGTGAATGTCTTGAG 
CGTAAATCAATAAAGCCGGACA 
B. quintana virB3-
homologue 
Fragment 
SBVir3Fwd 
SBVir3Rvc 
AATGAAGATACTCTTTTTCTTGCC  
TGACATCTGTTCAGTTCCTTATAA 
B. quintana virB6-
homologue 
Fragment 
SBVir6Fwd 
SBVir6Rvc 
TGCAAAATCAGAAACAGCGGAATCTA   
TATAATCAAAAACATTTGCGCTAGCG 
B. quintana virB8-
homologue 
Fragment 
SBVir8Fwd 
SBVir8Rvc 
ATGAAAAATTCTCTGATCAAAA 
TTTTATCACCTCTGGATCAGAT 
 
B. quintana virB11-
homologue 
Fragment 
SBVir11Fwd 
SBVir11Rvc 
TGTTTTAACAAAACTTGAACCCATC 
TTCAATGGTGATAATACGCTCATTA 
 
Plaque hybridization of a B. bacilliformis Genomic DNA Library 
 
Construction of a B. bacilliformis %  Phage Library.  A genomic DNA % phage library was 
created by digesting B. bacilliformis DNA with TSP5091 (New England Biolab).  Briefly, 
purified B. bacilliformis genomic DNA was digested for 22 minutes with TSP5091 (1:1 
diluted with Reaction buffer (10mM Bis-Tris-Propane HCl, 10mM MgCl2, 1mM 
Dithiothreitol, pH 7.0)) at 65°C until the reaction was stopped by the addition of 25:24:1 
mixture of phenol:chloroform:isoamyl alcohol (Boehringer Mannheim).   The digested 
genomic DNA was then extracted three times with phenol:chloroform:isoamyl alcohol 
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(Boehringer Mannheim); after each extraction the phases were separated by centrifugation of 
14,000xg at 4°C.  The DNA in the aqueous phase was precipitated by the addition of 1/10 
volume of 3M sodium acetate (pH 4.8) and three volumes of ice-cold 100% ethanol.  This 
mixture was then incubated overnight at -80°C.  The mixture was centrifuged at 14,000xg for 
15 minutes at 4°C, then decanted and allowed to air dry.  The precipitated DNA was 
dissolved in the appropriate volume of TE buffer containing RNase A (10mg/ml), and stored 
at 4°C until needed.  Digested genomic DNA was ligated into EcoRI-digested Lambda ZapII 
arms (Stratagene) according to the manufacturer’s instructions and the reaction mixture was 
incubated overnight at 4°C. The ligated genomic DNA library was then packaged into the % 
phage using the Stratagene Gigapack II gold packaging kit per the manufacturer’s 
instructions. Briefly, the ligated genomic DNA library was incubated with XL-1 Blue MRF’ 
cells at an MOI of 10:1 in the presence of the ExAssist phage at 37°C for 15 minutes.  Luria-
Bertani (LB) Broth was added to the reaction mixture and allowed to incubate three hours at 
37°C.  The cells were then allowed to lyse by heating at 65°C.  SOLR cells were added to 
titer the excised plasmids and were subsequently grown on LB-ampicillin overnight at 37°C.  
The packaged library products were incubated with XL-1 Blue MRF’ cells infected for 15 
minutes and plated onto NZY agar plates, then incubated overnight at 37°C.  SM buffer 
(0.1M NaCl, 0.05M MgSO4, 0.001% (w/v) gelatin) was used to cover each plate.  Following 
overnight incubation at 4°C, the contents were pooled, chloroform was added to give a 5% 
solution, and the sample was centrifuged at 5000xg for 10 minutes.  After centrifugation, the 
% phage library was divided into 1.5 ml aliquots.  Samples were stored at -70°C for future 
use. 
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B. bacilliformis-Phage Library Analysis using Bartonella-specific virB probes.  The % 
phage library was screened for B. bacilliformis genomic DNA and specifically for the 
presence of various genes of the virB operon.  DIG- labeled probes were reacted against the 
library contents as follows.  Briefly, XL-1 MRF’ cells were incubated with 5-10µL of % 
phage library for 15 minutes.  This cell/phage mix was plated onto NZY plates and incubated 
at 37°C overnight.  The plates were transferred to plaque hybridization membranes (Perkin 
Elmer) and washed with denaturation, neutralization and SSC solutions (Roche).  The 
membranes were UV cross-linked and pre-hybridized in EZ Hyb (Roche) solution at 42°C 
for two hours.  The membranes were probed overnight with previously prepared virB gene-
specific DIG-labeled probes.  The membranes were washed and blocked in a 5% skim milk 
solution overnight at 4°C.  Goat anti-DIG alkaline phosphatase- (AP) labeled antibodies were 
added and the membranes were incubated at room temperature.  Then the membranes were 
washed again, BCIP-NBT substrate was added, and the membranes were placed in the dark 
for color development.  Plaques that were positive were cored and placed into 1 ml of SM 
buffer containing chloroform and stored at 4°C, until needed.  SOLR cells were used to 
excise the phagemids, which were then allowed to circularize.  Plasmids were subsequently 
isolated from the SOLR cells according to the manufacture’s instructions for plasmid 
purification (Omega Bio-Tek).  These plasmids were sequenced using T3/T7 primers for the 
initial screening.  The DNA sequences were entered into Vector NTI (Invitrogen) and 
analyzed for open reading frames and the formation of contigs.  BLAST searches were also 
done to find homologous regions/genes.   
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GenomeWalking Sequence Analysis.  GenomeWalking was used with both B. quintana and 
B. bacilliformis genomic DNA in order to fill in any sequence gaps.  After preparation of 
Bartonella genomic DNA, a GenomeWalking DNA library was prepared per the 
manufacturers instructions (CloneTech) using the supplied EcoRV, DraI, PvuII and SspI 
restriction enzymes.  Briefly, Bartonella genomic DNA was digested at 37°C for two hours 
in separate reaction mixtures for each restriction enzyme, then vortexed briefly and incubated 
at 37°C overnight.   The mixture was purified using phenol (Sigma) followed by 
centrifugation at 14,000xg at room temperature to separate the aqueous layer.  The top, 
aqueous, layer was removed and chloroform (Sigma) was added followed by another 
14,000xg centrifugation at room temperature.  This aqueous layer was then removed and 
incubated with 95% ethanol and 3M sodium acetate (pH4.5), followed by centrifugation at 
14,000xg for 15 minutes at 4°C.  The supernatant was decanted and 80% ethanol was added 
followed by 14,000xg centrifugation for 10 minutes at room temperature.  The supernatant 
was again decanted and the digested DNA was dried, then dissolved in 20 µl of TE buffer, all 
per manufacturer’s instructions (CloneTech). The GenomeWalk libraries were kept at 4°C 
until needed.  In order to screen the libraries for specific regions of unknown sequence, 
previously sequenced virB regions were used to design GenomeWalk-specific virB primers 
according to the manufacturer’s instructions.  After the completion of the primary PCR 
GenomeWalk cycle using Gene Specific Primer 1 was complete (Table 1.3), the products 
were analyzed for expected base pair size using 1% agarose gel electrophoresis, and samples 
corresponding to the predicted size were subjected to secondary PCR GenomeWalk PCR 
cycles with the previously designed Gene Specific Primer 2.  The secondary 
GenomeWalking products were again analyzed using a 1% agarose gel and those of the 
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predicted size were sequenced. The DNA sequences were entered into Vector NTI 
(Invitrogen) and analyzed for open reading frames and the formation of contigs.  BLAST 
searches were also done to find homologous regions/genes. 
 
Table 1.3 – Gene Specific Primers for GenomeWalk Analysis of B. bacilliformis.   
GenomeWalker (Clonetech) primers which were used to scan the B. bacilliformis genome for 
specific virB operon homologues. 
 
Locus Primer Name Primer Sequence 5’ – 3’ 
virB4-
homologue 
GWVirB4Fwd 
GWVirB4Rvc 
TGTCAATTATGAAACGGGAGTCTTTACCTG 
GGTCATGTCATAACCAATGAATTGTGAGTC 
virB6-
homologue 
GWVirB6Fwd 
GWVirB6Rvc 
ATGAATACGACAGTGAGTGGGTTGTC 
CCACTATCGAGATAACGACAACAGGT 
virB8-
homologue 
GWVirB8Fwd 
GWVirB8Rvc 
ATTCTCTGATCAAAATACGGAAATCGCTCG 
GGATCGAGACCCAATGGGAAATATTTTCTT 
virB10-
homologue 
GWVirB10Fwd 
GWVirB10Rvc 
ATGATCGCAGTACAATAAAAGACGGTC 
GATACAAGAAGCGCAGATCCAATCCG 
virB11-
homologue 
GWVirB11Fwd 
GWVirB11Rvc 
ACCTGCATAAATTGAGCAATGAAACTGTCG 
TTGGACCAACAGAGGCTAAGCCTTGA 
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Results 
 
Isolation of the B. quintana virB Operon.  
 Since the original demonstration of a virB operon in B. henselae, there have been 
reports of virB homologues in at least three other Bartonella species (Padmalayam et al., 
2000a).  This raises the possibility that virB-encoded secretion systems are an integral part of 
the Bartonella molecular repertoire. 
In order to search for the virB operon in other Bartonella species, we designed 
consensus primers for gene amplification using sequences from other !-2-proteobacteria, 
such as A. tumefaciens, as a template.  Initially, the virB4 gene was selected for 
amplification, as it is the most conserved of the virB genes.  Plaque hybridizations on a newly 
created DraI-generated B. quintana phage library, prepared in our laboratory, were conducted 
using a virB4 probe created from the B. henselae virB4 gene.  This approach proved 
unsuccessful, however, and the GenomeWalking protocol was subsequently employed using 
newly prepared GenomeWalk-specific primers for the virB4 gene.  This protocol gave a 
single 1550 bp product from the B. quintana library.  Another primer for the B. quintana 
virB4 sequence (GSP2) was prepared using the B. quintana sequence obtained from the first 
GenomeWalk and yielded a 2000 bp product from a second GenomeWalk.  BLAST results 
indicated that the gene product from this round of GenomeWalking corresponded to the 
middle region of the B. henselae virB4 gene, as expected.  Unfortunately, due to the A-T rich 
nature of the B. quintana genome no further GenomeWalk primers could be designed which 
gave definitive products.   
Plaque hybridizations were also used to search for homologues to the virB9, virB10 
and virB11 genes.  Initially, a screening for virB11 using a B. henselae-derived probe gave 
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rise to a plasmid, designated 2A2, that contained B. quintana sequences with partial 
homology to B. henselae virB11.  Further GenomeWalking using a combination of B. 
henselae-based virB and T3/T7 primers to amplify 2A2 plasmid sequences revealed the 
presence of virB9, virB10 and the remainder of the virB11.   The remaining virB operon 
genes from B. quintana were determined using overlapping PCR reactions based on the 
sequences obtained from the above plaque hybridizations.  The known sequence for the 
17kDa antigen gene was used to design Bartonella-specific primers for both upstream and 
downstream PCR products, which allowed for the sequencing of the virB2, virB3, virB4, 
virB6, 15kDa antigen gene, virB8 and virB9 homologues to be completed.  After each 
sequencing round, the gene products were assembled into contigs and compared with known 
virB operon sequences from other species to ensure no sequence gaps were remaining.  The 
sequence was verified with the preparation of B. quintana-specific virB primers and the 
sequences were placed in GenBank  (Accession Number:  AY216720). 
Sequencing of the virB operon gene homologues from B. clarridgeiae was 
accomplished in much the same manner, with a higher level of success using Bartonella-
specific virB operon primers generated from previously sequenced virB genes from B. 
henselae and B. quintana.  Initially, the virB4 gene was sequenced using Bartonella-specific 
consensus primers.  This approach yielded a 1250-bp product, with BLAST analysis 
suggesting that the gene product corresponded to the distal portion of the B. clarridgeiae 
virB4 gene.  Bartonella-specific primers based on BLAST homologies for sequencing the 
virB2, virB3 and missing portions of the virB4 homologies were then used for PCR 
amplification in order to give rise to the corresponding B. clarridgeiae virB genes. 
Amplification of the virB11 and virB10 genes was accomplished using Bartonella-specific 
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consensus primers designed from information obtained after another round of PCR 
amplifications.  Finally, the remaining virB gene homologues, the 15kDa Antigen, VirB6, 
VirB8 and VirB9, were sequenced using a series of Bartonella-specific consensus primers 
initially designed from the published B. clarridgeiae 17kDa antigen sequence (Accession 
number: AF195506).  These primers were designed to target 1000-bp PCR products 
extending from the 17kDa antigen homologue upstream to the middle of the virB10 gene.  
These sequences were then verified by the preparation of B. clarridgeiae-specific primers to 
produce PCR primers of 1000-1250 bp which were then subjected to BLAST and AlignX 
(Invitrogen) analysis for accuracy. 
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Physical Arrangement of the virB Operon in B. quintana and B. clarridgeiae.    
Sequence analysis using Vector NTI (Invitrogen) was conducted in order to identify 
the open reading frames of the newly determined virB homologues from B. quintana and B. 
clarridgeiae, and to compare these open reading frames to those of B. henselae and B. 
tribocorum (Figure 1.1; a-d).  In all cases analyzed the gene organization within the virB 
operon was identical.  The physical arrangement indicates the first gene to be virB2, the 
smallest gene at 312-366 bp, followed by virB3 and largest gene of the operon virB4, at 
2361-3807 bp.  The location of the 17kDa antigen and 15kDa antigens remains constant in all 
Bartonella species examined, in every case flanking the ORF of the virB6 homologue.  
Similarly, each Bartonella contains a virB9, virB10 and virB11 homologues downstream of 
the virB8 homologue.  One feature that is unique to the B. quintana virB operon is the 
existence of two potential start codons for the virB8 gene, which would potentially generate 
both a long-form and a short-form version of the gene product.  The extra start codon is not 
present in any of the other Bartonella species that have been characterized. 
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c. 
 
d. 
 
 
Figure 1.1 – Physical Arrangement of the virB Operon in Bartonella Species.  
Vector NTI (Invitrogen) was used to analyze the open reading frames of the sequenced virB 
operon homologues in B. henselae (a), B. tribocorum (b), B. quintana (c) and B. clarridgeiae.  
Arrows indicate the direction of the designated open reading frames. 
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Homology analysis of the Bartonella species virB operons to the A. tumefaciens operon.  
  DNA-based alignments were created using AlignX (Invitrogen) to determine the 
degree of sequence identity between various Bartonella and A. tumefaciens virB-homologues 
(Table 1.4).  Identity levels between the Bartonella species virB genes and those of A. 
tumefaciens range from 34 to 50%.  The highest identify values are seen in the Bartonella 
virB4 genes, with an average of 49.5% identity to the A. tumefaciens homologue, while the 
lowest identity, averaging 35%, is observed with the virB2 gene. 
Table 1.4 – Comparison of virB Operon Sequences between A. tumefaciens and various 
Bartonella-species.   
Using the AlignX program (Invitrogen), DNA-based alignments were created to determine 
the degree of sequence identity between various Bartonella and A. tumefaciens virB-
homologues (Seubert et al., 2003a).  Alignment was conducted on virB gene open reading 
frames corresponding to each virB gene homologue (Padmalayam et al., 2000a; Schulein et 
al., 2002). 
 
 % Identity to A. tumefaciens virB genes 
 B. henselae B. quintana B. clarridgeiae B. tribocorum 
virB2 34 34 35 36 
virB3 44 44 43 41 
virB4 50 49 49 49 
17kDa N/A N/A N/A N/A 
virB6 40 41 40 38 
15kDa N/A N/A N/A N/A 
virB8 38 42 42 43 
virB9 41 41 40 41 
virB10 44 43 42 42 
virB11 48 43 44 47 
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VirB operon gene homology among Bartonella species.   
DNA-based alignments were created using the AlignX program (Invitrogen) to 
determine the degree of sequence identity between virB operons of each of the Bartonella 
species analyzed (Table 1.5).  A comparison of virB genes from B. quintana and B. 
tribocorum with the counterparts in B. henselae suggests a high level of homology. 
Interestingly, B. clarridgeiae shows a lower overall level sequence identity for most of the 
virB genes, with the exception of virB3, the 17kDa antigen and virB8. 
Table 1.5 – Comparison of VirB Operon Sequences between Bartonella species.   
Using the AlignX program (Invitrogen), DNA-based alignments were created to determine 
the degree of sequence identity between B. henselae virB operon open reading frames and 
those of other Bartonella species. 
 
 % Homology to B. henselae 
 B. quintana B. clarridgeiae B. tribocorum 
virB2 84 42 79 
virB3 87 82 84 
virB4 91 54 86 
17kDa 87 75 65* 
virB6 90 63 79 
15kDa 52 49 48 
virB8 78 75 78 
virB9 86 37 85 
virB10 72 52 81 
virB11 80 72 83 
* the 17kDa antigen was renamed VirB5 (CA51480.1) in B. tribocorum 
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Comparison of VirB protein sequences of B. quintana and B. clarridgeiae with those of 
other alpha-2 proteobacteria.   
An AlignX-based (Invitrogen) virB protein analysis was completed on B. quintana 
(Table 1.6) and B. clarridgeiae (Table 1.7) VirB-homologue proteins in order to determine 
their relative identity and similarity.  As Table 1.6 shows, there is a wide variation in the 
levels of amino acid sequence identity between the B. quintana VirB proteins and those of B. 
henselae, ranging from the low of 13.5% for VirB9 to a high of 88.7% for VirB3.  Overall, 
the level of identity between B. quintana and B. henselae VirB sequences averages 70%.  
When B. quintana virB protein sequences were compared to those of A. tumefaciens, the 
level of identity was significantly less, ranging from 6.7% for the 15kDa antigen to 35% for 
VirB4 and averaging approximately 21%.  Analysis between B. quintana and B. clarridgeiae 
indicates an average identity of 57%, with the lowest identity between the VirB11 protein at 
10.5% and the highest identity with VirB8 at 92%.  A similar degree of identity was observed 
when VirB comparisons were made between B. quintana and S. meliloti, where the average 
identity was 43%.  In this case, the highest level of amino acid identity between the two 
species was observed with VirB4 (60%) and the lowest was with VirB10 (33%).  Table 1.7 
shows a comparison of B. clarridgeiae VirB-homologue proteins with those of other alpha-2 
proteobacteria.  The overall variation between the VirB homologues of B. clarridgeiae to B. 
henselae ranges from 11.7% (for VirB11) to 97% (for VirB6), while the overall average of 
identity between the B. clarridgeiae and B. henselae virB operons is approximately 59%.  
When the sequences of B. clarridgeiae and A. tumefaciens VirB proteins are compared, there 
is an overall identity average of 16.6%, with the VirB10 homologues exhibiting the lowest 
identity level (9.5%), and the VirB2 homologue exhibiting the highest identity level (27%).  
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Interestingly, B. clarridgeiae and S. meliloti VirB operons show a lowest identity with 
virB11 (11%), and the highest identity with the VirB8 (46%).   Overall, the average identity 
of these VirB operons averages approximately 57%.  Finally, Table 1.8 shows the similarity 
between the amino acid sequences of B. henselae, B. clarridgeiae, B. quintana and S. meliloti 
with A. tumefaciens VirB operon proteins.  Our results indicate that while overall S. meliloti 
is most similar to A. tumefaciens, with 41% average similarity in analysis of VirB proteins; 
the Bartonella VirB proteins have a 33.9% similarity with A. tumefaciens across the proteins 
examined.  Our data shows that B. henselae is, of the Bartonella species, most similar to A. 
tumefaciens with 37%, B. quintana 36.1% and B. clarridgeiae the least similar at 28.8% 
average similarity of VirB proteins.  Given the protein identity and DNA sequence homology 
above it is not surprising that these Bartonella species overall very similar to A. tumefaciens 
(34%), while S. meliloti is 41.3% similar to A. tumefaciens. Among the Bartonella VirB 
proteins examined, VirB4 shows the highest level of similarity between all species at 49%, 
while the 15kDa antigen homologue shows the lowest similarity, without the inclusion of S. 
meliloti, at 16%.  
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Table 1.6 - Comparison of VirB Protein Sequences of B. quintana and B. henselae, B. 
clarridgeiae, A. tumefaciens and Sinorhizobium meliloti.   
Amino acid sequences of each of the above VirB homologues were compared to those of B. 
quintana using the AlignX program (Invitrogen).  Open Reading Frame (ORF) analysis 
utilized Vector NTI (Invitrogen) and was verified by BLAST analysis. 
 
 % Identity to B. quintana 
B. 
quintana 
B. 
henselae 
B. 
clarridgeiae 
A. tumefaciens S. meliloti 
virB2 80.4 90.7 27.3 38.5 
virB3 88.7 90.5 26.4 36.8 
virB4 88.7 34.6 35.5 59.6 
17kDa 68.3 66.5 N/A N/A 
virB6 87.9 89.4 16.0 28.3 
15kDa 56.8 14.0 6.7 N/A 
virB8 78.6 92.1 21.5 49.8 
virB9 13.5 49.4 9.7 50.5 
virB10 54.8 33.6 18.9 33.2 
virB11 81.5 10.5 32.9 50.0 
 
Table 1.7 - Comparison of VirB Proteins of B. clarridgeiae and B. henselae, B. quintana, A. 
tumefaciens and Sinorhizobium meliloti.   
Amino acid sequences of each of the above VirB operon homologues were compared to 
those of B. clarridgeiae using the AlignX program (Invitrogen).  Open Reading Frame 
(ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis. 
 
 % Identity to B. clarridgeiae 
B. 
clarridgeiae 
B. 
henselae 
B. quintana A. tumefaciens S. meliloti 
virB2 89.7 90.7 27.3 38.9 
virB3 85.4 90.5 26.9 34.9 
virB4 35.6 34.6 16.5 22.8 
17kDa 87.2 66.5 N/A N/A 
virB6 96.9 89.4 17.3 29.9 
15kDa 8.7 14.0 9.6 N/A 
virB8 72.4 92.1 19.8 45.9 
virB9 61.3 49.4 12.5 33.0 
virB10 39.9 33.6 9.5 18.8 
virB11 11.7 10.5 10.1 11.3 
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Table 1.8 - Comparison of VirB Protein Similarities of A. tumefaciens and B. henselae, B. 
clarridgeiae, B. quintana and Sinorhizobium meliloti.   
Amino acid sequences of each of the above VirB operon homologues were compared for 
similarity to those of A. tumefaciens using the AlignX program (Invitrogen).  Open Reading 
Frame (ORF) analysis utilized Vector NTI (Invitrogen) and was verified by BLAST analysis. 
 
  % Similarity to A. tumefaciens 
A. tumefaciens B. henselae B. clarridgeiae B. quintana S. meliloti 
virB2 40.5 38.8 40.5 43.0 
virB3 41.7 43.5 43.6 39.1 
virB4 56.2 29.3 52.8 57.3 
17kDa N/A N/A N/A N/A 
virB6 34.3 34.3 32.4 37.7 
15kDa 13.1 17.3 18.1 N/A 
virB8 36.6 37.0 40.1 40.5 
virB9 22.2 21.0 20.3 20.5 
virB10 37.7 16.6 30.0 41.3 
virB11 50.4 21.3 47.8 50.7 
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Search for a virB Operon in the B. bacilliformis genome.   
Both a GenomeWalk and a % Phage Library were prepared from isolated B. 
bacilliformis genomic DNA using the procedures that had successfully identified the virB 
genes in B. quintana and B. clarridgeiae.  Initially, the GenomeWalk library was screened 
using PCR primers prepared from consensus sequences derived from B. henselae, B. 
quintana and B. clarridgeiae genes in order to ensure the most Bartonella-specific 
GenomeWalking primers possible.  These GenomeWalk reactions did not yield any virB-
specific amplified products.  In those cases where PCR products were observed, subsequent 
sequence analysis revealed partial homology to genes that are unrelated to the virB operon 
(Table 1.9).  Further screening to verify the presence or absence of the virB operon in B. 
bacilliformis was conducted by carrying out a series of plaque hybridizations with the B. 
bacilliformis % Phage Library.  While the probes used were successful in screening both the 
B. quintana and B. clarridgeiae % phage libraries, once again no virB-specific cloned product 
was identified. 
Table 1.9 – Putative products identified from probes of the B. bacilliformis genome by virB 
gene-specific probes.   
The B. bacilliformis genome was probed using Bartonella-based virB-specific PCR primers.  
The sequence data obtained were then added to a Vector NTI (Invitrogen) database and 
BLAST analysis was used to identify homologues for each gene sequence.  The product of 
the gene exhibiting the highest homology is given. 
 
Probe Putative Product 
virA Methyltransferase, SocE 
virB2   
virB3 Cytosolic Protein 
virB4 Lysostaphin 
17kDa   
virB6 alanyl TRNA synthetase 
15kDa   
virB8 
Possible Flagellar 
Structural Genes 
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Southern hybridization of virB-specific probes to B. bacilliformis DNA.   
The inability to recover a virB operon homologue from B. bacilliformis DNA could 
be due to the lack of this operon in this species.  Alternatively, all or part of the virB operon 
sequences could be present, but these sequences might be organized in a way that precludes 
their identification.  To address this possibility, primers used in the PCR reaction were 
labeled with DIG and used as probes for Southern hybridization against enzymatically 
digested DNA from B. quintana, B. clarridgeiae, and B. bacilliformis.  Probing with the 
sequences from the 18.5 kDa antigen and virA, two genes known to be in B. bacilliformis, B. 
quintana, and B. clarridgeiae, clearly shows the presence of a single strong banding pattern, 
indicating the presence of those genes in the genomic DNA of each selected Bartonella 
species (Figure 1.2).  Screening of B. quintana and B. clarridgeiae DNA with probes derived 
from virB homologues also reveals hybridizing fragments, including characteristic banding 
patterns for homologues of virB4 and virB6, based on expected gene product sizes, and 
multiple banding patterns with the screening of virB3, virB9 and virB11 derived probes.  In 
no case, however, was positive hybridization observed with B. bacilliformis DNA (Table 
1.9).  From these data we conclude either that the genome of B. bacilliformis lacks an intact 
virB operon, or that any B. bacilliformis virB homologues present in the genome are so 
distinct from those of other Bartonella species that they do not cross-hybridize under any of 
the conditions tested.   
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Southern Blot Analysis in Search of a virB Operon in B. bacilliformis. 
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Figure 1.2 – Hybridization of virB DNA probes to Bartonella Genomic DNA. 
Southern blot analysis was carried out on EcoRI-digested Bartonella genomic DNA probed 
with DIG-labeled DNA probes from various virB genes.  Each membrane lane is as follows:  
1) DNA Marker, 2) B. bacilliformis, 3) B. quintana and 4) B. clarridgeiae digested DNA.  
Panel A, the derivation of the DNA probes is indicated at the bottom of each gel. 
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Table 1.9 – Hybridization of virB Operon Fragments to Bartonella Genomic DNA 
Southern blot analysis was conducted using probes from the designated Bartonella species 
after digestion of genomic DNA digestion by EcoRI, as indicated in Figure 1.2. 
 
Probe 
 
Specificity 
 
B. quintana 
 
B. clarridgeiae 
 
B. bacilliformis 
 
18.5kDa 
Antigen (B. 
bacilliformis 
Ctrl) 
 
B. 
bacilliformis 
 
Negative 
 
Negative 
 
Present 
 
virA 
 
B. quintana 
 
Positive 
 
Positive 
 
Negative 
 
virB3 
 
B. quintana 
 
Multiple 
Fragments 
 
Positive 
 
Negative 
 
virB4 
Internal 
Fragment 
 
B. 
clarridgeiae 
 
Positive 
 
Positive 
 
Negative 
 
virB6 
 
B. quintana 
 
Positive 
 
Positive 
 
Negative 
 
virB9 
 
B. quintana 
 
Multiple 
Fragments 
 
Positive 
 
Negative 
 
virB11 
 
B. quintana 
 
Multiple 
Fragments 
 
Multiple Fragments 
 
Multiple Fragments 
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Discussion 
 
In this study, we attempted to isolate the virB operon from three different Bartonella 
species using a variety of methods.  We report here the successful isolation and 
characterization of the operon from B. quintana and B. clarridgeiae, two of the three species 
we analyzed.   
The virB operon was initially identified in A. tumefaciens, where it codes for a TFSS 
that allows the transfer of the Ti DNA from the bacterium into the host cells, where it causes 
the formation of gall tumors in infected plants (Chen et al., 2002; Escudero et al., 1995; 
Loubens et al., 1997).  The A. tumefaciens virB operon is composed of 11 genes that are 
under the control of a virBox regulatory element located upstream of the operon (Berger et 
al., 1994; Christie, 1997).  VirB operon homologues have been identified in two Bartonella 
species, B. henselae and B. tribocorum (Maurin et al., 1997; Padmalayam et al., 2000a; 
Schulein et al., 2002). Functions ascribed to the virB operon of B. henselae and B. 
tribocorum include bacterial uptake, host cytoskeletal rearrangement and inhibition of 
apoptosis (de Paz et al., 2005; Dehio, 1999; Schmid et al., 2004; Schulein et al., 2005; 
Seubert et al., 2003a).  In addition, the 17kDa antigen, the fourth gene in the Bartonella virB 
operons, produces a protein that shows high antigenicity and is reactive with CSD-positive 
host sera (Padmalayam et al., 2000a; Sweger et al., 2000).   Despite the information that has 
been obtained about this operon, there has not yet been convincing evidence presented for a 
direct role for virB gene products in virulence. 
 Motif analysis was conducted on each B. quintana and B. clarridgeiae VirB 
homologue in order to determine the similarity of these genes to those of other bacteria, and 
to correlate predicted protein structure with possible functions (Soni, personal 
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communication). Due to their high homology analysis for both of these Bartonella species is 
given below.  
VirB2:  The virB2 gene was originally identified in A. tumefaciens, and has now been found 
in several Bartonella species, including B. henselae and B. tribocorum.  The virB2 genes 
from all three of these bacteria show high homology to the E. coli traA gene, a 12.3-kDa 
protein.  TraA contains an N-terminal cleaved signal sequence that is responsible for the 
export of the gene product to the inner membrane where it aggregates as part of the F-pilin 
subunit. F-pilin is using by E. coli during conjugation and is polymerized at the cell surface 
to form the F-pilus (Harris et al., 1999; Paiva et al., 1992).  Though it also contains a signal 
sequence, the VirB2 homologue from B. quintana exhibits less homology than the other 
Bartonella species to the E. coli traA gene product, and instead shows 36.8% amino acid 
identity to the type IV secretion protein of S. meliloti.  The B. clarridgeiae VirB homologue 
shows a 38.9% degree of identity to the S. meliloti secretion protein.  
VirB3:  The role of the VirB3 in bacteria has not yet been fully determined.  It is known that 
the A. tumefaciens VirB3 shows homology to the E. coli traL protein, which is required for 
assembly of the F-pilus (Hapfelmeier et al., 2000; Paiva et al., 1992).  Studies with B. 
henselae suggest that VirB3 interacts with the 15kDa antigen and VirB9 homologues to 
stabilize the periplasmic proteins which support the TFSS (Shamaei-Tousi et al., 2004).  It is 
likely that the virB3 of gene products of both Bartonella species examined here function 
similarly due to their high level of sequence identity (85.4% and 90.5% for B. quintana and 
B. clarridgeaie, respectively) to the corresponding B. henselae protein.  
VirB4:  The largest open reading frame encoded by the virB operon, the virB4 gene codes for 
a protein of undetermined function.  Although the VirB4 protein produced by B. quintana, B. 
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clarridgeiae and other Bartonella species is predicted to the highly hydrophilic in our 
laboratory suggests the B. henselae VirB4 protein is not immunoreactive with human sera 
from Bartonella-infected patients (Soni, personal communication).  All of the Bartonella 
VirB4 proteins contain a NTP binding domain, but binding to NTPs has not yet been 
demonstrated. 
17kDa Antigen:  The 17kDa Antigen is a highly immunogenic protein originally identified 
by its reactivity with human anti-sera from B. henselae-infected patients (Sweger et al., 
2000).  In fact, it was the characterization of the 17kDa antigen gene and the surrounding 
region that initially led to the discovery of the B. henselae virB operon (Padmalayam et al., 
2000a).  To date, no A. tumefaciens protein homologous to the 17kDa Antigen has been 
reported, although this protein is highly conserved among most of the Bartonella species.  
Instead, A. tumefaciens contains a distinct gene upstream of virB4, termed virB5, that does 
not have a counterpart in Bartonella species.  While the function of this gene has not been 
determined, the virB5 gene product is known to interact with VirB8 and VirB10 in A. 
tumefaciens (Yuan et al., 2005).  Studies with B. henselae show that the expression of the 
17kDa Antigen is triggered by a yet to be determined host cell signal (Schmiederer et al., 
2001).  Analysis of the open reading frame suggest that the 17kDa Antigen has an N-terminal 
cleavage signal and a high antigenic index (Jameson et al., 1988), a finding that correlates 
well with its immunoreactivity to human anti-sera from infected patients. 
VirB6:  The role of VirB6 in A. tumefaciens has yet to be determined, but it is predicted to 
have six transmembrane domains and may form several complexes with other virB proteins.  
The hydrophobicity plots of the B. quintana and B. clarridgeiae virB6 gene products show 
them to be hydrophobic and to have a predicted inner membrane location. 
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15kDa Antigen:  As with the other Bartonella species that contain this gene, the B. quintana 
and B. clarridgeiae 15 kDa antigen genes do not have a counterpart in A. tumefaciens.    In A. 
tumefaciens, the product of virB7, the gene located at this position, functions as a 
ribonucleotide reductase, converting ribonucleotides into their corresponding 
deoxyribonucleotides.  Instead the B. quintana and the B. clarridgeiae 15kDa antigens show 
a low protein sequence identity to the 15kDa antigen of B. henselae of 8.7% and 14.0%, 
respectively.  The two proteins appear to be truncated versions of the B. henselae homologue, 
however.  When compared to the 489-bp B. henselae 15kDa antigen, the B. quintana open 
reading frame for this protein contains only 312 bp while the B. clarridgeiae 15kDa antigen 
is encoded by 315 bp.  This truncation affects the N-terminal portion of both examined 
Bartonella species, with the B. henselae 15kDa antigen open reading frame containing 177 
bp, corresponding to approximately 59 amino acids, that neither the B. quintana nor the B. 
clarridgeiae 15kDa antigens possess.   
VirB8, VirB9 and VirB10:  Previous work with A. tumefaciens suggests that the virB8, virB9 
and virB10-encoded proteins are able to interact with one another to form a transport pore 
complex (Das et al., 1997; Finberg et al., 1995; Krall et al., 2002).  These studies also 
suggest that this three-protein interaction is required for DNA transfer and is inner membrane 
bound.  Studies with B. henselae suggest that the interaction of these virB gene homologues 
are similar to those in A. tumefaciens.  Analysis of VirB9 interactions suggests that it binds to 
the 15kDa antigen in the periplasm and may provide a periplasmic anchor of the virB2-
encoded pilus.  Further analysis has shown that VirB8 and VirB10 interact in the inner 
membrane, aided by the ATPase activity of VirB11, and that this complex acts in an 
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anchoring capacity for the TFSS formed by the virB gene products (Shamaei-Tousi et al., 
2004).    
VirB11:  Studies with A. tumefaciens virB11 reveal that it functions as an ATPase 
(Sagulenko et al., 2001; Stephens, KM et al., 1995; Stephens, Kathryn et al., 1995).  This 
ATPase activity is due to the presence of a NTP binding site and the localization of the 
virB11 protein in the membrane is directly tied to its ATPase activity.  Moreover, work has 
suggested that the virB11 gene product is required for pilus formation and the export of Ti 
DNA substrate in A. tumefaciens (Sagulenko et al., 2001).   In Bartonella, the VirB11 
homologue is known to interact with VirB8 and VirB10 in the inner membrane and may 
form a pore for the movement of various factors through the inner membrane and out the 
virB2-encoded pilus.  This pore-forming potential is augmented by the ATPase activity of 
VirB11 which may provide energy for factor movement through the putative virB-encoded 
TFSS (Shamaei-Tousi et al., 2004). 
The DNA sequence level-homology between A. tumefaciens and Bartonella suggests 
that the role of the virB operon in Bartonella may be similar to that of A. tumefaciens, or at 
least that the structures are similar. The individual virB genes also show an almost identical 
pattern of physical arrangement among all of the Bartonella species studied.  Only B. 
quintana shows a slight differentiation with the inclusion of a long-form virB8 homologue 
which shows multiple start sites, possibly indicating the production of slightly differing 
proteins.  The long-form virB8 contains 702 bp, coding for approximately 234 amino acids, 
while the short-form virB8 contains only 610 bp, resulting in a 203 amino acid protein.  DNA 
sequence analysis of these different virB8 forms indicates the long-form contains 96 bp 
upstream of the short-form start codon, encoding for 32 amino acids.  Collectively, the first 
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seven applicable virB operon genes of Bartonella show an average 41% DNA sequence 
identity to those of A. tumefaciens.  Examination of the extent of homology among all 10 
virB homologue genes reveals that a close homology between the B. quintana and B. 
henselae operons (80.7%) with a slightly lesser degree of homology between those of B. 
quintana and B. tribocorum (76.7%).  Studies were conducted to examine the extent of 
amino acid identity between virB proteins from A. tumefaciens and their counterparts in B. 
quintana and B. clarridgeiae.  B. quintana had the highest identity (21%) while B. 
clarridgeiae is slightly lower at 16.6%.  Protein similarity between the Bartonella VirB 
proteins and A. tumefaciens indicates a lower level of similarity between the two organisms.  
Our data shows an average 34% similarity between A. tumefaciens VirB proteins and 
Bartonella species examined with B. henselae having the highest similarity (37%) and B. 
clarridgeiae the lowest (28.8%).  While this similarity may be low as compared to S. meliloti 
(41.3%), it is important to point out that the role of the VirB proteins in Bartonella has not 
yet been fully elucidated and may be functionally different from A. tumefaciens.  
Interestingly, motif and cellular localization analyses of the virB homologues found in B. 
quintana and B. clarridgeiae reveal similarities to their A. tumefaciens counterparts, 
providing further evidence for the structural similarities between the Agrobacterium and 
Bartonella virB gene products while allowing them to provide differing functions. 
Following the successful sequencing of the virB operon from both B. quintana and B. 
clarridgeiae, we attempted to isolate the virB operon from B. bacilliformis.  While little 
research has been completed regarding the virulence factors produced and secreted by B. 
bacilliformis, this bacterium has been shown to use a variety of gene products to afford itself 
invasion into host cells.  Although the mechanics of invasion by B. bacilliformis into RBCs is 
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not yet elucidated, it is known that IalA and IalB are involved in the process, as is Deformin, 
the bacterially encoded protein that is able to produce invaginations into RBC membranes 
(Coleman et al., 2001; Hendrix et al., 2003; Mitchell et al., 1995; Xu et al., 1995).  Even less 
is known about the process by which B. bacilliformis invades host tissues, such as endothelial 
and epithelial cells, or the gene products that are involved.  Attempts to correlate virulence 
with virB operon gene products have been singularly unsuccessful.  In fact, B. bacilliformis, 
arguably the most virulent of all known Bartonella species, is the only Bartonella species 
tested to date that does not react with antisera directed against the highly immunogenic 
17kDa Antigen of B. henselae that is encoded within the virB operon.  DNA sequencing 
studies completed during screening of various Bartonella species had previously suggested 
that the 17kDa antigen was not found in the B. bacilliformis genome, even with the use of 
multiple PCR primer probes (Sweger et al., 2000).   
The attempted sequencing of a virB operon from B. bacilliformis was initiated using 
Bartonella specific virB primers designed from the previously determined Bartonella virB 
operon homologue gene sequences.  Sequence analysis of the PCR products found using 
these primers (Table 1.7) revealed similarities to several genes, including those coding for 
SocE, Lysostaphin, and some putative flagellar proteins, but no VirB homologues were 
identified.   The virB-specific primers were subsequently labeled with DIG and used as 
probes for screening several Southern Blots prepared using enzymatically digested DNA 
from B. quintana, B. clarridgeiae, and B. bacilliformis. The results (summarized in Table 
1.8) reveal a strong banding pattern with probes against two genes, the 18.5kDa antigen gene 
and virA, that are known to be present in all three Bartonella species.  The use of virB-
specific probes reveals the presence of all other virB homologues in DNA from B. quintana 
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and B. clarridgeiae, including the expected banding pattern, based on gene size, for 
sequences corresponding to virB4 and virB6 and multiple banding patterns with screening 
involving virB3, virB9 and virB11 sequences.  The presence of multiple bands in the 
Southern blot screenings could be due to incomplete hybridization of the probes to the 
digested DNA targets or the presence of multiple copies of these genes in their respective 
Bartonella genomes, and could be reflective of the overall genetic similarity among these 
three Bartonella species.  When the same DIG-based probes were used to screen Southern 
blots containing B. bacilliformis DNA, no significant banding patterns were observed.  The 
only probe to give a positive hybridization result was a B. quintana-specific virB11 sequence, 
which showed the presence of multiple bands.  This result may be due to the presence of 
sequences within the B. bacilliformis genome that are similar enough to the virB11 probe to 
produce a limited level of hybridization.  While these sequences have yet to be determined, it 
is unlikely that they represent a complete virB11 gene.  
 In January 2007 the genome of B. bacilliformis KC583 was released (GenBank 
Accession CP000524.1).  Like the results of the studies presented here with B. bacilliformis 
KC584, sequence analysis of the KC583 strain did not reveal the presence of a virB operon.  
While our studies were with a different strain, it is reasonable to surmise that B. bacilliformis 
KC584 also lacks the virB operon.  Detailed analysis of accession CP000524.1 shows that 
not only is B. bacilliformis KC583 lacking the virB operon but also the tra and bep operons 
found in several other Bartonella species that are involved in apoptosis and virulence, 
respectively.  While the role of the tra operon has not been studied in Bartonella, studies 
with E. coli indicate that the tra operon codes for a TFSS that is required for some 
Escherichia species DNA conjugation (Wu et al., 1987).  Previous work with B. henselae 
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and B. quintana has shown that bepA plays a role in the vascular cell anti-apoptotic effect 
seen during infection by these Bartonella species, and is able to prevent apoptosis by 
cytotoxic T cells as well (Schmid et al., 2006).   
 Collectively, these data suggest that the virB operon is not responsible for B. 
bacilliformis-induced formation of verruga peruana in Carrion’s Disease.  We have 
demonstrated that B. quintana and B. clarridgeiae along with several other Bartonella 
species do contain a virB operon homologue.  However, our search for a corresponding 
operon in B. bacilliformis was negative. Our results, combined with the recently published 
sequence for B. bacilliformis KC583 and previous studies of the 17kDa antigen, suggest that 
B. bacilliformis does not contain a virB operon and, further, that VirB homologues are not 
involved in the B. bacilliformis-induced formation of verruga peruana in Carrion’s Disease 
(Sweger et al., 2000).  There is some anecdotal evidence suggesting that Bartonella species 
that do contain the virB operon tend to become less virulent after multiple passages, and 
investigators have speculated that this decrease in virulence might be connected to the loss of 
VirB proteins on the bacterial surface (Padmalayam, personal communication).  However,  
this is clearly not the case for B. bacilliformis.  The virulence and angiogenic properties of B. 
bacilliformis must be the result of other factor(s). 
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Chapter II – Analysis of HMEC-1 Gene Expression during B. bacilliformis Infection 
 
Introduction 
 
Bartonella bacilliformis, the causative agent of Carrion’s Disease, produces 
proliferative angiogenic lesions in human hosts during the later phase of infection.  These 
lesions, which may be due to the infiltration of B. bacilliformis into both cutaneous and 
subcutaneous epithelial tissues, show histopathology similar to those of Kaposi’s Sarcoma 
(KS) (Garcia et al., 1990; Nayler et al., 1999; Ramirez et al., 1996; Ramirez Ramirez et al., 
1996). 
Kaposi’s Sarcoma of the AIDS-associated variety presents itself on the head, neck 
and trunk of the host after co-infection with HIV and the normally benign KS-associated 
herpesvirus (KSHV) or Human Herpes Virus 8 (HHV-8).  In immunocompromised patients, 
it has been established that HIV-1 exacerbates HHV-8 pathogenesis via immunosupression, 
by the alteration of the localized tissue microenvironment and by direct interaction of viral 
proteins with host tissues (Barillari et al., 1999; Dourmishev et al., 2003; Sinkovics, 1991).  
While both viruses (HIV and HHV-8) are sexually transmitted, there is evidence to support 
an evolutionary link between HHV-8 and humans, as HHV-8 infection is often suppressed by 
immunocompetent persons. 
The similarities in histopathology seen with B. bacilliformis infection and HHV-8 
infection include the involvement at the site of the lesion of several cell types, including 
epithelial, endothelial and infiltrating inflammatory cells.  Often “spindle” cells are involved.   
Spindle cells express both endothelial and macrophage markers but their origin remains 
undefined.  During both B. bacilliformis and HHV-8 infection, localized aberrant 
neoangiogenesis is seen, with the extent of neoangiogenesis being greater with Carrion’s 
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disease than with HHV-8 infection.  During HHV-8 infection, elevated levels of many 
cytokines, including bFGF, Interleukin-1 (IL-1), IL-6, IL-8, platelet-derived growth factor 
(PDGF), tumor necrosis factor (TNF), gamma interferon (INF-#), vascular endothelial 
growth factor (VEGF) and the transcription factor HIF1 (Hypoxia-inducible Factor-1), have 
been reported (Catrina et al., 2006; Sinkovics, 1991; Sodhi et al., 2000).  In HHV-8 lesions, 
these cytokines are produced by infiltrating spindle cells.   This is believed to allow for 
continued growth and expansion of the lesion, as these cytokines are proangiogenic and 
necessary for lesion viability (Fiorelli et al., 1995; Poole et al., 2002; Yang et al., 2000).  
Interesting, while micro-environmental cytokine levels increase, there does not appear to be a 
corresponding increase in cytokine levels in the host serum, and a correlation between HHV-
8 activity and serum cytokine levels has not been successfully established (Dourmishev et 
al., 2003).   
While the cells infected with HHV-8 have been found to express a wide variety of 
markers, immunohistochemistry studies have shown that the presence of LANA-1 (latency-
associated nuclear antigen) marker cells increases during KS lesion progression; this has 
been seen in multiple KSHV infected cell types (Dourmishev et al., 2003; Poole et al., 2002).  
Studies of the histopathology of HIV-1 infected patients implicate the HIV- Tat protein as 
inducing the KS-like lesions when over expressed in a bFGF rich environment (Mallery et 
al., 2003).  Ex vivo it has been demonstrated that extracellular Tat stimulates monocyte-
derived macrophages to secrete IL-8 and Gro!, both of which are known proangiogenic 
cytokines for endothelial cells (Poole et al., 2002; Samaniego et al., 1998).  HIV-1 Tat has 
also been shown to sustain growth of KS lesions in AIDS-associated KS by direct interaction 
with host anti-apoptotic genes and activation of Akt kinase activity (Deregibus et al., 2002).  
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Tat functions are mediated by direct interaction with VEGF receptor 2 (VEGFR2) and 
insulin growth hormone (IGF) receptor 1 (Catrina et al., 2005).  Tat is also able to bind to 
several host integrins which activate angiogenic and proliferative cascades (Dourmishev et 
al., 2003; Poole et al., 2002). 
To date, research into the interaction of B. bacilliformis with host cells is limited by 
the growth requirements of the bacterium.  Garcia et al. (1990) have shown that B. 
bacilliformis is able to induce proliferation when live bacteria are co-cultured with 
endothelial cells.  Concurrent with proliferation induction, there is an increase in host tissue 
plasminogen antigen (t-PA) production.  Further studies by this group implicated a 12-14 
kDa protein produced by B. bacilliformis in endothelial cell proliferation (Garcia et al., 1990; 
Garcia et al., 1992).  Studies have also shown that the infection of endothelial cells by B. 
bacilliformis decreases cellular mobility by interfering with the host’s ability to form new 
actin-based tubules while increasing cytoskeletal rearrangement (Verma et al., 2001).  
Cerimele et al. (2003) have shown that proteins produced by B. bacilliformis interact with 
both the VEGF receptor 1 and VEGF receptor 2 and that this results in the production of 
angiopoietin-2 by epithelial cells. By using co-cultures of epithelial and endothelial cells,  the 
authors demonstrated a cell-signaling link between these cell types as the endothelial cells 
responded to the angiopoietin-2 produced by the epithelial cells (Cerimele et al., 2003).  
Finally, in a series of experiments, Minnick et al. (2003) implicated B. bacilliformis GroEL 
as a mitogen acting directly on host endothelial cells.  A mechanism for this interaction has 
yet to be established.  
In this study, we report the global gene expression analysis of B. 
bacilliformis/HMEC-1 utilizing microarray technology.  HMEC-1 cells were infected with B. 
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bacilliformis and total RNA was extracted after six and thirty-six hours post-infection.   The 
RNA was hybridized to Affymetrix HG-U133 gene chips to evaluate the host transcriptional 
response to infection.  In order to place these responses into context, the information was 
further analyzed against published HHV-8 infected endothelial cell microarray data (Wang, 
2004).  
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Materials and Methods 
 
Bacterial Growth and Culture.  B. bacilliformis KC584 was obtained from the ATCC and 
only passages 2-6 were used.  B. bacilliformis was grown on BHI agar supplemented with 
10% sheep’s blood at 25°C for 5-7 days.  Growth was monitored by visual inspection; once 
confluent colonies were observed the bacteria were harvested by the addition of 15 ml of 
sterile PBS, pH 7.4, and the plate was gently scraped using a cell scraper (Fisher).  The PBS-
B. bacilliformis mixture was removed by aspiration and added to a sterile 15 ml tube 
(Falcon). Unused B. bacilliformis was placed in a 50% PBS/50% glycerol mixture and stored 
at -80C until needed. 
Human Cell Growth and Culture.  HMEC-1 cells were obtained as a generous gift from 
Dr. Thomas Lawley of Emory University and the Centers for Disease Control and Prevention  
(Ades et al., 1992).  HMEC-1 cells from passages 19-27 were grown in a 15 ml mixture of 
50% M199 (Cambrex) supplemented with 15% FBS, 2% penicillin-streptomycin and 50% 
EGM-2 (Cambrex).  This medium was changed every 2-3 days until 70-80% confluence was 
reached.  After they became confluent, the cells were released from the flask by decanting 
the growth media and adding 15mL of CellStripper (Cellgro).  The cells were allowed to 
incubate at room temperature for 10 minutes to facilitate cell release.  The cells were then 
gently scraped with a CellScraper (Sarstedt).  The cell mixture was aspirated into a 15 ml 
tube (Falcon) and centrifuged at 700xg for 10 minutes at room temperature.  The liquid was 
decanted and the pellet was resuspended in 1mL of sterile PBS, pH 7.4.   Cells not intended 
for use immediately were resuspended in DMSO Cryoprotectant (Cellgro), stored at -80oC 
overnight, and subsequently moved to liquid nitrogen for long term storage. 
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Infection of HMEC-1 with Live B. bacilliformis.  HMEC-1 were grown in T150 flasks 
containing 30 ml of a mixture of 50% M199 supplemented with 15% FBS, 2% penicillin-
streptomycin) and 50% EGM-2 media.  Cells were incubated at 37oC in 5% CO2 and 
saturated humidity.  The cells were grown to 90% confluence, as verified by visual 
inspection.  The medium was aspirated and replaced with 30 ml of M199 with 5% FBS, and 
the HMEC-1 were allowed to incubate for 24 hours at 37°C and 5% CO2 in saturated 
humidity.  A single flask of HMEC-1 was then counted to give an approximation of the 
growth in the remaining flasks.  Live B. bacilliformis, at an MOI of 100:1 in 100 µL, was 
added to each experimental flask, while 100 µL of sterile PBS, pH 7.4, was added to each 
control flask.  At the appropriate time points (6 and 36 hours post-infection), the media were 
aspirated and the HMEC-1 cells were detached from the flasks, as described above.  The 
cells were then centrifuged at 700xg for 10 minutes at 4oC.  The cells were immediately 
processed for total RNA.  
Preparation of HMEC-1 Total RNA.  Extraction of total RNA from HMEC-1 cells was 
accomplished using the Qiagen RNeasy column (Qiagen).  Briefly, the HMEC-1 were 
harvested as stated previously, but the pellet was resuspended by flicking the tube after 
adding 600 µL of RTL buffer with "-mercaptoethanol.  The lysate was pipetted into a 
QIAShredder spin column (Qiagen) for homogenization, and centrifuged at 14,000xg for 2 
minutes.  To the spin column, 700 µL of 70% ethanol was added, and the sample was mixed 
well with a pipette.  Into an RNeasy spin column, 700 µL of the lysate-ethanol mixture was 
added and the column was centrifuged at 14,000xg for 24 seconds.  The procedure was 
repeated until the entire mixture had been processed through the spin column, while the flow-
through was discarded.  Into the spin column, 700 µL of RW1 buffer was added, the spin 
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column was again centrifuged at 14,000xg for 24 seconds, and the flow-through was again 
discarded.  Next, two rounds of 500 µL of RPE buffer was added to the spin column and 
centrifuged at 14,000xg for 24 seconds for the first round, and 2 minutes for the second 
round of centrifugation.  Finally, 30 µL of RNase-free water was added to the spin column, 
which was then placed into a fresh 1.5 ml RNase-free microcentrifuge tube (USA Scientific).  
The spin column was held at room temperature for five minutes, then centrifuged at 14,000xg 
for one minute.  The eluate was placed back into the spin column and allowed to incubate for 
30 minutes at room temperature, after which the spin column was centrifuged again at 
14,000xg for one minute.  The samples were placed in a BioPhotometer (Eppendorf) to 
determine the RNA concentrations, and the total HMEC-1 RNA was stored at -80°C until 
needed. 
Microarray Analysis of B. bacilliformis Infected HMEC-1.  Purified total HMEC-1 RNA 
was used for microarray studies with the HG-U133A and HG-U133B Chip Sets 
(Affymetrix).  The manufacturer’s protocol was followed for the entire process, as follows.  
Briefly, cDNA for each sample was synthesized from 8 µg of total HMEC-1 RNA per 
reaction using the Affymetrix-supplied SuperScript II first strand synthesis kit.  This first-
strand cDNA was then used for the synthesis of second-strand cDNA.  The second-strand 
cDNA was then placed in Phase-lock gel tubes (Eppendorf) and extracted with 25:24:1 
phenol:chloroform:isoamyl alcohol (Boehringer Mannheim).  Next, the second-strand cDNA 
was used to synthesize Biotin-labeled RNA using the Enzo BioArray High Yield RNA 
Transcription Labeling Kit, as suggested by Affymetrix.  After synthesis, the labeled RNA 
was cleaned using the Qiagen RNeasy columns, as recommended by Affymetrix.  The cRNA 
was quantified via the included IVT Product calculations, and once it was determined that the 
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concentration and purity of the cRNA were within the manufacturer’s recommendations the 
cRNA was fragmented using the supplied fragmentation buffer.  The fragmented cRNA was 
then spiked with the supplied Affymetrix controls, including the B2 Oligonucleotide and 
Eukaryotic Hybridization Controls.  The spiked cRNA from each sample was subsequently 
hybridized onto the HG-U133A chip for 16 hours at 45°C rotating at 60 rpm.  After HG-
U133A hybridization, the spiked cRNA was removed and added to the HG-U133B chip, 
which was hybridized as described above.  The hybridized chips were then washed and 
stained, as per the supplied Affymetrix protocols, using the GeneChip Fluidics Station for 
automated washing and staining.  The chips were subsequently scanned using the GeneArray 
scanner operating with GeneChip Operating System (GCOS) 5.; normalized values for each 
gene spot were given via normalization from 0.1 to 1 as compared to spiked-in endogenous 
chip controls.  Raw data from the GCOS analysis were then used for microarray analysis by 
GeneSpring v7.3 (Agilent). 
GeneSpring Analysis of Human Microarray Data.  GeneSpring v7.3 (Agilent) was used 
for the analysis of the microarray data.  All data were initially preprocessed using the CHP 
file preprocessor. Following file preprocessing, all data were normalized by setting raw 
signal values below 0.01 to 0.01.  The 50.0th percentile of all measurements in that sample 
divided each measurement.  Each gene was divided by the median of its measurements in all 
samples. If the median of the raw values was below 10, then each measurement for that gene 
was divided by 10 if the numerator was above 10; otherwise, the measurement was thrown 
out. Genes selected for pathway and further analysis were identified by Fold-Change 
analysis.  The significantly differentially expressed genes from the fold-change data were 
built by comparing "Timed Control" with "Timed Experimental" using all normalized genes.  
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Statistical analysis was conducted using the parametric test, assuming unequal variances.  
Genes that were differentially expressed passed this testing method defined by Fold 
Difference: 2 and a P-value Cutoff: 0.1. 
Data from Human Herpes Virus-8 (HHV-8) infected human Blood Endothelial Cells 
(BEC) were used in various microarray-based comparison studies to B. bacilliformis infected 
HMEC-1.  Microarray data generated by Wang, et al. (2004) from HHV-8 cells were 
obtained from the Array Express public microarray database and subjected to the same 
statistical and sorting methodology as noted above for the HMEC-1 microarray data  
RT-PCR Verification of Selected HMEC-1 Genes.  Further analysis of fold-change data 
from the HG-U133A and HG-U133B (Affymetrix) microarray data was done via RT-PCR 
analysis of selected genes at each time point as follows.  Previously collected B. 
bacilliformis-infected HMEC-1 total RNA was used for first strand cDNA synthesis using 
the SuperScript III Platinum Two-Step qRT-PCR kit (Invitrogen) containing 500 ng of total 
RNA in RT reaction mix, RT enzyme mix, and DEPC-treated water.  These reagents were 
then gently mixed and incubated at 25°C for 10 minutes, then 42°C for 50 minutes per 
manufacturer’s instructions.  The reaction was terminated by heating the mixture at 85°C for 
5 minutes, and the sample was then chilled on ice.  After termination, 1 µL of E. coli RNase 
H was added and incubated with the reaction mixture at 37°C for 20 minutes.  This reaction 
mix was stored at -20°C, and used for second-step RT-PCR as needed.   The second step RT-
PCR reactions were completed using the TaqMan& Universal PCR Master Mix (Applied 
Biosystems, Inc.).  An endogenous control, peptidylpropyl isomerase A (PPIA), was chosen 
as an mRNA housekeeping gene using the TaqMan Endogenous Control Array kit (Applied 
Biosystems, Inc.)  In brief, each reaction was prepared in triplicate with 100 ng of the above 
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prepared cDNA, a target-gene specific TaqMan Gene Expression Assay Primer pair (Applied 
Biosystems Inc.) for HIF1! (Hs00936368_m1), CASP3 (Hs00234387_m1) and CASP8 
(Hs00154256_m1) and the TaqMan two-step RT-PCR Master Mix reagent kit (Applied 
Biosystems, Inc.)  The cycling parameters for the Applied Biosystems 7500 sequence 
detection system were RT at 48°C for 30 minutes, AmpliTaq activation at 95°C for 10 
minutes, denaturation at 95°C for 15 seconds, and annealing-extension at 60°C for 1 minute 
(repeated 40 times).  The generated triplicate Ct values were analyzed using Excel 
(Microsoft) by the comparative Ct (''Ct) method, per Applied Biosystems, Inc. instructions.  
The amount of target, calculated using the formula RQ =2-''Ct, or –''Ct = log2(RQ),   was 
determined by normalization to the endogenous control (PPIA) and expression relative to a 
calibrator (uninfected, same time point HMEC-1 sample).  Relative quantification between 
microarray and RT-PCR data was done using previously normalized values for control 
(uninfected) and experimental (infected) data from microarray data, obtained by dividing the 
experimental data by the control data.  From the normalized ratio (NR), the log 2-based fold-
change calculations were performed using Excel. 
Fold-Change Calculations.  Fold-change calculations were completed using both the 
Normalized Ratio (NR), derived from microarray analysis, and RQ values, derived from the 
comparative Ct (''Ct) method for RT-PCR analysis, with the following formula: IF(NR or 
RQ<1,-1/NR or RQ) (Ingenuity™).  A NR greater than 1.0 represents fold-change directly 
and no calculation was required.  According to this formula if the NR is more than 1, then 
this value represents a positive fold change or gene up-regulation, however if the NR is less 
than one, then the values are divided by -1 to give a negative integer representative of gene 
down-regulation.  Finally, if normalized ratio is 1, then this value represents no change in 
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gene expression.  RT-PCR data was processed in a similar manner, once RQ values were 
obtained, using the RQ value as a substitute for the normalized ratio, thus producing fold-
change data for RT-PCR RQ values. 
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Results 
 
Scatter plot analysis of HG-U133A Microarray chips.   
Scatter plot analysis based on control versus experimental gene expression profiles 
was conducted on the HG-U133A chip following hybridization with HMEC-1 mRNA.  As 
shown in Figure 2.1, HG-U133A microarray data exhibit expected expression variability at 
both time points with B. bacilliformis-infected HMEC-1 cells.  As the plot indicates, blue 
dots represent a down-regulation and orange/red dots represent an up-regulation of the 
experimental samples relative to the controls.  Panel A, the scatter plot generated from host 
cell gene expression levels 6 hours post infection, reveals 2.3% of the host genes to be up-
regulated (as indicated by the orange/red dots), and 6.7% to be down-regulated (as indicated 
by the blue dots).  Panel B, the scatter plot obtained with RNA isolated 36 hours post-
infection, shows a similar overall effect on gene expression levels, with 2.6% of the genes 
being up-regulated and 7.6% being down-regulated.  
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Figure 2.1 – Scatter plot analysis of Affymetrix HG-U133A Microarray chips at various time 
points.   
HMEC-1 cells were infected with B. bacilliformis at a MOI of 100:1 at 37° C.   Host mRNA 
was harvested at six and thirty-six hours post-infection.  Cellular total mRNA was isolated 
post-infection and hybridized to Affymetrix HG-U133A microarray chips containing 
approximately 54,681 human transcripts.  The two panels above indicate the time point data 
used to generate gene expression profiles from two replicate samples, as follows: Panel A: 6 
hours post-infection; and Panel B: 36 hours post-infection. Each data point above represents 
the relative mean hybridization intensity of one of the mRNA transcripts purified from the 
infected cells, represented on the y-axis, versus a PBS-mock infected control, represented on 
the x-axis. Genes whose expression was unchanged in the infected cells compared to controls 
are shown as yellow dots; genes whose expression was down-regulated as compared to 
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control are represented as blue dots; and genes whose expression was up-regulated compared 
to controls are represented as orange/red dots.  The green bars indicate the two-fold change 
range for each chip hybridized.   
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Scatter plot Analysis of HG-U133B Microarray chips.   
Scatter plot analysis of the HG-U133B microarray chips reveals a level of variability 
of gene expression distribution similar to that shown in the HG-U133A microarray chips.  As 
shown in Figure 2.2, Panel A, which plots data obtained at the 6-hour time point, shows that 
2.0% of genes are up-regulated, while 6.8% are down-regulated.  Panel B, which 
incorporates data from the 36-hour time point, shows percentages of up- and down-regulated 
genes at 2.5% and 8.4%, respectively.  
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Figure 2.2 – Scatter plot analysis of Affymetrix HG-U133B Microarray chips at various time 
points.   
Analysis was conducted as described in Figure 2.1
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Fold Change Analysis of Highly Differentially Expressed Functional HMEC-1 Genes. 
 
   Analysis of the most highly differentially expressed functional HMEC-1 genes was 
conducted utilizing data from the fold change ratios prepared from signal intensity data 
obtained by hybridization of B. bacilliformis-infected and mock-infected HMEC-1 cellular 
RNA onto HG-U133A and HG-U133B (Affymetrix).  The fold change data shown in Tables 
2.1a and 2.1b represent approximately 40 of the mostly highly differentially-expressed 
functional genes at each monitored time point, as organized by highest fold change ratios.  
These genes were selected due both to their high level of fold change versus the mock-
infected control and their role as functional proteins in the host cell.  Putative or hypothetical 
genes were eliminated from this analysis.  For example, at 6 hours post-infection, the high-
level up-regulation of catalase (a 9-fold increase) may indicate an altered immune response 
mechanism for B. bacilliformis clearance, while the down-regulation of IL-17 and IL-26 
precursors may indicate a bacterial mechanism by which infiltration of immune cells is 
temporally reduced (Table 2.1a).  Furthermore, up-regulation of epidermal growth factor 
receptor(s) and IL-22 binding proteins may indicate an increased responsiveness to micro-
environmental growth factors and inflammatory response.  The down-regulation of several 
CDC42-related genes may further indicate the effect B. bacilliformis infection has on cellular 
polarity and alteration of actin fibers (Table 2.1b)
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Table 2.1a – Highly differentially expressed functional HMEC-1 genes 6 hours after B. bacilliformis infection. 
Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus 
HMEC-1 cells infected B. bacilliformis.  Total RNA extracted from mock and infected cells was hybridized to HG-U133A and  HG-
U133B (Affymetrix) microarray chips.  Hybridization data were then used to determine the fold change of the highly differentially 
expressed HMEC-1 genes. 
 
Gene product 
Accession 
No. 
Fold 
Change  Gene product 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
SET and MYND domain 
containing 3 
AW074336 16.04 
 
Interleukin 17A precursor Z58820 -19.763 
Polycystic kidney disease 
2-like 2 
AF182034 14.69 
 
Potassium inwardly-
rectifying channel J15 
BG542347 -14.535 
UV excision repair protein 
RAD23 homolog B 
T93562 14.26 
 
RAP2B, member of RAS 
oncogene family 
NM_002886 -12.887 
F-box only protein 3 
isoform 1&2 
AL162053 13.68 
 
Cardiomyopathy associated 
4 isoform 1&2 
AI800785 -12.837 
Basic helix-loop-helix 
domain containing, class B, 
3 
R93946 13.65 
 
Myeloid/lymphoid or 
mixed-lineage leukemia 
translocated to, 10 isoform 
A&B 
N64035 -12.837 
Spermatogenesis 
associated 1 
NM_022354 12.41 
 
N-methyl-D-aspartate 
receptor subunit 2A 
precursor 
T65537 -11.198 
Synaptopodin 2-like NM_024875 12.04 
 
Mitochondrial ribosomal 
protein S31 
AW007410 -10.627 
Inad-like protein; inad-like 
protein isoform 4 
AB044807 11.47 
 
Hepatocyte nuclear factor 
4, gamma 
AI916600 -10.593 
Glutamate receptor, 
ionotropic, AMPA 1 
AF007137 11.19 
 
Ras homolog gene family, 
member A 
AW173151 -10.194 
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Gene product (con’t) 
Accession 
No. 
Fold 
Change  Gene product (con’t) 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
CD24 antigen precursor BG327863 11.03 
 
Nude nuclear distribution 
gene E homolog like 1 (A. 
Nidulans) isoform A&B 
AI963104 -10.173 
Regulator of G-protein 
signaling 1 
NM_002922 10.88 
 
Replication protein A3, 
14kda 
AI022132 -9.901 
Cerebellar degeneration-
related protein 1, 34kda 
NM_004065 10.67 
 
Jun D proto-oncogene AI339541 -9.524 
Spartin AI640145 10.11  CDC42 small effector 2 AL122039 -9.346 
Muts homolog 6 D89646 10.05 
 
Protocadherin gamma 
subfamily A, 3 isoform 
1&2 precursor 
AF152509 -9.259 
Mohawk homeobox R59304 10.04 
 
Adaptor-related protein 
complex 1 sigma 2 subunit 
N74507 -9.259 
Golgin-67; golgi 
autoantigen, golgin 
subfamily a, 8A 
AI829170 9.983 
 
Polymerase (DNA 
directed), beta 
S69873 -9.009 
Cholinergic receptor, 
nicotinic, beta polypeptide 
4 
NM_000750 9.63 
 
Epidermal retinal 
dehydrogenase 2 
AI440266 -8.850 
Actin related protein 2/3 
complex subunit 1A 
AF070647 9.276 
 
Retinoic acid receptor, beta 
isoform 1&2 
NM_015854 -8.696 
Neuropeptide Y receptor 
Y2 
U32500 9.217 
 
Interleukin 26 precursor NM_018402 -8.547 
Catalase AU147084 9.162 
 
Inhibitor of Bruton's 
tyrosine kinase 
AB037838 -8.403 
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Gene product (con’t) 
Accession 
No. 
Fold 
Change  Gene product (con’t) 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
Homeodomain interacting 
protein kinase 3 
AI640624 9.004 
 
Solute carrier family 13 
(sodium/sulfate 
symporters), member 1 
NM_022444 -8.333 
Alpha 1 type XI collagen 
isoform A,B&C 
preproprotein 
BG028597 8.967 
 
Homeobox B6 AI125255 -8.065 
Cytochrome c oxidase 
subunit 8C 
AW269746 8.827 
    
Low density lipoprotein-
related protein 2 
R73030 8.817 
    
RAS-like, estrogen-
regulated, growth inhibitor 
AW668616 8.679 
    
Tropomodulin 2 (neuronal) NM_014548 8.48     
Protocadherin beta 14 
precursor 
NM_018934 8.332 
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Table 2.1b – Highly differentially expressed functional HMEC-1 genes 36 hours after B. bacilliformis infection. 
Fold change analysis for the top selected functional genes, via GeneSpring comparison of mock-infected control HMEC-1 cells versus 
HMEC-1 cells infected B. bacilliformis.  Total RNA extracted from mock and infected cells was hybridized to HG-U133A and  HG-
U133B (Affymetrix) microarray chips.  Hybridization data were then used to determine the fold change of the highly differentially 
expressed HMEC-1 genes. 
 
Gene product 
Accession 
No. 
Fold 
Change  Gene product 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
Progesterone receptor AI378893 15.02 
 
Fumarylacetoacetate 
hydrolase 
AA700567 -17.065 
G protein-coupled receptor 
98 precursor 
AL136541 12.89 
 
Phosphodiesterase 3B, 
cgmp-inhibited 
AW974995 -13.986 
Glutamate-rich 1 AA767385 12.27 
 
Sulfotransferase family, 
cytosolic, 1C, member 1 
isoform A&B 
AF026303 -13.947 
Delta-sarcoglycan isoform 
1 & 2 
U58331 11.27 
 
Diaphanous 2 isoform 156 AA778894 -13.263 
Cathepsin S preproprotein BC002642 10.8 
 
Membrane-spanning 4-
domains, subfamily A, 
member 3 isoform A,B&C 
L35848 -12.690 
Tachykinin receptor 1 
isoform long 
AI492860 10.53 
 
Dystrobrevin alpha isoform 
1-8 
R49412 -11.765 
N-acetylated alpha-linked 
acidic dipeptidase 2 
AJ012370 10.5 
 
Isoleucine-tRNA 
synthetase 
AW135765 -11.534 
Tripartite motif-containing 
58 
AL080170 10.49 
 
Cell cycle related kinase 
isoform 1&3 
AA758116 -10.449 
Sidekick homolog 1 R38712 10.46 
 
Tetratricopeptide repeat 
domain 8 isoform A,B&C 
AW293826 -10.417 
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Gene product (con’t) 
Accession 
No. 
Fold 
Change  Gene product (con’t) 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
ZXD family zinc finger C 
isoform 2 
AA702187 10.4 
 
IQ motif containing H 
isoform 1&2 
NM_022784 -9.524 
Family with sequence 
similarity 9, member C 
AI650599 10.23 
 
R7 binding protein H05023 -9.434 
Leucine rich repeat 
containing 7 
H07100 10.18 
 
CDC42 small effector 2 AI535736 -9.259 
Ubiquitin-conjugating 
enzyme E2O 
NM_022066 10.06 
 
XK, Kell blood group 
complex subunit-related, 
Y-linked 2 
NM_004677 -9.091 
Epidermal growth factor 
receptor pathway substrate 
8 
AI344149 9.853 
 
Deoxyribonuclease I 
precursor 
AA720770 -8.929 
Glutamate receptor, 
metabotropic 3 precursor 
AA608964 9.802 
 
CDC42 small effector 2 AL117571 -8.850 
Calcitonin receptor AB022177 9.763 
 
Protocadherin 11 Y-linked 
isoform a, b & c 
AI732427 -8.475 
Sodium potassium chloride 
cotransporter 2 
AI632015 9.537 
 
Pleckstrin homology 
domain containing, family 
A member 5 
AK026344 -8.403 
Phosphoinositide-3-kinase, 
regulatory subunit 4, p150 
AK025026 9.411 
 
Calcium-dependent cell-
cell adhesion 
AI912122 -8.403 
Latrophilin 3 precursor R20529 9.4  PAR-6 gamma protein AB044556 -8.403 
Fc receptor-like and 
mucin-like 1 
AL560266 9.179 
 
Brain-specific protein p25 
alpha 
AA126642 -8.264 
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Gene product (con’t) 
Accession 
No. 
Fold 
Change  Gene product (con’t) 
Accession 
No. 
Fold 
Change 
Up-regulated Gene Products   Down-regulated Gene Products  
Similar to FERM domain-
containing protein 4B 
(GRP1-binding protein 
GRSP1) isoform 1 
AK000244 9.164 
 
Zinc finger protein 750 NM_024702 -7.874 
Interleukin 22-binding 
protein isoform 1, 2 & 3 
BE348657 9.076 
 
Calcium binding protein 
P22 
AF116689 -7.813 
    Protein phosphatase 2 AI052441 -7.692 
 
 
90 
Differential regulation of selected HMEC-1 genes during B. bacilliformis infection.   
The infection of HMEC-1 by B. bacilliformis alters the global gene expression profile 
in several ways.   Table 2.2 shows the alteration of selected genes, which are grouped into 
specific host cell functions. Infection of B. bacilliformis alters the expression patterns of 
several angiogenesis-related genes throughout its infection cycle from 30 minutes
1
 to 36 
hours.  Analysis of early infection gene regulation from 30 minutes to 3 hours indicates an 
overall change in hypoxia factors and plasminogen factors as well as VEGF production. The 
infection of HMEC-1 cells by B. bacilliformis induces a down-regulation, by almost four-
fold, in hypoxia inducible factor 1 alpha (HIF1!) gene expression at 30 minutes of infection.  
This down-regulation in HIF1! production diminishes but is still evident by 3 hours, where 
the levels of gene expression are almost two-fold lower than those of the control.  However, 
the early infection cycle also reveals an increase of hypoxia inducible factor 3 (HIF3!) 
expression at both one hour, with an almost seven-fold up-regulation, and at 3 hours, with a 
three-fold up-regulation.  In addition, there is an increased expression of microvascular 
endothelial differentiation gene(s), plasminogen activators, and VEGF and VEGF-C. By 36 
hours, these increases are no longer apparent.  There is a slight increase in IL-8 expression of 
about two-fold over that of the control, and a two-fold decrease in VEGF-A expression at 36 
hours.   
Differential analysis of anti-apoptotic proteins during B. bacilliformis infection of 
HMEC-1 cells shows an alteration in host gene expression of selected anti-apoptotic genes at 
the early stages of infection.  The data in Table 2.2 reveal a striking increase in anti-apoptotic 
                                                
1
 Raw microarray hybridization signal data from 30 minutes, 1 hour and 3 hours post-B. 
bacilliformis infection provided by T. Soni, following the same infection protocol as noted 
above.   
91 
 
gene expression at 30 minutes post infection.  This increase can be seen most dramatically in 
the almost 8.5-fold increase in expression of the Id2 (Inhibitor of DNA-binding 2) gene as 
well as the four-fold up-regulation in the BAG-family molecular chaperone regulator.  Other 
genes whose expression is increased include those controlling the B cell lymphoma and 
myeloid cell leukemia sequences.  
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Table 2.2 - Selected dynamically regulated host genes of infected HMEC-1 cells during  
B. bacilliformis infection.   
The follow table shows an analysis of selected dynamically regulated host genes of infected 
HMEC-1 cells during B. bacilliformis infection.  Genes discussed in the text are indicated in 
red.   
 
  Fold change at h post-infection 
Gene name and 
function  
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Angiogenesis        
Angiopoetin-2 NM_001147 -1.092 3.391 1.313 2.292 1.062 
bFGF2 AW592991 2.076 2.484 2.408 1.107 2.308 
Ephrin B2 AF025304 2.596 1.032 -1.355 1.065 -1.163 
Ephrin B4 NM_004444 1.234 1.185 -1.057 1.081 -1.368 
Fms-related tyrosine 
kinase 
AA058828 -1.431 1.336 1.818 -1.553 1.263 
Hypoxia-inducible 
factor 1, alpha 
subunit 
AA777349 -3.922 -1.138 -2.301 1.763 1.359 
Hypoxia-inducible 
factor 2, alpha 
subunit 
AA913703 -1.172 2.036 8.001 3.398 -1.350 
Hypoxia-inducible 
factor 3, alpha 
subunit 
AK021881 -1.321 7.329 2.776 -1.109 -1.274 
ICAM1 AA284705 1.696 2.612 2.86 -2.070 -2.198 
IL-8 C terminal 
variant 
AF043337 -1.122 -1.59 -1.706 -1.634 2.249 
Inhibitor of DNA 
binding 3 
NM_002167 1.276 1.383 1.32 -1.276 1.208 
Insulin-like Growth 
Factor 
M37484 1.858 4.893 2.548 -1.776 -6.757 
Insulin-like Growth 
Factor Receptor 1 
H05812 3.634 2.221 -3.521 1.198 1.485 
Matrix 
metalloproteinase 1 
NM_002421 1.789 -1.976 -1.3 -1.127 -1.062 
Microvascular 
endothelial 
differentiation gene 1 
NM_012328 3.446 1.232 -1.081 1.099 1.881 
Plasminogen activator 
inhibitor 2 
NM_002575 1.046 2.356 -1.116 -1.605 1.318 
Plasminogen 
activator, tissue 
NM_000930 1.729 -1.196 1.013 1.01 -1.321 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Platelet-derived 
Growth Factor 
Receptor 1 
M22734 1.514 3.538 4.482 2.285 5.307 
PPAR (gamma) 
angiopoietin related 
protein 4 
NM_016109 -1.667 -2.257 -1.957 -1.016 -1.802 
Stanniocalcin AI300520 1.146 -1.58 -1.139 -1.192 1.353 
Thrombomodulin NM_000361 1.761 -1.068 -1.205 1.083 -1.647 
Tissue inhibitor of 
metalloproteinase 1 
NM_003254 1.259 -1.248 -1.073 -1.181 -1.176 
Urokinase 
plasminogen activator 
receptor precursor 
AY029180.1 1.857 1.405 1.04 -1.164 1.128 
Urokinase-type 
plasminogen activator 
receptor 
U08839.1 1.496 1.303 -1.088 -1.236 1.038 
Vascular endothelial 
growth factor C 
(VEGFC) 
U58111.1 3.451 -1.592 1.031 1.256 1.287 
Vascular permeability 
factor VEGF 
(VEGFA) 
M27281.1 -1.174 -1.109 1.454 -1.667 -2.066 
VEGF AF022375.1 4.595 -1.401 -1.104 -1.008 1.276 
       
Antiapoptotic        
BAG-family 
molecular chaperone 
regulator-2 
AF095192.1 4.193 -1.244 -1.393 1.125 1.037 
Basic helix-loop-helix 
domain containing, 
class B, 2 
BG326045 3.663 -1.114 -4.525 -1.58 -1.156 
B-cell lymphoma 6 NM_001706 2.025 -1.538 1.013 1.043 -1.377 
BCL2-related protein 
A1 
NM_004049 -1.25 -1.003 1.172 -1.379 -1.403 
Cyclin-dependent 
kinase inhibitor 1A 
NM_000389 1.517 -1.88 -1.149 -1.121 -1.129 
Fas-interacting 
serinethreonine 
kinase 3 
AF305239.1 1.652 1.339 1.144 -1.03 -1.156 
Human IAP 
homologue C 
U37546.1 1.433 -1.071 1.385 3.529 -1.456 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Inhibitor of DNA 
binding 2 (Id2) 
NM_002166 8.495 1.044 1.191 -1.08 1.303 
Leukemia inhibitory 
factor 
NM_002309 -1.773 -3.215 1.511 -1.408 -1.761 
Myeloid cell 
leukemia sequence 1 
AI275690 2.085 -1.634 -1.742 -1.269 -1.014 
Phospholipid 
scramblase 4 
NM_020353 1.63 1.171 -1.11 -1.259 -1.199 
TNF alpha-induced 
protein 3 
NM_006290 1.004 -1.536 -1.016 -1.185 1.314 
TNF-induced protein 
(GG2-1) 
BC005352 -1.024 -1.111 -1.211 -1.287 -1.239 
       
Cancer signatures        
Absent in melanoma 
1 
U83115.1 1.463 -1.637 -1.186 1.007 1.014 
Insulin-induced gene 
1 
NM_005542 2.322 -1.067 -1.196 -1.376 1.062 
N-myc downstream 
regulated 
NM_006096 1.618 -1.19 -1.233 -1.053 -1.351 
Nucleoside 
phosphorylase 
NM_000270 1.848 -1.381 -1.181 -1.172 1.152 
Potential tumor 
suppressor (ST7) 
NM_013437 -2.053 -2.89 -1.25 1.068 -2.179 
Snail 1 (Drosophila 
homologue) 
NM_005985 3.413 1.447 1.081 1.39 1.43 
Uridine 
phosphorylase 
NM_003364 1.103 -1.761 1.001 1.415 -1.372 
       
Cell and structural dynamics       
Cytovillin 2 (ezrin) J05021.1 2.101 -1.009 -1.279 1.006 -1.25 
Integrin, alpha 2 NM_002203 -1.104 1.065 1.024 1.103 -1.05 
Nephropontin M83248.1 -6.211 -2.747 1.718 -2 1.259 
Plectin, intermediate 
filament binding 
protein 
Z54367 1.024 2.35 -1.089 -2.165 -1.658 
Protein kinase-related 
oncogene (PIM1) 
M24779.1 1.454 -1.202 -1.433 -1.292 1.152 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Cytokines        
Cytokine gro-ß M57731 -1.908 -2.959 1.12 1.036 1.111 
Cytokine, Cys-X-Cys, 
member 10 
NM_001565 3.231 1.522 -1.008 -1.664 -1.488 
GRO1 oncogene NM_001511 -1.14 -1.314 1.01 1.074 1 
GRO3 oncogene 
(GRO-gamma) 
NM_002090 1.056 1.198 -1.431 -1.247 -4.065 
Interleukin 1 ß M15330 -1.224 1.305 -1.458 -1.186 1.673 
Interleukin 4 receptor NM_000418 3.176 -1.241 1.052 1.188 -1.274 
Interleukin 6 
(interferon, ß 2) 
NM_000600 -1.186 1.182 -1.515 -1.318 -1.247 
Macrophage-specific 
CSF-1 
M37435.1 2.753 -1.196 1.094 1.043 -1.565 
Monocyte 
chemotactic protein 
MCP1 
S69738.1 2.832 1.373 -1.297 -1.548 2.062 
Pre-B-cell colony-
enhancing factor 
BF575514 1.151 -1.126 -1.122 1.064 -1.58 
Prostate 
differentiation factor 
AF003934 1.042 -1.795 1.241 -1.012 -1.047 
RAFTK NM_004103 -2.653 -2.294 -2.667 1.667 1.18 
STAT-induced STAT 
inhibitor 3 
NM_003955 5.037 -2.841 1.605 -1.567 1.405 
       
IFN responsive        
2-5oligoadenylate 
synthetase 2 (OAS2) 
NM_016817 3.835 -1.215 1.385 1.213 1.101 
IFN-inducible, 67kD 
guanylate binding 
protein 1 
BC002666 1.338 -1.353 1.237 -1.142 -1.311 
IFN-stimulated T-cell 
alpha chemoattractant 
AF030514 -12.21 -1.626 3.137 3.639 5.249 
Interferon regulatory 
factor 1 
NM_002198 -1.018 1 1.564 1.135 1.188 
Interferon regulatory 
factor 2 
AW968775 -1.019 5.385 2.848 -1.316 -2.632 
Interferon regulatory 
factor 2 Binding 
Protein 
BF968057 5.727 -1.025 -1.832 1.408 -1.422 
Interferon regulatory 
factor 4 
D78261 -6.250 4.23 2.701 2.541 -4.082 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Interferon regulatory 
factor 5 
BF223643 4.777 -2.336 -3.984 -1.323 1.263 
Interferon regulatory 
factor 7, transcript 
variant c 
NM_004030 1.691 -1.224 -1.054 1.409 -1.52 
Interferon-stimulated 
protein, 15 kDa 
NM_005101 1.099 -1.199 -1.122 -1.155 1.132 
ISGF-3 BC002704 3.352 -1.054 1.21 -1.188 -1.471 
Mx resistance 1, IFN-
inducible protein p78 
NM_002462 1.763 -1.481 1.19 1.053 -1.527 
       
Metabolism        
Carnitine 
octanoyltransferase 
NM_021151 2.823 1.023 -1.389 -1.333 -1.508 
Glutamine-fructose-
6-phosphate 
transaminase 2 
NM_005110 1.131 -1.437 1.078 1.056 -1.524 
GTP cyclohydrolase 
1 
NM_000161 1.085 -1.664 -1.034 1.007 -1.377 
Prostaglandin-
endoperoxide 
synthase 2 (Cox2) 
NM_000963 -1.379 1.018 -3.096 2.743 -3.115 
Tryptophanyl-tRNA 
synthetase 
NM_004184 1.416 -1.013 -1.508 -1.006 1.076 
Hexokinase 1 NM_000188 1.412 -1.183 -1.024 1.13 -1.205 
Phosphofructokinase, 
liver 
NM_002626 2.201 1.418 -1.035 -1.232 -1.342 
Phosphofructokinase, 
platelet 
NM_002627 1.69 1.287 -1.25 1.014 1.099 
       
Molecular 
chaperons  
      
DnaJ-like heat shock 
protein 40 
NM_007034 1.204 1.496 -1.435 -1.335 1.613 
Superoxide dismutase 
2 
X15132.1 1.754 -1.119 1.042 -1.852 -1.186 
Zinc finger protein 
133 
U09366 -1.263 1.223 1.003 1.233 -1.279 
Zinc finger protein 
238 
AJ223321 1.541 -1.043 -1.453 -1.171 -1.151 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Proteolysis/protein processing       
Secretory granule, 
neuroendocrine 
protein 1 
NM_003020 -1.148 1.006 1.553 1.141 1.478 
Ubiquitin-conjugating 
enzyme E2D 1 
AL545760 1.657 1.62 1.18 1.13 1.436 
       
Signal transduction        
A kinase (cAMP) 
anchor protein 13 
AK022014 -4.386 5.275 -4.348 1.185 1.44 
ADP-ribosylation 
factor-like 7 
BG435404 1.36 -1.012 -1.056 1.055 1.077 
Diphtheria toxin 
receptor 
NM_001945 1.854 -1.161 -1.318 -1.012 1.139 
Dual specificity 
phosphatase 1 
NM_004417 1.406 -2.114 -1.795 -1.157 1.065 
Dual specificity 
phosphatase 5 
U16996 2.579 -1.224 -1.013 1.111 -1.145 
Dual specificity 
phosphatase 6 
BC005047 -3.367 -2.02 -1.224 2.079 -1.675 
Heparin-binding 
EGF-like growth 
factor 
M60278 1.948 -1.203 -1.949 -1.047 -1.235 
Immediate early 
response 3 
NM_003897 1.815 -1.323 -1.577 1.044 1.062 
Inositol 1,4,5-
triphosphate receptor, 
type 1 
NM_002222 -1.049 -2.208 1.738 1.33 -1.381 
Mitogen-activated 
protein kinase 3 
AA780381 1.549 -1.066 -1.117 1.344 -1.066 
Phospholipase A2, 
group IVA 
M68874 1.857 1.029 1.458 1.486 1.092 
Phospholipid 
scramblase 1 
NM_021105 3.443 -1.034 1.039 -1.193 -1.101 
Phosphoprotein 
regulated by MAPK 
pathways 
NM_025195 -1.182 -2.632 -1.149 1.244 1.11 
Preprourokinase K03226.1 1.331 1.013 -1.193 -1.196 -1.03 
Protein kinase C, 
delta 
NM_006254 2.377 2.129 1.013 -1.403 -2.387 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Regulator of G-
protein signaling 16 
U94829.1 -2.262 -2.667 -1.134 1.098 -1.1 
Serum-inducible 
kinase 
NM_006622 1.432 1.056 -1.28 1.048 1.151 
SMAD7 NM_005904 1.354 -1.374 1.7 1.418 -1.143 
Sprouty (Drosophila) 
homologue 2 
NM_005842 1.609 -1.61 -1.147 -1.151 -1.174 
Sprouty (Drosophila) 
homologue 4 
W48843 -1.13 -1.189 2.184 1.328 -1.517 
       
Small molecular/vesicle transport       
Aquaporin N74607 -1.099 -1.701 1.287 1.274 -1.022 
Importin alpha 3 U93240.1 -1.014 -1.104 -1.106 -1.134 -1.233 
Niemann-Pick 
disease, type C1 
NM_000271 1.263 1.16 1.174 1.306 1.078 
RAB31, member 
RAS oncogene family 
BE789881 2.315 -1.001 -1.101 1.311 -1.025 
Ral guanine 
nucleotide 
dissociation 
stimulator 
AI421559 1.06 1.085 1.02 1.519 -1.036 
RAN binding protein 
2-like 1 
AL043571 1.909 1.099 1.076 1.135 1.029 
Solute carrier family 
2 
NM_006931 1.461 1.312 -1.183 -1.037 -1.481 
Solute carrier family 
20, member 1 
NM_005415 1.418 -1.174 -1.271 1.237 -1.258 
Solute carrier family 
4, NaHC03 
cotransporter 3 
AF047033.1 -3.745 -1.142 1.022 -1.07 1.309 
       
Transcription factors/proto-oncogenes      
B-cell CLL 
lymphoma 3 
AI829875 1.115 2.087 1.065 1.037 1.135 
Cas-Br-M, retroviral 
transforming 
sequence-b 
U26710.1 -1.292 2.021 -1.067 1.128 -1.294 
CCAAT enhancer 
binding protein 
(CEBP), delta 
NM_005195 -1.185 1.205 -1.044 -1.156 -1.031 
CCAAT enhancer 
binding protein, ß 
AL564683 1.749 -1.548 -1.195 1.036 1.041 
99 
 
Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
DNA-binding zinc 
finger 
AB017493 1.155 1.228 1.067 -1.33 1.077 
Early growth 
response 1 
NM_001964 -1.443 -1.623 -1.05 -1.292 2.033 
Early growth 
response 3 
NM_004430 -2.083 1.232 3.765 1.02 1.092 
ELL-related RNA pol 
II elongation factor 
NM_012081 1.515 1.071 -1.064 -1.235 -1.013 
Estrogen-responsive 
B box protein 
NM_006470 1.455 1.206 -1.393 -1.065 -1.149 
Forkhead box O1A NM_002015 1.056 -1.136 -1.661 -1.007 -1.074 
FOS-like antigen 2 NM_024530 3.272 1.434 -1.024 -2.096 -1.016 
FOS-like antigen-1 BG251266 2.183 -1.106 1.001 1.215 1.439 
Glucocorticoid 
receptor alpha-2 
U01351.1 1.157 1.154 -1.351 -1.233 -1.174 
HIV-1 enhancer-
binding protein 2 
AL023584 -1.142 4.605 -1.565 -1.264 -2.865 
jun B NM_002229 4.503 -1.783 -2.674 1.143 -1.309 
NF- kappa B 
enhancer in B cells 1 
(p105) 
M55643.1 1.056 -1.458 1.018 1.184 -1.174 
NF-kappa B enhancer 
in B-cells 2 
(p49p100) 
NM_002502 1.13 1.508 1.911 -1.379 -1.161 
Nf-kappa B enhancer 
in B-cells inhibitor, 
alpha 
AI078167 2.305 -1.072 -1.126 1.817 1.255 
Nuclear factor, 
interleukin 3 
regulated 
NM_005384 2.103 -1.282 -1.218 1.011 -1.079 
Nuclear receptor 
subfamily 2, group F, 
member 2 
AL554245 3.262 1.051 -1.053 1.037 -1.095 
p54 (EGR binding 
protein 1) 
AF045451.1 1.698 1.075 -1.054 -1.294 1.05 
Pleckstrin homology-
like domain, family 
A,1 
NM_007350 1.36 -1.832 1.3 -1.34 1.159 
ß-Glucocorticoid 
receptor 
X03348.1 2.126 -1.277 -1.359 -1.282 -1.142 
TGFB-inducible early 
growth response 
NM_005655 2.098 -1.33 1.026 1.009 -1.111 
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Gene name and 
function (cont’t) 
Accession no.  30mins 1hr 3hrs 6hrs 36hrs 
Transcription factor 8 
(represses IL2 
expression) 
NM_030751 -1.359 -1.404 -3.077 -1.908 -1.529 
Transcriptional 
coactivator with 
PDZ-binding motif 
AA081084 1.162 -1.29 -1.314 -1.063 -1.004 
v-ets homologue 2 NM_005239 1.44 1.167 1.007 1.007 -1.49 
v-maf, oncogene 
family, protein F 
AL021977 2.237 -1.582 -1.471 -1.284 -1.035 
Zinc finger protein 
homologous to Zfp-
36 
NM_003407 -1.076 -1.048 1.279 -1.312 -1.212 
       
Others        
IFN-induced 
transmembrane 
protein 1 
AA749101 1.299 -1.106 1.279 -1.427 -1.116 
Progesterone 
membrane binding 
protein 
NM_006320 1.246 -1.018 -1.004 1.088 1.011 
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Real Time RT-PCR Validation of Microarray Data.   
In order to validate the microarray data obtained from the hybridization of total 
mRNA onto the HG-U133A and HG-U133B (Affymetrix) microarray chips, a series of real 
time RT-PCR reactions were completed for genes coding for the transcription factor HIF1! 
(AA913703), and the apoptotic enzymes caspase-3 (CASP3; NM_004346) and caspase-8 
(CASP8; NM_001228).  For each reaction (Figure 2.3), pre-validated RT-PCR primers (ABI) 
corresponding to each gene selected were used and the results were compared to an internal 
control, PPIA (cyclophilin A, CAG32988), which has been shown to have little significant 
regulation changes throughout the experimental time points (Soni, personal communication).  
Every RT-PCR primer set gave products of the expected size.  As shown in Table 2.3, all 
three genes examined agreed 100% between the RT-PCR and microarray fold change values, 
as defined by falling within 2.5 fold of one another with overall regulation agreement (Gao et 
al., 2004; Stintzi, 2003).  While the data presented here fall within our correlation scheme, as 
with any microarray study we can expect some discordance between RT-PCR and microarray 
fold change analysis.  We have noted this discordance with other genes at earlier infection 
time points including: 30 minutes, 1 hour and 3 hours post-infection (Soni, personal 
communication).  When correlation analysis includes these time points, with the same genes, 
the RT-PCR and microarray fold change correlation decreases to 73%, which remains 
acceptable for microarray validation (Draghici, 2002; Nadon et al., 2002).   
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Table 2.3 – Validation of Microarray Experiment via RT-PCR 6 and 36 hours post-infection. 
Validation of the HG-U133A&B (Affymetrix) microarray chips was completed via RT-PCR 
of selected HMEC-1 host genes.  Raw RT-PCR data analysis was completed with respect to a 
PPIA internal control and uninfected HMEC-1 cells to give the relative gene expression 
value (RQ) versus GeneSpring fold change value at each time point.  Correlation is noted by 
values within ±2.5-fold change of GeneSpring analysis value. 
 
Selected 
Gene Entrez ID Time Point 
RT-PCR 
Fold 
Change 
GeneSpring Fold 
Change Analysis   
HIF1! AA913703 6hrs 1.35 1.76 Correlate 
    36hrs 1.91 1.36 Correlate 
            
CASP3 NM_004346 6hrs 0.00 0.87 Correlate 
    36hrs 2.91 0.79 Correlate 
            
CASP8 NM_001228 6hrs 1.06 0.34 Correlate 
    36hrs 1.61 1.25 Correlate 
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with 
B. bacilliformis and two-day post-infection BEC infected with HHV-8.   
 Venn diagram analysis was carried out on data from B. bacilliformis-infected HMEC-
1 cells 36 hours post-infection versus two-day post-infection HHV-8 infected primary blood 
endothelial cells (BEC) (Table 2.4).  Analysis of B. bacilliformis-infected HMEC-1 cells 
versus HHV-8 infected BEC cells was conducted because of the functional similarities 
between the two endothelial cell lines.  Genes showing a two-fold change or greater were 
selected for comparison and then these genes were grouped by pathway/function 
commonalities.  Groupings included angiogenic, apoptotic, cell adhesion, cell signaling, and 
immune response factors.  Analysis shows a dramatic increase in the expression of 
angiogenic genes in HHV-8 infected cells relative to B. bacilliformis-infected cells.  For 
example, infection with HHV-8 results in a 15-fold up-regulation in IL-8 production with an 
increase in IL-8 in B. bacilliformis-infected cells of two fold.  Platelet derived growth factor 
(PDGF) is up-regulated during B. bacilliformis infection by almost two fold, while in HHV-8 
infected cells PDGF gene production is down-regulated almost 2.5-fold.  Examination of 
apoptosis/cell death functional genes indicates that HHV-8 infection of BEC cells results in 
an increase of chemokine ligand 2 (CCL2) expression that is almost four-fold higher than 
HMEC-1 cells infected by B. bacilliformis (6.4-fold vs. 2.1-fold increase, respectively).  
Also, TNF superfamily receptor 21 is down-regulated almost six-fold in B. bacilliformis 
infected HMEC-1 cells while its gene expression is up-regulated almost five-fold in HHV-8 
infected BEC cells.  Cell adhesion and mobility regulated genes show almost universal 
down-regulation during infection with B. bacilliformis, as opposed to those infected by 
HHV-8.  This includes the down- regulation of Claudin 1 (CLDN1), epithelial V-like antigen 
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(EVA1), Alpha 5-integrin (PLTP) and laminin gamma 2 (LAMC2), all of which are down-
regulated during the infection of B. bacilliformis but are up-regulated during the infection by 
HHV-8.  It should be noted that thrombospondin 3 (THBS3) is down-regulated almost three 
fold in B. bacilliformis infected cells, while it is up-regulated two fold in HHV-8 infected 
cells. Cell signaling genes show similar gene expression patterns between HHV-8 infected 
cells and B. bacilliformis infected cells; however, HHV-8 infected cells exhibit an increased 
cytokine receptor 7 (CMKOR1) expression of eight fold, whereas B. bacilliformis infected 
HMEC-1 cells CMKOR1 expression increases by 2.5-fold.  Ficolin (FCN3) gene expression 
is up-regulated almost three-fold in B. bacilliformis infected HMEC-1 cells, but is down-
regulated 2.5-fold in HHV-8 infected cells.  The immune response is also differentially 
regulated in Bartonella infected cells and HHV-8 infected cells.  For example, CD69 is up-
regulated almost 5.5-fold by HHV-8 infected cells, but is down-regulated over three-fold in 
B. bacilliformis infected cells, while B. bacilliformis infection increases chemokine ligand 11 
(CXCL11) production over five-fold versus a 3.5-fold increase by HHV-8 infected cells.  
HHV-8 infection induces production of IL-2 receptor and IL-32 greater than B. bacilliformis, 
showing almost a seven-fold increase in the production of IL-32 versus B. bacilliformis 
infected cells.  B. bacilliformis, however, induces an up-regulation of IL-6 signal transducer 
production with a 2.6-fold increase versus a two-fold decrease in HHV-8 infected cells.  B. 
bacilliformis also induces the increased expression of G-protein signaling regulator genes 
(RGS1) by a four-fold greater rate than that of HHV-8 infected cells, while HHV-8 infected 
cells appear to induce the production of Selectin E (SELE) over five-fold greater than that of 
B. bacilliformis.  Host cell metabolism gene expression patterns are very similar between B. 
bacilliformis infected cells and HHV-8 infected cells.  The only exception is the expression 
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of the carboxypeptidase E gene (CPE), which shows a two-fold decrease during B. 
bacilliformis infection and a two-fold increase during HHV-8 infection.  Lastly, analysis of  
proliferation-related genes in B. bacilliformis infected HMEC-1 indicates a down-regulation 
of almost three-fold for Cyclin D2 (CCND2), while HHV-8 infected cells up-regulate 
CCND2 expression two-fold.  Breast cancer marker 2 (BRCA2) gene expression shows a 
modest difference between HHV-8 and B. bacilliformis infected cells, increasing about four-
fold during B. bacilliformis infection and two fold following infection with HHV-8.   
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Table 2.4 – Venn Diagram Analysis comparing genes overlapping between 36hrs B. 
bacilliformis-infected HMEC-1 Cells and 2 day HHV-8 infected Primary Blood Endothelial 
Cells.   
Venn diagram analysis was conducted comparing HMEC-1 36 hour post-infection with B. 
bacilliformis versus HHV-8 two-day infected BEC; genes were selected by two-fold or more 
change over control and those which overlapped between both infective conditions.  Genes 
discussed in the text are highlighted in red.  
 
Gene name and function Accession no. 
B. 
bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
Angiogenesis    
EPH receptor B2 D31661 -2.392 2.481 
Interleukin 8 AF043337 2.249 15.500 
Interleukin 8 receptor beta NM_001557 3.828 2.198 
Platelet-derived growth factor 
alpha polypeptide X03795 2.173 -2.519 
    
Apoptosis/Cell Death    
Chemokine (C-C motif) ligand 
2 S69738 2.062 6.417 
GULP, engulfment adaptor 
PTB domain containing 1 AK023668 -4.000 -2.252 
Interferon induced with 
helicase C domain 1 NM_022168 2.133 2.188 
Tumor necrosis factor receptor 
superfamily, member 21 NM_016629 -5.780 4.258 
Tumor necrosis factor receptor 
superfamily, member 9 BC006196 2.992 2.020 
    
Cell Adhesion & Mobility    
BH-protocadherin (brain-
heart) NM_002589 2.105 2.054 
Cadherin-like 22 AF035300 -4.926 -2.037 
Claudin 1 NM_021101 -5.525 2.035 
Epithelial V-like antigen 1 NM_005797 -4.808 2.649 
Extracellular link domain 
containing 1 NM_016164 -2.283 -3.077 
Gelsolin (amyloidosis, Finnish 
type) BE675337 -2.381 -2.262 
Heparan sulfate proteoglycan 
2 (perlecan) AI991033 5.000 2.863 
Integrin, alpha V  NM_006227 -3.106 2.275 
Laminin, gamma 2 NM_005562 -2.646 3.967 
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Gene name and function 
(con’t) Accession no. 
B. bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
PDZ domain containing 2 AF338650 2.961 2.123 
Thrombospondin 3 L38969 -3.049 2.059 
 
Cell Signaling    
Chemokine (C-X-C motif) 
receptor 7 AI817041 2.477 8.148 
Ficolin NM_003665 2.892 -4.566 
G protein-coupled receptor 37 
(endothelin receptor type B-
like) T16257 2.836 2.321 
G protein-coupled receptor 4 NM_005282 -2.037 -2.262 
PDZ domain containing 1 NM_002614 -2.336 2.059 
    
Immune Response    
CD69 molecule L07555 -3.115 5.426 
Chemokine (C-X-C motif) 
ligand 11 AF030514 5.249 3.855 
Interleukin 1 receptor 
antagonist BE563442 3.346 2.190 
Interleukin 2 receptor, gamma  NM_000206 -2.096 2.253 
Interleukin 32 NM_004221 2.101 7.348 
Interleukin 6 signal transducer BE856546 2.681 -2.033 
RAB7, member RAS 
oncogene family AK024417 2.192 2.031 
Regulator of G-protein 
signaling 1 NM_002922 8.016 2.028 
Selectin E (endothelial 
adhesion molecule 1) NM_000450 3.813 18.500 
Serine proteinase inhibitor AB046400 -3.597 -9.009 
Tachykinin NM_003182 3.469 2.001 
    
Metabolism    
Carboxypeptidase E NM_001873 -2.179 2.182 
Glutamate-ammonia ligase 
(glutamine synthase) domain 
containing 1 NM_016571 2.965 2.483 
Klotho NM_004795 2.600 2.091 
Phosphatidylinositol glycan, 
class C AL035301 2.141 2.201 
    
Proliferation    
Cyclin D2 AI635187 -3.367 2.043 
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Gene name and function 
(con’t) Accession no. 
B. bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
Breast cancer 2, early onset NM_000059 3.834 2.038 
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with 
B. bacilliformis and seven-day post-infection BEC infected with HHV-8.   
Venn diagram analysis was conducted comparing gene expression in B. bacilliformis 
infected HMEC-1 36 hours post-infection with that observed in HHV-8 infected BEC seven 
days post-infection. Groups of genes were selected as noted above (Table 2.5).  This analysis 
was completed in order to determine the expression of genes during both infected conditions 
to establish commonalities of expression during both infective conditions.  Analysis of cell 
adhesion and mobility differentially regulated genes indicates B. bacilliformis infection at 36 
hours is down regulated (-5.2 fold) versus up regulation (2.1 fold) in HHV-8 infected cells 
after seven-days.  Cell signaling Venn analysis of overlapping regulated genes indicates B. 
bacilliformis infection down-regulates the production of Aquaporin 8 (AQP8) (2.3 fold), as 
opposed to a two-fold increase of AQP8 (2.1 fold) during HHV-8 infection. A three-fold 
decrease in somatostatin receptor (SSTR2) expression levels is seen in B. bacilliformis 
infected cells (-3.0 fold) versus a two-fold increase (2.0 fold) in HHV-8 infected cells.  
Immune response gene regulation between B. bacilliformis infected cells and HHV-8 
infected BEC cells indicate similar expression patterns.   However, B. bacilliformis up-
regulates the expression of cytotoxic and regulatory T cell molecules (CRTAM) to a four-
fold greater extent than HHV-8 (8.1 fold vs. 2.0 fold).  Also, CD 28 gene (CD28) expression 
is up-regulated two-fold during B. bacilliformis infection (4.0 fold) when compared to HHV-
8 infection (2.1 fold). Interestingly, both IgE fragments (FCER1A) and serpin peptidase 
inhibitor (SERPINF2) show a down-regulation during B. bacilliformis infection (-3.3 fold 
and -2.6 fold versus 2.2 fold and 2.3 fold, respectively) while infection with HHV-8 shows 
an increase in the expression of both of these genes.  Finally, analysis of genes which are 
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differentially regulated regarding metabolism reveals a three-fold down-regulation in 
fucosyltransferase 9 (FUT9) and almost a four-fold down regulation of SMA4 (SMA4) 
expression in B. bacilliformis infected HMEC-1 cells, while both of these genes are up-
regulated in HHV-8 infected cells (2.0 fold and 2.2 fold). 
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Table 2.5 – Venn Diagram Analysis comparing genes overlapping between 36 hrs B. 
bacilliformis-infected HMEC-1 Cells and 7 day HHV-8 infected Primary Blood Endothelial 
Cells.  
Venn diagram analysis was conducted comparing B. bacilliformis-infected HMEC-1 36 hour 
post-infection with HHV-8 infected BEC 7 days post-infection. Genes with 2-fold change 
over control were selected and those which overlapped between both infective conditions.  
Genes referred to in the text are highlighted in red. 
 
Gene name and function  Accession no.  
B. bacilliformis-
Infected Fold 
Change 
7 day HHV-8 
Infected Fold 
Change 
Cell Adhesion & Mobility    
Dynein, axonemal, HC3 AK026793 2.901 2.288 
Formyl peptide receptor-like 1 U81501 -5.208 2.129 
K-cadherin NM_004932 -3.472 2.107 
Leucine rich repeat neuronal 5 AK024867 2.430 2.064 
    
Cell Signaling    
Aquaporin 8 NM_001169 -2.398 2.134 
Interleukin 5 receptor, alpha M96651 3.743 2.023 
Phosphodiesterase 6C, cGMP-
specific, cone, alpha prime U31973 3.057 2.047 
Somatostatin receptor 2 BC000256 -3.086 2.062 
Tetraspanin 7 NM_004615 -2.294 -2.045 
    
Immune Response    
Apolipoprotein H NM_000042 3.811 2.120 
CD28 molecule AF222343 4.015 2.177 
Chemokine (C-X-C motif) 
ligand 14 NM_004887 2.462 2.193 
Cytotoxic and regulatory T cell 
molecule NM_019604 8.193 2.086 
Dedicator of cytokinesis 2 D86964 3.174 2.130 
Fc fragment of IgE BC005912 -3.367 2.244 
Myelin basic protein M13577 2.426 2.116 
Serpin peptidase inhibitor NM_000934 -2.667 2.308 
Urotensin 2 NM_021995 2.794 2.041 
    
Metabolism    
Fucosyltransferase 9 BC001879 -3.096 2.048 
Proline dehydrogenase 
(oxidase) 2 U95090 2.284 2.363 
SMA4 X83300 -4.274 2.208 
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Gene name and function 
(con’t) Accession no. 
B. bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase 2 Y15014 2.094 2.120 
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Comparative gene expression analysis of 36 hour post-infection HMEC-1 infected with 
B. bacilliformis versus two-day and seven-day post-infection BEC infected with HHV-8.       
 A final Venn diagram analysis was completed comparing B. bacilliformis infected 
HMEC-1 36 hour post-infection with HHV-8 infected BEC two- and seven-day post-
infection.   Genes were selected as noted above (Table 2.6).  One major outcome of this 
analysis as it relates to angiogenesis genes concerns the differential response of the cells with 
respect to the expression of IL-8.  In HHV-8 infected cells, there is an up-regulation in IL-8 
expression at both time points, while the gene is two-fold down-regulated in cells infected 
with B. bacilliformis   Overall, the immune response genes show similar expression patterns 
following infection with either B. bacilliformis or HHV-8, with the exception of the Fc 
fragment of IgA and the von Hippel-Lindau tumor suppressor, both of which are down-
regulated in B. bacilliformis infected cells and up-regulated in HHV-8 infected cells.  Cell 
Adhesion-related genes exhibit a dissimilar gene regulatory pattern between B. bacilliformis 
and HHV-8 infected cells, with the most dramatic differences seen with the Epithelial V-like 
antigen 1 gene, which is 2-fold down-regulated in B. bacilliformis infected cells but 7-fold 
up-regulated at the two-day post HHV-8 infection BECs.  The up-regulation of Pappalysin in 
B. bacilliformis-infection HMEC-1 cells does not correlate with the down-regulation of this 
gene by HHV-8 infection.  Finally, analysis of the expression changes in Transport-related 
genes reveals differences in the expression of the glutamate receptor, which is down-
regulated 7.5 fold in  B. bacilliformis-infected cells, but up-regulated in HHV-8 infected cells 
at both time points.  
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Table 2.6 – Venn Diagram Analysis comparing genes overlapping between 36hrs B. 
bacilliformis-infected HMEC-1 Cells and 2 & 7 day HHV-8 infected Primary Blood 
Endothelial Cells.  
Venn diagram analysis was completed comparing HMEC-1 36 hour post-infection with B. 
bacilliformis versus HHV-8 day-two and seven-day infected BEC; genes were selected due 
to their two-fold change over control and those which overlapped between all three infective 
conditions.  Genes discussed in the text are highlighted in red. 
 
Gene name and 
function Accession no.  
B. 
bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
7 day HHV-8 
Infected Fold 
Change 
Angiogenesis     
Interleukin 8 X77737 2.249 15.500 2.579 
Aminopeptidase A NM_001977 2.342 2.235 2.191 
Kruppel-like factor 5 AF132818 4.193 2.214 2.112 
Endothelin receptor 
type A AU118882 7.052 2.221 2.311 
     
Immune Response     
Immunoglobulin 
lambda locus D01059 2.137 2.129 2.131 
Immunoglobulin 
heavy constant g1 AJ275383 2.375 -3.175 -2.404 
Major 
Histocompatibility 
Complex, class II, DR 
beta 1 AJ297586 -2.212 -2.994 -2.283 
T cell receptor alpha 
locus AE000659 2.452 2.414 2.311 
Fc fragment of IgA U56237 -3.096 2.250 2.350 
Interleukin 26 NM_018402 2.211 2.090 2.082 
von Hippel-Lindau 
tumor suppressor NM_000551 -2.041 2.297 2.064 
     
Cell Adhesion     
CD1c molecule NM_001765 2.371 -2.762 -2.174 
Epithelial V-like 
antigen 1 AF275945 -2.320 7.489 2.121 
Embryonal Fyn-
associated substrate NM_005864 -2.294 2.328 2.056 
Neurofibromin 2 BC003112 3.939 2.106 2.246 
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Gene name and 
function Accession no.  
B. 
bacilliformis-
Infected Fold 
Change 
2 day HHV-8 
Infected Fold 
Change 
7 day HHV-8 
Infected Fold 
Change 
     
Cell Cycle Regulation     
Pappalysin 2 BF435151 7.014 -4.049 -3.205 
fyn-related kinase NM_002031 5.549 2.130 2.054 
     
Transport     
Glutamate receptor AU156204 -7.519 2.161 2.113 
Transferrin NM_014111 2.112 2.424 2.375 
Cystic Fibrosis 
transmembrane 
conductance regulator  W60595 7.713 2.172 2.128 
Solute carrier family 
13 m1 AF260824 -2.825 2.029 2.051 
CD36 molecule M98399 2.879 3.774 3.103 
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Discussion 
 
The infection of host endothelial cells by B. bacilliformis results in the alteration of 
numerous gene regulation profiles.  To date, little research has been done to analyze these 
regulatory changes. The experiments described herein were undertaken to provide 
information about the global regulation of host genes in response to infection with B. 
bacilliformis KC584. Genes analyzed were divided into several key categories, depending on 
their roles in angiogenesis, apoptosis, the immune response and signal transduction.  A  
comparison of gene regulatory patterns induced by B. bacilliformis infection with those 
observed following infection by HHV-8, the etiological agent of Kaposi’s Sarcoma (Naranatt 
et al., 2004; Wang, 2004) was also carried out  due to the striking histopathological 
similarities between the clinical presentation of Kaposi’s Sarcoma and that of verruga 
peruana.  
Microarray analysis of cellular gene expression in response to infection by B. 
bacilliformis  
 Work in our laboratory has focused on the response of HMEC-1 cells during early 
(within 3 hours) and late (36 hours) B. bacilliformis infection, as determined by microarray 
analysis.  Early host response has shown the expression of several key host genes relating to 
angiogenesis, apoptosis and immune response (Soni, personal communication).  Early 
infection, within 30 minutes, of B. bacilliformis shows the highest degree of change in 
overall gene expression change (21.9%), with 7.9% of the genes being up-regulated and 
14.0% being down-regulated. Those genes relating to angiogenesis that are up-regulated 
through the first three hours of infection include bFGF, ICAM-1, Insulin-like growth factor 
(IGF), and Platelet-derived Growth Factor Receptor 1 (PDGFR-1). While bFGF and IGF 
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have been clearly associated with angiogenesis and blood vessel formation, PDGFR1 up-
regulation may indicate that infected endothelial cells are priming not only for angiogenesis, 
but also involvement of the immune system in clearance of the B. bacilliformis infection. Up-
regulation of ICAM-1, a cellular adherence factor, may indicate the restructuring and 
increased attachment of endothelial cells as they begin priming for the angiogenic cascade.  
Several angiogenesis-related genes, including HIF2! and HIF3!, Insulin-like Growth Factor 
receptor I (IGFR-1), Microvascular endothelial differentiation gene I and VEGF, are only 
transiently up-regulated early in infection.  While HIF2! gene expression is a known 
response to hypoxia and able to induce angiogenesis via the VEGF pathway, recent research 
suggests that HIF3! may actually be involved in a destruction of tubules by a yet unknown 
method (Hirota et al., 2006).  HHV-8 has been found to contain genetic elements which are 
activated in hypoxic environments (HRE); these genetic elements have not been found in B. 
bacilliformis (Haque et al., 2003).  HIF1! expression has also been implicated in the 
infective cycle of HHV-8; its accumulation is believed to be due to the presence of up-
regulated IGF-I and the subsequent induction of VEGF (Catrina et al., 2006).  Research into 
the role of HIF1! has shown that B. henselae infection actively increases HIF1! expression 
and decreases ATP stores.  Interestingly, this study suggests that B. henselae strains which 
are pilus negative do not induce HIF1! or VEGF expression, thus indicating the role of the 
pilus in HIF1! activation.  However, to date the role and presence of a B. bacilliformis pilus 
homologue has not been established in HIF1! induction (Kempf et al., 2005).  Our data, 
however, show a constant down-regulation of the transcription factor HIF1! throughout 
early B. bacilliformis infection. The down-regulation of HIF1! upon B. bacilliformis 
infection is unexpected, since HIF1! plays a significant role in mediating VEGF expression 
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during HHV-8 infection.   Under these conditions, HIF1! activation is achieved through 
phosphorylation by p38 and proteins in the MAPK signal pathways (Sodhi et al., 2000).  
HHV-8 induced tumors express the gene coding for the IGF-I receptor, suggesting an 
autocrine role during angiogenesis.  The 3.6-fold increase in IGF-1 gene expression seen 
early in B. bacilliformis infection may indicate that this protein is also involved in the 
formation of verruga peruana (Catrina et al., 2005).  
 Expression of anti-apoptotic genes during early B. bacilliformis infection reveals the 
transient up-regulation of several genes.  Of these, the Id2 (Inhibitor of DNA binding-2) 
gene, whose expression is increased 8-fold 30 minutes post-infection, is the most highly up-
regulated.  ID2 is able to inhibit cellular differentiation and may actually act as a tumor 
suppressor (Lavarone et al., 1994).  In a manner similar to that of HHV-8 infection, the host 
response in the early stages of B. bacilliformis infection exhibits an interferon-based immune 
response (Dourmishev et al., 2003; Naranatt et al., 2004).  Transiently up-regulated genes 
include CXC10, MCP-1, MS-CSF and STAT-induced stat inhibitor 3 (SSI-3) which are 
involved in the recruitment and chemotaxis of immune cells to sites of inflammation and 
infection (Poole et al., 2002).  Consistently down-regulated during early B. bacilliformis 
infection, RAFTK, a focal adhesion kinase, is expressed in cells infected by HHV-8 and acts 
as a coordinator of cytokine, integrin receptor, cytoskeletal and actin processes by direct 
activation of JNK (Liu et al., 1997).  While RAFTK activation can be induced by bFGF, IL-6 
or VEGF in B. bacilliformis infection, RAFTK down-regulation may indicate that B. 
bacilliformis is bypassing this kinase while still able to alter the angiogenic cascade.  Several 
transcription factors are also activated during early infection by B. bacilliformis, including 
the activation of multiple NF-kB factors. The role of NF-kB as a downstream gene 
119 
 
transcription factor and its involvement in pathogenesis has been established by the work by 
Fuhrmann et al. (2001).  These authors report that B. henselae is able to activate NF-"B, 
thereby increasing PMN rolling and adhesion to infected endothelial cells during infection.  
During the later phase of infection  (6 and 36 hours post infection) far fewer genes 
show altered expression as compared with their earlier time point levels.  Those that are up-
regulated include the Interferon-inducible T Cell Alpha Chemoattractant (I-TAC) gene and  
the gene coding for Chemoattractant Protein-1 (MCP-1).  Both I-TAC and MCP-1, an 
activator protein of monocytes, are able to induce monocyte influx into the site of infection.  
At six hours post-infection an up-regulation of the gene coding for IAP homologue C, a 
known inhibitor of apoptosis via the TRAF pathway, is also seen.  This gene product may 
play a role in the established anti-apoptosis strategy of many Bartonella species (Dehio, 
2003; Kirby et al., 2002; Liberto et al., 2004).  This continued depression of the apoptosis 
pathway suggests a mode and methodology of continued survival not only for infected 
endothelial cells, but also a way by which B. bacilliformis can avoid the immune response.  
A wider examination of the regulation patterns indicates several up and down-
regulatory trends over the 36 hour infection period studied.  For example, the bFGF gene 
shows an overall up-regulation, and therefore could act as a stimulant for angiogenesis 
throughout the 36 hours of B. bacilliformis infection.  However, this is in contrast to the 
overall down regulation of the IL-8, one of the primary inducers of angiogenesis, which may 
indicate that the angiogenesis seen during B. bacilliformis infection does not involve the IL-8 
signaling pathway.  Also down-regulated throughout the time period under investigation are 
the tissue inhibitors of MMP-1, a protein involved in the degradation of extracellular matrix.  
This is an essential prelude to the migration of endothelial cells and tubule formation.   An 
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overall decrease in this inhibitor would therefore result in a higher potential activity for 
MMP-1 activity in the localized area surrounding infected tissues.  Several anti-apoptosis 
genes were also down-regulated throughout the monitored 36 hour infective cycle studied; 
including BCL-2, and the leukocyte inhibitory factor.  Down-regulation of these genes is 
probably due to the influx of immune response cells and follows the up-regulation trend of 
these genes at earlier time periods, which was discussed previously.   These observations 
suggest that there is a robust interferon-dominated immune response and an alteration of host 
cell apoptosis during B. bacilliformis infection.  It should also be noted that there is an 
overall down-regulation of the TNF induced genes, an indication that TNF is not involved in 
infection during B. bacilliformis.  Since TNF expression is closely linked to LPS infectivity, 
B. bacilliformis LPS may not play a role in the infection or in the immune response of the 
cell to B. bacilliformis infection.  The analysis of known cancer signatures reveals an overall 
down-regulation of tumor suppressor genes during the infection of HMEC-1 cells by B. 
bacilliformis and may indicate similarities between tumorgenesis and B. bacilliformis 
infection.  Interestingly, there is an overall down-regulation of IL-6 gene expression during 
B. bacilliformis infection, which may be counteracted by the influx of highly activated 
immune cells.  These cells are able to produce IL-6, which could potentially act in an 
autocrine manner, affecting the immune cells themselves in addition to infected and 
uninfected endothelial cells.  As expected, metabolism genes such as phosphofructokinase 
are up-regulated throughout the entire 36-hour infective cycle.  It has previously been 
established that HIF1! expression increases several glycolytic enzymes (Greijer et al., 2005).  
While our 36 hour microarray-based infection study of HMEC-1 cells infected by B. 
bacilliformis does not seem to provide a clear-cut model by which B. bacilliformis is 
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inducing angiogenesis, there are several key points that can be taken away from this study.  
We suggest that a high number of genes are up-regulated within 30 minutes of B. 
bacilliformis infection of HMEC-1 cells.  This high level of gene up-regulation may result in 
the expression of genes that are directly involved in angiogenesis or are involved in the 
pathways which lead to the angiogenesis cascade.  Next, our data have shown that hypoxia 
factors HIF1!, HIF2! and HIF3! are clearly involved at several different stages of B. 
bacilliformis infection.  While HIF1! and HIF2! are known to be involved in VEGF 
expression, HIF3! may actually be involved in the degradation of newly formed and pre-
existing endothelial tubules which are created during periods of high oxygen consumption.  
This may in fact be a key element in the poor tubule formation during B. bacilliformis 
infection (discussed in Chapter 3).  The resulting expression of HIF1! and HIF2! may result 
in the induction of the angiogenic cascade through both VEGF and other factors, including 
the constitutively up-regulated bFGF.  However, due to the presence of up-regulated HIF3!, 
the tubules formed are weak and/or highly permeable.  This could result in the pooling of 
blood in the subcutaneous location of B. bacilliformis infection, producing the clinical 
presentation of verruga peruana formation (Hirota et al., 2006).  Also, the transient rather 
than continual increase in ICAM-1 expression may indicate that while endothelial cells are 
able to migrate and form tubules, cell-to-cell contact is not properly reinforced.  Therefore, 
the tubules that are formed are highly permeable, establishing another route of blood leakage 
into the localized subcutaneous environment. Our microarray studies also suggest a role for 
the interferon dominated immune response during the infection of B. bacilliformis.  During 
the 36 hour time window, several chemoattractant genes regulated by interferon-# are up-
regulated, and may be involved in the chemoattraction of monocytes, macrophages and 
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activated T cells into the localized infective environment.  These cells in turn could produce 
several factors involved in endothelial cell migration and tubule formation. 
The study presented here of the gene regulation pattern of B. bacilliformis infected 
HMEC-1 cells is similar to the results seen by Dehio et al. (2005) during their study of B. 
henselae infection of HUVEC cells, with a few key differences.  As with our studies, Dehio 
and his coauthors used the Affymetrix HG-U133 human microarray set to study the global 
gene regulation pattern of infected endothelial cells.  They chose to harvest RNA for analysis 
at 6 and 30 hours post infection, and to use HUVEC cells rather than HMEC-1 hosts.  Their 
findings indicate a significant increase in interferon-dependent gene transcription factors, 
which is also seen during the B. bacilliformis infection.  Similarly, Dehio et al. (2005) 
suggest that interferon (IFN) is involved in the immune response during B. henselae 
infection, even though its expression was not found via ELISA detection from infected 
HUVEC cells.   Although our study did not seek to determine if IFN was produced by 
HMEC-1 cells during B. bacilliformis infection, we would expect the results to be similar to 
those reported by Dehio et al. (2005). .  The authors are also able to show the involvement of 
the NF-kB transcriptional factor in B. henselae infection, as we have in our studies, which 
relates to the up-regulation of IL-6, IL-8, ICAM-1 and CXC cytokine family members.  Our 
study shows the involvement of these and several other NF-"B -induced gene products.  
While Dehio et al. (2005) suggest a role for the virB/Bep operon in the induction of NF-"B, 
research in our lab, as well as the published B. bacilliformis KC583 genome, indicates that 
the virB operon is not present in B. bacilliformis (see Chapter 1).  Therefore, the induction of 
NF-"B during B. bacilliformis infection must be mediated by some other factor(s).  Lastly, 
Dehio et al. (2005) examined the genes related to angioproliferation, and were able to show 
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that 22% of the 100 most highly differentially regulated genes were related to angiogenesis.  
These results correlate well with our own studies of B. bacilliformis infection.  While 
infection by the two Bartonella species resulted in the up-regulation of several similar 
angioproliferative genes, infection by B. henselae did not show an increase in Hypoxia-
inducible factors (HIF) of any kind, while our results reveal differential regulation patterns 
consistent with a key role for these factors in the on-going angiogenesis seen in verruga 
peruana formation during Carrion’s disease. 
Real-time RT-PCR analysis was also conducted on three genes as a way to verify the 
microarray data (Table 2.3).  The RT-PCR data and the microarray fold-change analysis 
show a 73% correlation when both early and late time points are included in the validation 
analysis. Most successful microarray studies prefer a fold-change range of no more than a 2.5 
fold difference between microarray and RT-PCR data (Draghici, 2002; Firestein et al., 2002; 
Gao et al., 2004; Nadon et al., 2002; Stintzi, 2003).  Differences between RT-PCR and 
microarray data are commonly ascribed to several factors, including the different microarray 
hybridization probes used for each technique.  Even a slight difference in binding locations 
can result in differential fold-change data.  Also, the required use of microarray imaging 
software, such as GCOS, can result in analysis of microarray data with different 
hybridization intensity levels.  While intensity levels were adjusted to be as close to one 
another as possible, slight gene spot intensity differences will lead software-based analysis to 
different fold change results.  While we did not obtain the expected correlation between 
microarray and RT-PCR data at all time points, we are confident that these studies will 
provide the necessary tools for further research into the interaction of Bartonella species with 
their hosts. 
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Venn diagram-based analysis of B. bacilliformis infected HMEC-1 cells versus Kaposi's 
sarcoma BEC infected cells. 
Due to the histopathological similarities between B. bacilliformis infected endothelial 
cells and HHV-8 infected blood endothelial cells, a Venn diagram-based comparison was 
conducted utilizing microarray data from B. bacilliformis-infected HMEC-1 cells 36 hours 
post-infection versus HHV-8 infected blood endothelial cells (BEC) after two and seven days 
post-infection. Microarray data from HHV-8 infected cells was generated by Wang, et al. 
(2004) and published to the ArrayExpress database (www.ebi.ac.uk) accession number E-
MEXP-66.  These data were treated in the same manner as B. bacilliformis data with regard 
to software-based analysis. Gene regulation analysis of genes with at least a two-fold change 
from mock infected cells was completed on several basic categories of host gene pathways 
including angiogenesis, apoptosis, cell adhesion, and immune response.  Table 2.3 shows the 
comparison between B. bacilliformis-infected cells and two-day HHV-8 infected BECs.  The 
first striking difference between Bartonella infected cells and HHV-8 infected cells is the 
expression of IL-8, a hallmark of angiogenesis.  Expression of the IL-8 cytokine is up-
regulated by 15-fold in HHV-8 infected but only by two-fold in B. bacilliformis infected 
cells.  These data suggest that HHV-8 infected cells are more responsive to and produce 
higher levels of IL-8, thus indicating its role in infection by the virus, while suggesting that 
IL-8 may play only a small role in angiogenesis seen in B. bacilliformis-infected cells.  This 
difference in IL-8 expression raises the possibility that the role of IL-8 may be offset in B. 
bacilliformis-infected cells by the up-regulation of Platelet-derived Growth Factor (PDGF), 
as compared to the down-regulation of the same gene in HHV-8 infected cells. PDGF is a 
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known vascular growth factor able to induce proliferation while acting as a chemoattractant 
for a wide variety of immune cells.  Upon examination of apoptosis-related genes, it is 
interesting to note the down-regulation of GULP in both infective conditions, as this gene is 
responsible for an increase in the engulfment of cells which have undergone apoptosis via 
phagocytes.  This observation may indicate a survival strategy for both infective conditions, 
since it will decrease uptake by host cells that are actively undergoing apoptosis or have 
recently undergone apoptosis, thereby allowing B. bacilliformis a protected location for 
continued growth.  Interestingly, a five-fold down-regulation of tumor necrosis factor 
receptor 21 (TNFR21) is seen in B. bacilliformis infected cells while up-regulation of four-
fold of this gene is observed in HHV-8 infected cells.  This may indicate that TNF plays a 
less important role in B. bacilliformis infection as compared with HHV-8 infection.  Analysis 
of genes involved in cell adhesion and mobility again indicates differences between 
Bartonella infection and HHV-8 infection.  The up-regulation of Perlecan in both infective 
conditions indicates yet another possible mode of survival.  Induction of this gene results in 
the inhibition of apoptosis in fibroblasts following the initiation of apoptosis in nearby 
endothelial cells. Perlecan binds to the fibroblast !2$1 integrin, and may inhibit apoptosis 
via integrin activation.  Interestingly, this analysis shows the down-regulation of several 
genes that are directly involved in endothelial cell maintenance, including Claudin 1, 
Laminin and Thrombospondin 3. All three are involved in binding of the extracellular matrix 
and have been implicated in endothelial cell permeability in vivo.  The down-regulation of 
each of these genes may provide deeper clues into the overall effect that B. bacilliformis 
infection has on endothelial cells and their ability to form tight junctions and maintain tubule 
integrity during infection.  The analysis of cell signaling molecules, a category which shows 
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the highest difference in gene regulation between B. bacilliformis-infected and HHV-8 
infected cells, reveals the different possible roles the immune system plays in clearance of 
both infective conditions.  HHV-8 infected cells show a higher level of up-regulation of 
chemokine receptor 7, a B cell binding site and attractant, and a greater down-regulation of 
Ficolin, a protein functioning in the clearance of non-self foreign material from the host.  The 
weaker levels of chemokine receptor 7 up-regulation in B. bacilliformis-infected cells may 
indicate that the B cell response does not play as important a role in B. bacilliformis infection 
as it does in HHV-8 infection.  The up-regulation of Ficolin expression may indicate that 
phagocytosis or other direct uptake methods for infective clearance are more important 
during B. bacilliformis infection than during HHV-8 infection.  The immune response gene 
regulation patterns indicate a high similarity of regulatory patterns between B. bacilliformis-
infected cells and HHV-8 infected cells.  The down regulation of CD69 expression following 
B. bacilliformis infection may further indicate the lack of a TNF-! response, as CD69 
expression is induced by TNF-! expression in endothelial cells.  The eight-fold up regulation 
of G-protein signaling involved in Rho/rac proteins suggests that these proteins play a role 
during infection (Verma et al., 2000; Verma et al., 2002). 
Venn diagram analysis was also used to compare the overall gene expression profiles 
between B. bacilliformis-infected HMEC-1 and seven-day HHV-8 infected BEC, using the 
same methodology as described above (Table 2.4).  Most interesting is the overall similarity 
of immune response gene regulatory patterns between the two infective conditions. An 
example of this similarity is the up-regulation of the cytotoxic and regulatory T cell molecule 
which, while up-regulated more during B. bacilliformis infection than HHV-8 infection, still 
reveals the immune response similarities between the two infective conditions. This again 
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suggests a role for INF-# in both infective conditions, with a possible higher immune 
response in B. bacilliformis infection of HMEC-1. 
A final analysis was completed using 36 hour B. bacilliformis-infected HMEC-1 cells 
and two- and seven-day HHV-8 infected BECs via a Venn diagram analysis (Table 2.5).  
These data overall show the striking similarity by which B. bacilliformis infection and HHV 
infection alter endothelial cell gene profiles, as indicated by the 50% overall similarity in 
gene expressions.  Interestingly, several genes involved in B. bacilliformis infection are 
indicative of the slightly difference host responses to B. bacilliformis infection versus HHV-8 
infection.  An example of this is the up-regulation of angiogenesis-related endothelium 
receptor type A (ET1RA) expression, ET1RA is a mitogen involved in the escape from 
apoptosis and the induction of angiogenesis via a pathway mediated by ILK, an integrin 
linked kinase involving !2$1 and !3$1 integrins.  The up-regulation of this factor indicates a 
continued strategy of B. bacilliformis to alter host apoptosis while implicating various 
integrins in the induction of angiogenesis.  This analysis shows an almost four-fold increase 
of Neurofibromin 2, a protein that is able recruit rac proteins, which in turn promote 
mitogenesis of host cells.  This protein up-regulation provides further evidence for the 
proposed survival strategy used by B. bacilliformis:  by inducing cell proliferation, B. 
bacilliformis gains increasing numbers of host cells that can support bacterial proliferation 
and provide a place to avoid host immune responses. Finally, we note the up-regulation of 
two genes involved in cell cycle regulation, Pappalysin 2 and fyn-related kinase.   Pappalysin 
2 interacts with the localized matrix metalloproteins, while fyn-related kinase is an inducer of 
cell proliferation via insulin receptors. 
This comparative analysis between B. bacilliformis-infected HMEC-1 cells and 
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HHV-8 infected BEC reveals the striking commonality of endothelial cell host response to 
both of these infective conditions.  While individual commonalities may be difficult to 
determine, it is clear that with over 50% similarity in the up- or down-regulation of the 
various genes examined, the infective condition of both B. bacilliformis and HHV-8 do 
induce similar gene regulation profiles in the host cells.  These similar host gene regulation 
profiles may provide vital insights into the formation of both verruga peruana and Kaposi's 
Sarcoma lesions while providing key information about the commonalities in the 
histopathology between both infective states.  It should be noted that the cell lines used for 
these studies do differ in function and localization.  HMEC-1 cells consist of an established 
immortalized microdermal endothelial cell line which would be commonly found lining 
vessels, while BEC are a progenitor cell line which can differentiate into lymphatic or other 
endothelial cells as necessary.  This contrast may account for the slight difference in degrees 
of fold-change seen during different infective conditions. 
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Chapter III – Bacterial Components & Secreted Protein(s) 
Introduction 
 
Bartonella bacilliformis is the causative agent of Carrion’s disease, a serious infection 
that exhibits a biphasic disease progression.  The first phase, Oroya fever, is characterized by 
colonization of red blood cells followed by a severe hemolytic anemia (>80% untreated 
fatality rate).  The disease can then progress into the second phase, termed verruga peruana, 
which is marked by cutaneous and subcutaneous eruptions of angiogenic lesions (Anderson, 
1997).  Verruga peruana resembles a similar condition called Bacillary Angiomatosis (BA), 
that is observed in immunocompromised individuals infected with B. henselae or B. quintana 
(Berger et al., 1993; Cockerell, 1992).  In both cases, the lesions are the result of 
uncontrolled angiogenesis involving host endothelial and epithelial cells with a 
histopathology similar to the lesions resulting from HHV-8 (Human Herpesvirus 8) infection 
that are seen in patients with Kaposi’s Sarcoma (Dourmishev et al., 2003; Nayler et al., 
1999).  Several attempts have been made to identify the factor(s) from B. henselae that are 
responsible for BA; however, to date no definitive factor has been found (Dehio, 1999; 
Kirby, 2004; McCord et al., 2005; Resto-Ruiz et al., 2002; Schmidt, 1998; Schulte et al., 
2006).  Similarly, research into the angiogenic factor(s) encoded by B. bacilliformis has 
provided relatively few insights.   
When applied to vascular endothelial cells, a soluble fraction of a B. bacilliformis cell 
homogenate has been reported to produce a mitogenic effect approximately threefold greater 
than that of control cells (Garcia et al., 1990).  The mitogenic factor(s) has been shown to be 
angiogenic in a rat model.  The authors were able to eliminate lipopolysaccharide (LPS) as 
the mitogen in these studies, and also tentatively identified the factor as a protein based on its 
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heat lability (Garcia et al., 1990).  Additional studies have demonstrated that live B. 
bacilliformis is able to produce these proliferate lesions when co-cultured with human 
umbilical vascular endothelial cells (HUVEC cells) (Garcia et al., 1992).  Knobloch, et al. 
have shown that serum from Carrion’s disease positive patients exhibits reactivity to a 65kDa 
B. bacilliformis produced protein, which could implicate this antigenic protein in lesion 
formation (Knobloch et al., 1990).  Recently, the suggestion was made that this 65kDa 
protein is a homologue of GroEL, a stress-induced molecular chaperone that is highly 
conserved among prokaryotes (Chatellier et al., 1998; Keskin et al., 2002; Zeaiter et al., 
2002).  The assignment of a role in angiogenesis for B. bacilliformis GroEL is based on 
several findings.  First, a study in which HUVEC cells were infected with a strain of B. 
bacilliformis that overproduces GroEL revealed that the secretion of GroEL was 
accompanied by a 6- to 20- fold increase in endothelial cell growth (Minnick et al., 2003).  A 
positive correlation between GroEL levels and the degree of mitogenesis supported a role for 
GroEL in this increase.  In addition, mitogenesis was found to be significantly inhibited in 
the presence of anti-GroEL antiserum. 
GroEL is a highly conserved Type I chaperone, with non-specific substrate-binding 
requirements.  In the cell, the GroE system consists of two proteins which function together 
to aid in conformational changes of both nascent and mature proteins, by hydrolyzing ATP 
and possibly providing a protected environment for protein rearrangement (Amir et al., 2004; 
Poso et al., 2004).  Structurally, the GroE system consists of two proteins: GroES, a seven-
member ring composed of 10kDa GroES subunits; and GroEL, a cylinder of 14 identical 
57kDa GroEL subunits arranged back-to-back in a seven-member ring (Gomez-Puertas et al., 
2004; Grallert et al., 2001; Wong et al., 2004).  When functional, the stacked GroEL rings 
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are capped by GroES, which provides an ATP-binding site.  The GroEL rings are open in the 
absence of ATP, and have a high affinity for unfolded or misfolded substrates.  With the 
binding of ATP, the cavity of the ring structure closes and protein re-folding can take place 
with the hydrolysis of ATP.  Once the ATP has been hydrolyzed, the GroEL ring cavity re-
opens and the folded substrate is released (Amir et al., 2004; Poso et al., 2004; Wong et al., 
2004).   
While the role of the GroE system in protein folding has been known for some time, 
it is only recently that researchers have considered GroEL to be a protein with pathological 
implications.  Upon infection, bacterial GroEL can be exposed to host immune machinery by 
lysis or by active bacterial secretion.  During M. tuberculosis infections, for example, 
populations of T cells show reactivity to chaperone 60.2 (the GroEL homologue) and the 
active secretion of two populations of M. tuberculosis GroEL homologues are seen inside 
macrophages (Ranford et al., 2000).  GroEL production from E. coli has been seen to 
correlate with the increase of numerous signaling molecules with as little as 1ug/ml of GroEL 
in co-culture with HUVEC cells (Galdiero et al., 1997; Ranford et al., 2000; Retzlaff et al., 
1994).  Several other bacteria, including Helicobacter, Legionella, and Actinobacillus, have 
all been shown to use GroEL as a factor in their pathology (Garduno et al., 1998; Ranford et 
al., 2000; Zhang et al., 2004).  These data, combined with previous research into the role of 
B. bacilliformis GroEL as a mitogen, raises the possibility that GroEL might play an 
important part in the eruption of verruga peruana lesions during the B. bacilliformis infective 
cycle.  In order to determine the role of GroEL in angiogenesis, we have isolated GroEL 
from low-passage number B. bacilliformis cultures and examined its angiogenic potential 
using purified GroEL co-cultured with Human Microdermal Endothelial Cells (HMEC-1).  
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We report here an increase in HMEC-tubule formation in the presence of purified B. 
bacilliformis GroEL.   
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Materials and Methods 
 
Bacterial Growth and Culture.  B. bacilliformis KC584 was grown as previously described 
in Chapter I (page 30).  Unused B. bacilliformis was placed in a 50% PBS/50% glycerol 
mixture and stored at -80°C until needed. 
Human Cell Growth and Culture.  HMEC-1 cells were obtained as a generous gift from 
Dr. Thomas Lawley, of Emory University and the Centers for Disease Control and 
Prevention (Ades et al., 1992).  HMEC-1 cells were grown and cultured as previously 
described in Chapter II (page 70).  Cells not intended for use immediately were resuspended 
in DMSO Cryoprotectant (Cellgro) and stored at -80
o
C overnight, then moved to liquid 
nitrogen for long term storage. 
The HUVEC cells (Cambrex) were prepared via growth of the first passage HUVEC 
cells in EGM-2 media (Cambrex) until 70-80% confluent in a T-75 flask (Starsdt). Upon 
reaching confluency, the EGM-2 media was aspirated and 15 ml of trypsin-EDTA (CellGro) 
solution was added and incubated until the cells began to round up and detach from the flask.  
The trypsin solution was neutralized with the addition of 15 ml of EGM-2 media (Cambrex) 
and the cell slurry was aspirated and transferred to a 50 ml conical tube (Falcon).  The T-75 
flask was then washed with 5 ml of HBSS (CellGro) and this was added to the conical tube 
cell slurry.  The HUVEC cells were then centrifuged for 8 minutes at 200xg, the supernatant 
was decanted and the cells were resuspended in 5 ml of EGM-2 media.  Aliquots of these 
primary cells were made and those not intended for immediate use were resuspended in 
DMSO Cryoprotectant (CellGro) and stored at -80
o
C overnight, then moved to liquid 
nitrogen for long-term storage.  Due to the unique nature of the primary HUVEC cell line, 
only cells passaged 2-6 were used for experimental purposes. 
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The epithelial cell line HEp-2 (ATCC) was maintained in T-75 flasks containing 
M199 media (CellGro) replaced every 2-3 days depending on confluence.  Upon reaching 
75-80% confluency, the cells were released using 15 ml of Trypsin-EDTA (CellGro), after 
aspiration of the M199 media.  After allowing the cells time to round up, M199 with 5% FBS 
was added to neutralize the trypsin and the detached cells were decanted into a 50 ml conical 
tube (Fisher).  The T-75 flask was rinsed with 5 ml of HBSS, which was also transferred into 
the 50 ml tube.  The cells were then pelleted by centrifugation at 200xg for 8 minutes. The 
supernatant was then decanted and the HEp-2 cells were resuspended in 5 ml of M199 media.  
Aliquots of these cells were made and those not intended for immediate use were 
resuspended in DMSO Cryoprotectant (CellGro) and stored at -80
o
C overnight, then moved 
to liquid nitrogen for long-term storage. 
Host Cross-talk Analysis via Corning TransWell System.  Analysis of cross-talk between 
B. bacilliformis infected endothelial (HUVEC) and epithelial (HEp-2) cells, and uninfected 
endothelial (HUVEC) cells, was done using the Corning TransWell Insert system.  Briefly, 
24-wells cell culture plates (Corning) were coated with Matrigel™ (BD BioSciences) and 
after drying 750ul of M199 media was added.  The wells were inoculated with 2x10
6 
cell/ml 
of PBS-washed HUVEC cells (Cambrex) (lower chamber).  The HUVEC cells were then 
allowed to grow at 37°C, 5% CO2 in a humidified incubator for 24 hours. After 24 hours of 
incubation unused wells were filled with 1 ml of M199 media, to which a single TransWell 
Insert was added.  Into the TransWell insert chamber 300 µL of M199 media and HUVEC 
cells (2 x 10
6
 cells/ml) added into the TransWell Insert (upper chamber).  The cell culture 
plates were allowed to incubate for 24 hours at 37°C, 5% CO2 in a humidified incubator.  
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 B. bacilliformis KC584 were grown and harvested as previously described in Chapter 
I (page 30).  Bacteria were diluted in PBS to a MOI of 100:1 for the infection of upper 
chamber HUVEC cells.  The TransWell inserts were gently removed from their well and 
placed into the wells containing previously grown HUVEC cells with Matrigel™ (lower 
chamber), after fresh M199 media was added to both wells and inserts.  To the TransWell 
inserts (upper chamber), 10 µL of previously diluted B. bacilliformis was added and the plate 
was incubated at 37°C, 5% CO2 in a humidified incubator.  At each time point, 
photomicrographs were taken of the lower uninfected HUVEC cells for angiogenic potential 
analysis. 
 Analysis of cross-talk between infected epithelial (HEp-2) and uninfected (HUVEC) 
cells was accomplished using similar methods.  Again, after HUVEC cells had incubated for 
24 hours on Matrigel™, unused wells were filled with 1 ml of M199 media.  A single 
TransWell Insert was added to the well followed by 300 µL of M199 media (upper chamber) 
and HEp-2 cells (4x10
5
 cells/ml) were added into the TransWell Insert directly (upper 
chamber).  The cell culture plates were allowed to incubate for 24 hours at 37°C, 5% CO2 in 
a humidified incubator.  Infection and photomicrograph monitoring were carried out as 
described above, except that HEp-2 cells were infected with B. bacilliformis after 24 hours of 
growth in the upper chamber.  
Separation of B. bacilliformis Membranes.  B. bacilliformis inner and outer membranes 
were separated via sucrose gradient (Minnick, 1994) as follows.  Previously harvested B. 
bacilliformis was prepared in 5 ml of ice-cold 0.2M Tris-1mM MgSO4 (pH 8.0), and 
centrifuged at 6000xg for 5 minutes at 4
o
C. The B. bacilliformis pellet was then re-suspended 
in 5 ml of 0.2M Tris pH8.0.  The suspension was mixed sequentially with 5 ml of 1M 
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sucrose in 0.2M Tris (pH8.0), 10 !L of 0.5M EDTA and 75 !L of freshly prepared lysozyme 
(25mg/ml stock), then incubated on ice for three hours.  After the three-hour incubation, 10 
ml of ice-cold deionized H2O was forcefully added to the mixture and the incubation was 
continued for 30 minutes on ice; then 20 ml of 0.2M dithiothreitol (DTT) was added.  To 
break the cells completely, the mixture was passed through a French press at least twice.  
Cell debris was removed by centrifuging at 10,000xg for 15 minutes at 4
o
C.  The supernatant 
was collected into ultracentrifuge tubes and diluted with one volume of deionized H2O.  The 
supernatant was then centrifuged at 240,000xg for 2 hours at 4
o
C to isolate the total 
membrane fraction.  The total membrane pellet was re-suspended in 0.5 ml of 20% sucrose-
1mM EDTA-2mM DTT.  The sample was then layered onto a two-step sucrose gradient of 
53%-70% sucrose-1mM EDTA and centrifuged at 160,000xg, for 16-18 hours at 4
o
C. The 
inner membrane was isolated between the 20% and 53% interphase and the outer membrane 
between the 53% and 70% interphase.  The two membranes were carefully aspirated and 
placed in separate ultracentrifuge tubes.  The remaining proteins were precipitated from the 
membrane fractions with four volumes of 5% (wt/vol) trichloroacetic acid for 16 hours at 
4
o
C, and then centrifuged at 16,000xg for 15 minutes.  The isolated membranes were re-
suspended in 0.2 volume of Laemmli sample buffer (100mM Tris-HCl, pH6.8, 200 mM 
dithiothreitol, 4% SDS, 0.2% bromophenol blue and 20% glycerol) and stored at -20°C until 
needed. 
Proliferation and Cytokine Production Analysis of HMEC-1 in the presence of B. 
bacilliformis Membranes.  HMEC-1 were detached as described previously, and diluted in 
sterile PBS, pH 7.4, to a concentration of 5x10
5
 cells/ml.  100 µL of the HMEC-1 cell 
dilution was added to a low-fluorescence 96-well plate(s) (Fisher) containing 100 µL of pre-
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warmed M199 (Cambrex) containing 15% FBS and 2% penicillin-streptomycin.  The 
dilution was calculated to provide each well with 50,000 cells total.  The 96-well plate was 
gently shaken to distribute the cells and then incubated at 37°C in 5% CO2 for 24 hours.  
After 24 hours’ incubation, the medium was aspirated and replaced with pre-warmed M199 
containing 5% FBS.  The incubation was continued for 24 hours in the same conditions.  For 
the testing of inner and outer membranes, extracted as described above, 50uL (50mg/ml) of 
purified inner and outer membranes were added to each well containing growing HMEC-1. 
Controls were included for each test condition by adding equivalent volumes of sterile PBS, 
pH 7.4.  After incubation for the prescribed time period, the medium was removed and 
replaced with 50 µL of 1x CyQuant Proliferation mix (Invitrogen), and the cells were 
allowed to incubate at 37
o
C, 5% CO2 for 45 minutes.  The 96-well plate was then read using 
the Typhoon Variable Imaging System (GE/Amersham) set at 600V using the 520-nm blue 
laser filter.  The data were subsequently transferred to the ImageQuant Analysis software 
(Amersham) and the pixel values were calculated for each well following the 96-well 
template.  Raw pixel data were then transferred to Excel and cell numbers were calculated 
from a previously prepared HMEC-1 specific standard curve.  ELISA analysis was 
conducted on collected testing media for each time point noted and ELISA analysis was 
conducted for each cytokine noted.  Each ELISA was done with the manufacturer’s standards 
and completed with a single control media and two experimental media.  The plates were 
read on a SPECTRAmax plate reader (Molecular Devices) at OD405.  Raw data were 
collected and correlated to a best-fit of the given cytokine standard per manufacturer’s 
instructions.  Control and experimental data were averaged to give a final result noted in 
cytokine concentration (pg/ml).  
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Proliferation Analysis by Infection of HMEC-1 with Live and Dead B. bacilliformis.  
HMEC-1 were detached as described previously, and diluted in sterile PBS, pH 7.4, to a 
concentration of 5x10
5
 cells/ml.  100 µL of the HMEC-1 cell dilution was added to a low-
fluorescence 96-well plate(s) (Fisher) containing 100 µL of pre-warmed M199 (Cambrex) 
containing 15% FBS and 2% penicillin-streptomycin.  The dilution was calculated to provide 
each well with 50,000 cells total.  The 96-well plate was gently shaken to distribute the cells 
and then incubated at 37°C in 5% CO2 for 24 hours.  After 24 hours’ incubation, the medium 
was aspirated and replaced with pre-warmed M199 containing 5% FBS.  The incubation was 
continued for 24 hours in the same conditions.  For the testing of live bacteria, B. 
bacilliformis (passage 2-4) was added at a MOI of 100:1, and the cells were washed three 
times in sterile PBS, pH 7.4.  For the testing of dead bacteria, formalin-killed B. bacilliformis 
(passage 2-4) was added at a MOI of 100:1, and the cells were washed three times in sterile 
PBS, pH 7.4.  Negative growth controls were prepared by adding 25-50 uL of sterile PBS, 
pH 7.4, which had been incubated on BHI plates containing 10% sheep’s blood for eight 
days at 25°C under conditions of saturated humidity.  Controls were included for each test 
condition by adding equivalent volumes of sterile PBS, pH 7.4.  After incubation for the 
prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant 
Proliferation mix (Invitrogen), and the cells were allowed to incubate at 37
o
C, 5% CO2 for 45 
minutes.  The 96-well plate was then read using the Typhoon Variable Imaging System 
(GE/Amersham) set at 600V using the 520-nm blue laser filter.  The data were subsequently 
transferred to the ImageQuant Analysis software (Amersham) and the pixel values were 
calculated for each well following the 96-well template.  Raw pixel data were then 
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transferred to Excel and cell numbers were calculated from a previously prepared HMEC-1 
specific standard curve. 
HMEC-1 growth on Matrigel.  Angiogenesis analysis was conducted with HMEC-1 cells 
grown on Matrigel% (BD BioSciences).  Briefly, HMEC-1 cells were grown in T75 flasks 
(Starsted) as noted above. Following cell pellet re-suspension in sterile PBS, the cells were 
counted via hemocytometer and diluted to 1x10
6
 cells/ml in sterile PBS.  100 µl of the 
HMEC-1 dilution was added to each well containing a 1ml mixture of 50% M199 (Cambrex) 
(15% FBS and 2% penicillin-streptomycin) and 50% EGM-2 (Cambrex), along with 100 µl 
of pre-warmed, solidified Matrigel%.  The cells were then incubated for 24 hours in 5% CO2 
at 37°C.  After 24 hours, the medium was aspirated and replaced with pre-warmed M199 
with 5% FBS (Cambrex), and the cells were allowed to incubate in 5% CO2 at 37°C for 
either 24 hours for “Newly-formed Vessels” or 48 hours for “Pre-formed Vessels,” 
depending on the testing to be completed. 
Angiogenesis Analysis of HMEC-1 Infection by Live and Dead B. bacilliformis.   
HMEC-1 were grown as previous stated on Matrigel until “Newly-Formed and Pre-formed 
Vessels” were present for testing.  Live B. bacilliformis or formalin-killed B. bacilliformis, 
prepared as described above and diluted in 100 µL of sterile PBS, pH 7.4, to give an MOI of 
100:1, were added to each well.  At the time of infection (time zero), two randomly chosen 
areas in each well were marked and microphotographs were taken. At each prescribed time 
point, the same field of view was photographed again.  Once all time points had been 
captured, the microphotographs were compiled and printed using a color laser printer.  Each 
microphotograph was analyzed for the number of angiogenic nodes, defined as the 
convergence point of three vessels.  These raw data were averaged for each well per time 
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point in Excel (Microsoft) and graphed as needed.  Each of these experiments was completed 
in triplicate. 
Growth of B. bacilliformis for Enhanced GroEL Production.  B. bacilliformis KC584 
(passage 2) were grown by the inoculation of 100 µL of bacteria stock onto 10 BHI plates 
supplemented with 10% sheep’s blood and a subsequent incubation at 25°C with saturated 
humidity for 96 hours.  After 96 hours, 15 ml of sterile PBS, pH 7.4, was added to each of 
the B. bacilliformis-containing plates and the plates were incubated at 25°C with saturated 
humidity for another 96 hours.  The B. bacilliformis was gently harvested as described above, 
and the PBS/B. bacilliformis mixture was placed in 50-ml (Falcon) tubes.  The bacteria were 
centrifuged at 2000xg for 15 minutes at room temperature and stored at 4°C until needed.   
Crude Purification of B. bacilliformis GroEL from Culture Supernatants.  B. 
bacilliformis GroEL was harvested immediately from B. bacilliformis culture supernatants.  
To precipitate the proteins, ammonium sulfate was added to the culture supernatants to give a 
50% saturated solution, and the samples were equilibrated for 1 hour at 4°C.  The mixture 
was then centrifuged at 12000xg for 30 minutes.  The precipitated proteins were re-
suspended in 5 ml of Equilibration Buffer (50mM Tris-HCl, 0.5mM KCl, 0.5mM NaCl, 
0.2mM PMSF and 5mM MgCl2, pH 7.5), which was then measured for protein concentration 
using the Bradford method (Bradford, 1976).   The presence of GroEL was determined by 
SDS-PAGE on a 4-12% Bis-Tris gel (Invitrogen) and Western blot analysis.  
Purification of B. bacilliformis GroEL via FPLC.  Crude B. bacilliformis GroEL fractions 
were further purified by FPLC.  Briefly, an ATP-agarose column (Kamireddi et al., 1997; 
Kandekar et al., 1993) was equilibrated with Equilibration Buffer (50mM Tris-HCl, 0.5mM 
KCl, 0.5mM NaCl, 0.2mM PMSF and 5mM MgCl2, pH 8.2) at a flow rate of 0.2 ml/min for 
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five column volumes.  To the equilibrated column, 1 ml of the crude purification of B. 
bacilliformis culture supernatants was added to the equilibrated ATP-agarose column; and 
allowed to re-circulate for 12-16 hours at 4°C at 0.2mL/min.  One column volume of 
Equilibration Buffer was then allowed to move through the column before the Elution Buffer 
(Equilibration Buffer containing 10mM ATP, pH 8.2) was added.  Fractions of 2 ml were 
collected and these were then subjected to SDS-PAGE to determine whether they contained a 
band corresponding in size to that predicted for GroEL (65kDa). All fractions containing B. 
bacilliformis GroEL were then concentrated further using an Amicon 30,000 dalton cutoff 
membrane centrifuged for 10 minutes at 5000xg at 4°C.  SDS-PAGE and Western blot 
analysis were subsequently used to verify the presence and estimate the purity of B. 
bacilliformis GroEL. 
Proliferation Analysis of HMEC-1 Exposed to Purified B. bacilliformis GroEL with 
HMEC-1.  HMEC-1 were grown as previous stated and diluted to 5x10
5
 cells/ml in sterile 
PBS, pH 7.4.  100 µL of diluted cells were inoculated into each well of the low-florescence 
96 well plate(s) containing 100 µL of pre-warmed M199 (Cambrex) (15% FBS and 2% 
penicillin-streptomycin) to a final concentration of 50,000 cells per well.  The cells were then 
incubated at 37
o
C and 5% CO2.  After 24 hours, the medium was aspirated and replaced with 
100 µlLof M199 containing 5% FBS, and the cells were subsequently incubated at 37oC and 
5% CO2. After 6 hours, 10 ng of GroEL was added to each well in a volume of 10 µL, while 
10 µL of sterile PBS was added to each control well. Following an incubation for the 
prescribed time period, the medium was removed and replaced with 50 µL of 1x CyQuant 
Proliferation mix (Invitrogen) and allowed to incubate at 37°C and 5% CO2 for 45 minutes.  
The 96-well plate was then read using the Typhoon Variable Imaging System 
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(GE/Amersham) set at 600V and using the 520 nm blue laser filter.  The data were then 
transferred to the ImageQuant Analysis software (Amersham) and the pixel values were 
calculated for each well following a 96-well template.  Raw pixel data were then transferred 
to Excel (Microsoft) and cell numbers were calculated from a previously prepared HMEC-1 
specific standard curve. 
Angiogenesis Analysis of HMEC-1 in the Presence of Purified B. bacilliformis GroEL.  
HMEC-1 were grown on Matrigel as previously described until “Newly-Formed and Pre-
formed Vessels” were present for testing.  Ten ng of purified B. bacilliformis GroEL was 
added to each experimental well in 10 µL of sterile PBS, pH 7.4. At the time of infection 
(time zero) two randomly chosen areas in each well were marked and microphotographs 
were taken. At each prescribed time point, the same field of view was photographed again.  
Once all time points had been captured, the microphotographs were compiled and printed 
using a color laser printer.  Each microphotograph was analyzed for the number of 
angiogenic nodes, defined as the point of convergence of three vessels.  The raw data were 
averaged for each well per time point and graphed as needed.   
Angiogenesis Analysis of HMEC-1 in the Presence of Purified E. coli GroEL.  HMEC-1 
were grown and inoculated as previous stated, except that10 ng of purified E. coli GroEL in 
10 µL of sterile PBS, pH 7.4, was added to each experimental well. Analysis of angiogenic 
potential was completed as described above.   
Angiogenesis Analysis of HMEC-1 in the Presence of Purified B. bacilliformis GroEL 
and Rabbit E. coli Anti-GroEL antibodies. HMEC-1 were grown as previous described on 
Matrigel until “Newly Formed Vessels” were present for testing.  10 ng of purified B. 
bacilliformis GroEL (in 10 ml of sterile PBS, pH7.4) was added to each experimental well 
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along with a 1:5000 dilution of Rabbit Anti-E. coli GroEL antibodies that had been 
previously shown to react to purified B. bacilliformis GroEL.  Analysis of angiogenic 
potential was completed as described above.   
Analysis of Cytokine Production by ELISA.  Testing for the production of various 
cytokines was done per the manufacturers’ recommendations.  HMEC-1 cells were seeded in 
96 well plates at 50,000 cells per well, and grown for 24 hours in pre-warmed EGM-2 media 
(Cambrex).  After 24 hours, the medium was decanted and replaced with pre-warmed M199 
containing 5% FBS. After the addition of live B. bacilliformis, dead B. bacilliformis, or 
purified B. bacilliformis GroEL, testing media were collected and ELISA analysis was 
conducted for each cytokine noted.  Each ELISA was done with the manufacturer’s standards 
and completed with a single control media and two experimental media.  The plates were 
read on a SPECTRAmax plate reader (Molecular Devices) at OD405.  Raw data were 
collected and correlated to a best-fit of the given cytokine standard per manufacturer’s 
instructions.  Control and experimental data were averaged to give a final result noted in 
cytokine concentration (pg/ml).  
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Results 
Effect of B. bacilliformis during infection of HMEC-1 
 
HMEC-1 proliferation in the presence of B. bacilliformis.   
 HMEC-1 cells were analyzed for the induction of proliferation in the presence of live 
and formalin-killed B. bacilliformis over a period of 48 hours.  As shown in Figure 3.1, the 
initial response by HMEC-1 cells to B. bacilliformis is indistinguishable from that of mock-
infected control HMEC-1 cells.  However, there is a dramatic 5.5-fold increase in HMEC-1 
cell number at six hours post infection with live B. bacilliformis, with a continued 
proliferative effect at 12 hours of almost 2.5-fold.  This effect is also evident at 24 hours post 
infection, with a 1.5-fold increase in HMEC-1 infected cells, but drops to less than 
background levels at 36 hours post infection.  Cell proliferation is not seen when HMEC-1 
cells are infected with formalin-killed B. bacilliformis, as most time points are not 
significantly different from those seen with mock-infected control cells. 
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Figure 3.1 – HMEC-1 Proliferation during Infection with B. bacilliformis. 
HMEC-1 cells were grown in EGM-2 media for 24 hours, then in M199 with 5% FBS for 
another 12 hours.  Live or formalin-killed B. bacilliformis, at an MOI of 100:1, were added to 
the HMEC-1 cells and proliferation was assessed after various time points using CyQuant 
(Invitrogen) dye, measured at 520 nm. 
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HMEC-1 Tubule Formation in the Presence of B. bacilliformis.   
 Infection studies were conducted using HMEC-1 cells grown on Matrigel, an 
environment that is optimized for tubule formation.  HMEC-1 tubules allowed to grow for 48 
hours before infection clearly showed a decrease in angiogenic vessels beginning at 24 hours 
post infection with live B. bacilliformis.  The maximum effect was observed at 72 and 96 
hours, at which time there was nearly a 30-fold difference in nodule formation between the 
infected and uninfected cultures (Figure 3.2).  However, this effect was only observed 
following infection with live bacteria: the presence of formalin-killed B. bacilliformis 
produced no significant decrease in tubules relative to the uninfected control cells. HMEC-1 
cells that were allowed to produce tubules for 24 hours prior to infection showed a slightly 
decreased response as related to those that were allowed to grow for 48 hours before 
infection; a decrease in vessel number of approximately 2.5 relative to the control is observed 
after 72-96 hours (Figure 3.3).  Again, the presence of dead Bartonella bacilliformis had no 
overall effect on the angiogenic profile of these HMEC-1 cells.   
 
 
147 
 
 
Figure 3.2 – Pre-formed HMEC-1 Tubule-formation in the presence of B. bacilliformis. 
HMEC-1 cells were grown on Matrigel in EGM-2 media for 48 hours.   The medium was 
then changed to a low serum medium, M199 with 5% FBS, and the incubation was continued 
for 12 additional hours before Bartonella was added at a MOI of 100:1.  Photomicrographs 
were taken at the time points noted above and each frame was analyzed for the presence of 
blood vessel nodules.  These were then used as a comparison from Time Point 0 (normalized 
to 100%).   
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Figure 3.3 – Newly-formed HMEC-1 Tubule formation in the presence of B. bacilliformis. 
HMEC-1 cells were grown on Matrigel in EGM-2 medium for 24 hours.  The medium was 
then changed to a low serum media, M199 with 5% FBS, and the incubation was continued 
for an additional 12 hours before Bartonella was added at a MOI of 100:1.  
Photomicrographs were taken at the time points noted above and each frame was analyzed 
for the presence of blood vessel nodules.  These were then used as a comparison from Time 
Point 0 (normalized to 100%).   
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Analysis of Crosstalk between Infected and Uninfected Endothelial cells.   
Cell to cell crosstalk studies were conducted using the Corning TransWell% system, 
which allows for the movement of proteins across a membrane but does not allow the 
crossing of live bacteria from one chamber to the next.  Uninfected HUVEC cells were 
allowed to grow in the lower chamber in a tubule-forming environment for 48 hours before 
the upper layer of HUVEC cells was infected with B. bacilliformis at an MOI of 100:1.  
Photomicrographs were taken at various time points over the subsequent 48-hour period. 
While mock infected cells (data not shown) showed no appreciable degredation in tubules 
formed over the 48 hour monitoring period, a dramatic decrease in tubules was noted after 24 
hours of incubation in the lower chamber of uninfected HUVEC cells, which continues 
through the monitored 48 hours (Figure 3.4).  Further cell crosstalk studies were conducted 
using infected HEp-2 cells, an epithelial cell line, in the top chamber of the Corning trans-
well system while uninfected HUVEC cells were grown in a tubule-forming environment in 
the bottom.  The photomicrographs reveal that within 8 hours there is a decrease in the 
number of angiogenic vessels as compared to the previous time points measured (Figure 3.5), 
while studies with mock infected cells showed no tubule degredation (data not shown).  
These results indicate that the presence of live B. bacilliformis is not required for the 
degradation of pre-formed tubules during the infection of endothelial and epithelial cells, and 
suggests instead that a protein or some other soluble factor able to cross the TransWell 
barrier promotes tubule degradation. 
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Figure 3.4 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected 
HUVEC cells.   
Cross-talk studies were conducted using the Corning TransWell% system allowing for the 
diffusion of small molecules from the upper chamber, which contains B. bacilliformis-
infected HUVEC cells, to the lower chamber, which contains uninfected HUVEC cells 
growing in a tubule-forming environment.  Photomicrographs were taken at the times noted 
after addition of B. bacilliformis to the upper chamber (MOI 100:1). 
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Figure 3.5 – Cross-talk analysis of uninfected HUVEC cells in the presence of infected HEp-
2 cells. 
Cross-talk studies were conducted using the Corning TransWell% system allowing for the 
diffusion of small molecules from the upper chamber, which contains B. bacilliformis-
infected HEp-2 cells to the lower chamber, which contains HUVEC cells growing in a 
tubule-forming environment.  Photomicrographs were taken at the times noted after addition 
of  B. bacilliformis to the upper chamber (MOI 100:1).  
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ELISA Analysis of HMEC-1 Cells in the Presence of B. bacilliformis.   
ELISA analysis was conducted to determine the production of various cytokines over 
the course of infection by B. bacilliformis of HMEC-1 cells growing in a non-tubule forming 
environment.   Initial studies were conducted with IL-2, IL-6 and TNF-alpha.  IL-2 and TNF-
alpha showed no overall change from control conditions (Figures 3.6-3.8); however, at 24 
hours post infection there was a slight decrease in IL-6 production in infected cells (Figure 
3.7).   Changes in the production of these cytokines was also monitored after infection with 
formalin-killed bacteria. Again, there was no statistically significant change in production 
(figure 3.9-3.11), with the single exception of a three-fold decrease in IL-6 after 36 hours of 
infection (Figure 3.10).   
 Further studies were carried out with a larger battery of cytokines.  IL-17 production 
by HMEC-1 infected with live B. bacilliformis increased approximately 2.5-fold 48 hours 
post infection (Figure 3.12).  All other cytokines such as IGF-I (data not shown), IL-8 
(Figure 3.13) and IL-18 (Figure 3.14) showed no overall change in production during 
infection with live B. bacilliformis as compared with the uninfected control.  However, there 
were significant increases in the production of several cytokines in the presence of formalin-
killed bacteria.  Infection with formalin-killed B. bacilliformis showed an increase of IL-17 
production at both six and 48 hours post infection, with a maximum increase of three-fold 
after 48 hours (Figure 3.12).  ELISA analysis of IL-8 production also showed increases at 
six, 24 and 48 hours, with the largest increase (approximately seven-fold) occurring at 48 
hours (Figure 3.13).  Finally, the production of IL-18 in the presence of formalin-killed B. 
bacilliformis with HMEC-1 cells showed an increase (relative to the control) of 
approximately six fold at the 48 hour time point (Figure 3.14).  It should be noted that in 
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nearly all cases formalin-killed B. bacilliformis induced cytokine production at a higher rate 
than live B. bacilliformis. 
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Figure 3.6 – ELISA analysis of IL-2 production during infection with live B. bacilliformis. 
IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. 
bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was replaced 
with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1.  ELISA was 
carried out per manufacturer’s instructions using a single control and two experimental 
media.  After the ELISA reaction was complete the 96-well plate was read using a 
SPECTRAmax plate reader set at 450 nm.  
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Figure 3.7 – ELISA analysis of IL-6 production during infection with live B. bacilliformis. 
IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. 
bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was replaced 
with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1.  ELISA was 
carried out per the manufacturer’s instructions using a single control and two experimental 
media.   After the ELISA reaction was complete, the 96-well plate was read using a 
SPECTRAmax plate reader set at 450 nm.  
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Figure 3.8 – ELISA analysis of TNFa production during infection with live B. bacilliformis. 
TNF-! production by HMEC-1 cells was determined by ELISA analysis after the addition of 
B. bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was 
replaced with M199 with 5% FBS and live B. bacilliformis was added at a MOI of 100:1.  
ELISA was carried out per the manufacturer’s instructions using a single control and two 
experimental media.  After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.9 – ELISA analysis of IL-2 production during infection with formalin-killed B. 
bacilliformis. 
IL-2 HMEC-1 production was determined by ELISA analysis after the addition of formalin-
killed B. bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was 
replaced with M199 with 5% FBS and formalin-killed B. bacilliformis was added at a MOI 
of 100:1.  ELISA was carried out per the manufacturer’s instructions using a single control 
and two experimental media.  After the ELISA reaction was complete, the 96-well plate was 
read using a SPECTRAmax plate reader set at 450 nm.  
 
 
158 
 
 
Figure 3.10 – ELISA analysis of IL-6 production during infection with formalin-killed B. 
bacilliformis. 
IL-6 production of HMEC-1 was determined by ELISA analysis after the addition of 
formalin-killed B. bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The 
medium was replaced with M199 with 5% FBS and formalin-killed B. bacilliformis was 
added at a MOI of 100:1.  ELISA was carried out per the manufacturer’s instructions using a 
single control and two experimental media.   After the ELISA reaction was complete, the 96-
well plate was read using a SPECTRAmax plate reader at set 450 nm.  
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Figure 3.11 – ELISA analysis of TNFa production during infection with formalin-killed B. 
bacilliformis. 
TNF-! production was determined by ELISA analysis after the addition of formalin-killed B. 
bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was replaced 
with M199 with 5% FBS and formalin-killed B. bacilliformis was added at a MOI of 100:1.  
ELISA was carried out per the manufacturer’s instructions using a single control and two 
experimental media.  After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.12 – ELISA Analysis of IL-17 Production in the presence of B. bacilliformis. 
IL-17 production of HMEC-1 was determined by ELISA analysis after the addition of B. 
bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was replaced 
with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of 
100:1.  ELISA was carried out per the manufacturer’s instructions using a single control and 
two experimental media.  After the ELISA reaction was complete the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  Analysis was completed based on per cell 
number data obtained from proliferation assays in the presence of live and formalin-killed B. 
bacilliformis. 
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Figure 3.13 – ELISA Analysis of IL-8 Production in the presence of B. bacilliformis. 
IL-8 production by HMEC-1 cells was determined by ELISA analysis after the addition of  
B. bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was 
replaced with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a 
MOI of 100:1.  ELISA was carried out per the manufacturer’s instructions using a single 
control and two experimental media.  After the ELISA reaction was complete the 96-well 
plate was read using a SPECTRAmax plate reader set at 450 nm.  Analysis was completed 
based on per cell number data obtained from proliferation assays in the presence of live and 
formalin-killed B. bacilliformis.  
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Figure 3.14 – ELISA Analysis of IL-18 Production in the presence of B. bacilliformis. 
IL-18 production of HMEC-1 was determined by ELISA analysis after the addition of B. 
bacilliformis.  HMEC-1 cells were grown for 24 hours in EGM-2.  The medium was replaced 
with M199 with 5% FBS and live or formalin-killed B. bacilliformis was added at a MOI of 
100:1.  ELISA was carried out per the manufacturer’s instructions using a single control and 
two experimental media.  After the ELISA reaction was complete the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  Analysis was completed based on per cell 
number data obtained from proliferation assays in the presence of live and formalin-killed B. 
bacilliformis. 
164 
 
HMEC-1 proliferation in the presence of B. bacilliformis membranes.   
 HMEC-1 cells were studied for their proliferative response to the presence of inner 
and outer B. bacilliformis membranes.  As the data indicate (Figure 3.15), the presence of 
inner membranes from B. bacilliformis induced an increase of approximately 1.5 fold in 
HMEC-1 cell concentration at both 6 and 36 hours relative to the untreated control cells.  In 
contrast, the presence of B. bacilliformis outer membranes caused a four-fold decrease in cell 
number at 36 hours post infection, with a similar but less dramatic decrease at six hours post 
infection.  
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Figure 3.15 – HMEC-1 Proliferation in the presence of B. bacilliformis membranes. 
HMEC-1 cell proliferation was determined after the addition of B. bacilliformis inner (IM) 
and outer (OM) membranes.  HMEC-1 cells were grown in EGM-2 media for 24 hours, then 
in M199 with 5% FBS for another 12 hours.  Purified B. bacilliformis membranes, as noted, 
were added to the HMEC-1 cells and proliferation was assessed after six and 36 hours using 
CyQuant (Invitrogen) dye, as measured at 520 nm. 
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ELISA analysis of HMEC-1 cells in the presence of B. bacilliformis cellular components
 Production of IL-2, IL-6 and TNF&alpha by HMEC-1 cells was measured in the 
presence of B. bacilliformis inner and outer membranes in order to determine the cytokine 
response of HMEC-1 cells to these bacterial components.  As shown in Figure 3.16, IL-2 
production in the presence of either inner or outer membrane fractions decreased by 
approximately 1.5 fold relative to the control at 36 hours post incubation.  Analysis of IL-6 
production shows an increase at both six and 36 hours in the presence of B. bacilliformis 
outer membranes and at 36 hours in the presence of B. bacilliformis inner membranes (Figure 
3.17).  Finally, TNF-alpha production exhibits an overall decrease at 36 hours in the presence 
of B. bacilliformis outer membranes (Figure 3.18).   
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Figure 3.16 – ELISA analysis of IL-2 production in the presence of B. bacilliformis 
membranes. 
IL-2 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. 
bacilliformis inner (IM) and outer (OM) membranes.  HMEC-1 cells were grown for 24 
hours in EGM-2.  The medium was replaced with M199 with 5% FBS and B. bacilliformis 
membranes were added.  ELISA was carried out per the manufacturer’s instructions using a 
single control and two experimental media.  After the ELISA reaction was complete the 96-
well plate was read using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.17 – ELISA analysis of IL-6 production in the presence of B. bacilliformis 
membranes. 
IL-6 production by HMEC-1 cells was determined by ELISA analysis after the addition of B. 
bacilliformis inner (IM) and outer (OM) membranes.  HMEC-1 cells were grown for 24 
hours in EGM-2.  The medium was replaced with M199 with 5% FBS and B. bacilliformis 
membranes were added.  ELISA was carried out per the manufacturer’s instructions using a 
single control and two experimental media.  After the ELISA reaction was complete the 96-
well plate was read using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.17 – ELISA analysis of TNF! production in the presence of B. bacilliformis 
membranes. 
TNF! production by HMEC-1 cells was determined by ELISA analysis after the addition of 
B. bacilliformis inner (IM) and outer (OM) membranes.  HMEC-1 cells were grown for 24 
hours in EGM-2.  The medium was replaced with M199 with 5% FBS and B. bacilliformis 
membranes were added.  ELISA was carried out per the manufacturer’s instructions using a 
single control and two experimental media.  After the ELISA reaction was complete the 96-
well plate was read using a SPECTRAmax plate reader set at 450 nm.  
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Analysis of Production of B. bacilliformis GroEL. 
 Recent studies have shown that extracts containing the molecular chaperone GroEL 
have a proliferative effect on B. bacilliformis-infected cells.  To determine whether the 
protein plays a direct role in cell proliferation, we purified GroEL and measured its 
mitogenic abilities in culture.  As a first step, we sought to optimize conditions for the 
isolation and purification of B. bacilliformis GroEL.    Initial studies evaluated GroEL 
production by both Bartonella bacilliformis KC584 and Bartonella bacilliformis JB584 on 
BHI (Figure 3.19a) and TSA (Figure 3.19b) agar with a supplement of 10% sheep's blood.  
After 10 days of growth on BHI agar (Figure 3.19a), the bacteria were physically removed 
from the plate and and concentrated via centrifugation.  The re-suspension was then 
examined using SDS-PAGE and Western blot analysis for bacterial GroEL.  After 10 days of 
growth on solid media, no detectable amount of Bartonella GroEL was visualized via SDS-
PAGE or Western blot.  Further studies were conducted with B. bacilliformis KC584 grown 
on TSA with 10% sheep's blood (Figure 3.19b), and again the bacteria were physically 
harvested and clarified using centrifugation.  GroEL production was monitored at growth 
days 1, 3, 5, 7 and 10 using SDS-PAGE and Western blot (data not shown).   As shown in 
Figure 3.19, bacterial GroEL was not obtained under these conditions either.  Further studies 
were conducted in liquid media consisting of Schaedler broth supplemented with 10% 
sheep's blood.  Bartonella bacilliformis KC584 was evaluated for the secretion of GroEL in 
this liquid environment over a 10-day time course.    At days 1, 3, 5, 7, and 10 the liquid was 
clarified by centrifugation and the supernatant was subjected to both SDS-PAGE and 
Western blot analysis (Figure 3.20).   These conditions resulted in the identification of a 
protein migrating at approximately 65 kilodaltons, the size predicted for B. bacilliformis 
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GroEL.  The 65-kilodalton protein was observed at high concentrations on both the SDS-
PAGE and Western blot starting at growth day four.  The SDS-PAGE is further distinguished 
by a characteristic double banding pattern produced in response to rabbit-produced E. coli 
anti-GroEL antibodies. This additional band has been reported previously with purified 
GroEL fractions from other Bartonella species (Haake et al., 1997), and has been attributed 
to dimerization of GroEL or the presence of additional proteins bound to GroEL.  Further 
studies were conducted to verify the secretion of GroEL in the presence of both HUVEC 
cells and HMEC-1 cells, and production of GroEL was evident in both tissue culture 
environments (data not shown).   
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Figure 3.19 – SDS & Western blot Analysis of B. bacilliformis Growth on Solid Media.   
Figure A - B. bacilliformis KC584 (I) and JB584 (II) were grown on solid BHI and samples 
taken after 10 days growth, Western blot analysis was done against GroEL using anti-E. coli 
GroEL antibodies. Figure B - TSA agar (B) supplemented with 10% sheep’s blood over the 
course of 10 days, with samples of B. bacilliformis taken every other day starting at Day 1 
post inoculation (growth day indicated above lanes) .  SDS-PAGE was conducted on each 
sample, after clarification, as noted above, and Western blot analysis was completed (data not 
shown). 
B. bacilliformis 
KC584 & JB584 
Grown on BHI w/10% SB 
I II I II M 
B. bacilliformis 
Grown on TSA w/10% 
SB over 10 Days 
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Figure 3.20 – SDS-PAGE and Western Blot Analysis of B. bacilliformis growth in liquid 
media.  
B. bacilliformis was grown in 100 ml bottles of Schaedler broth supplemented with 10% 
sheep’s blood.  Samples were taken, and after sample clarification and RBC lysis with double 
distilled H2O each sample was run on SDS-PAGE (lanes indicate growth day 1, 3, 5, 7, 9 & 
10). Western blot analysis was completed using rabbit-based E. coli Anti-GroEL antibodies.  
The arrows indicate the position expected for GroEL (65 kDa) and the position of a possible 
dimer (145 kDa).    
B. bacilliformis grown 
in Schaedler broth  
with 10% SB 
M 3 7 10 1 5 9 3 7 10 1 5 9 
145kDa 
65kDa 
98kDa 
62kDa 
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GroEL purification.   
 Purification of GroEL was carried out on extracts of Bartonella bacilliformis KC584 
using both ammonium sulfate and ATP-agarose column purification (Figure 3.21 and 3.22).  
At each step, the presence of an immunoreactive protein with the predicted molecular weight 
of GroEL (65 KDa) was monitored by SDS-PAGE and Western blot analysis. Western blot 
analysis (Figure 3.23) was conducted using rabbit-produced E. coli anti-GroEL antibodies.  
Each positive Western blot shows a unique double banding, with immunoreactive proteins 
migrating at approximately145kDa and 65kDa.  This additional band has been reported 
previously with purified GroEL fractions from other Bartonella species (Haake et al., 1997), 
and has been attributed to GroEL dimerization or the presence of additional proteins bound to 
GroEL. 
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Figure 3.21 – SDS-PAGE analysis of B. bacilliformis GroEL purification after Ammonium 
Sulfate Fractionation. 
B. bacilliformis was grown on BHI with 10% sheep’s blood for 4 days followed by 4 days of 
growth under PBS, then harvested by scraping.  After clarification, the sample was mixed 
with 50% ammonium sulfate and the proteins were allowed to precipitate.  This mixture was 
then centrifuged and re-suspended in buffer and a sample, shown in lane 2, was run on SDS-
PAGE.  A Western blot was carried out (not shown) in order to verify the presence of the 65 
kDa GroEL protein (indicated by the arrow). The position of a possible dimer migrating at 
approximately 145 kDa is also shown. 
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Figure 3.22 – SDS-PAGE Analysis of B. bacilliformis GroEL purification after ATP-Agarose 
elution. 
An ATP-agarose column was used to further purify B. bacilliformis GroEL, after ammonium 
sulfate fractionation.  The crude fraction believed to contain GroEL was added to the ATP-
column and allowed to circulate for 16 hours, then eluted in 10mM ATP containing buffer.  
The SDS-PAGE gel shows the fractions collected in lanes 2-7.  The positions of proteins 
reacting against anti-E. coli GroEL antibodies are indicated by the arrows (65 kDa and 145 
kDa). 
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Figure 3.23 – SDS-PAGE and Western Blot Analysis of B. bacilliformis GroEL purification 
after Amicon Filtration. 
After ATP-column purification the B. bacilliformis GroEL was polished using an Amicon 
filter, MW Cutoff 30,000 kDa, as per the manufacturer’s instructions.  The SDS-PAGE (A) 
indicates purified GroEL (145kDa and 65kDa), lane 1 shows the protein marker (Bio-Rad, 
All Blue), and lane 2 shows purified GroEL after Amicon polishing.  Western blot analysis 
(B) indicating the presence of purified GroEL using anti-E. coli GroEL antibodies.  
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Induction of HMEC-1 Proliferation by Purified Bartonella bacilliformis GroEL.   
 Purified B. bacilliformis GroEL was evaluated for its ability to induce proliferation of 
HMEC-1 cells in 96-well plates.  After a series of purified B. bacilliformis GroEL infection 
studies were completed to determine the best possible proliferative dilutions (data not 
shown), a range of 10 ng to 1 ng of purified GroEL was chosen as the optimal conditions for 
the proliferation studies.  Further experiments showed that GroEL at most of these 
concentrations had no detectable effect on proliferation of HMEC-1 cells that were not in a 
tubule-forming environment; only 10 ng of GroEL gave any consistent yet weak proliferative 
effect (data not shown). 
HMEC-1 Tubule Formation in the Presence of purified GroEL.   
 Purified B. bacilliformis GroEL was incubated with HMEC-1 cells that were allowed 
to grow in a tubule-forming environment for either 24 or 48 hours prior to GroEL addition.  
Incubation of cells with 5 ng of purified GroEL produced an overall increase in angiogenesis 
as compared to controls, with a maximum increase of two fold at 48 hours with 24-hour, 
“newly-formed” HMEC-1 tubules (data not shown).  Studies using 10 ng of purified 
Bartonella bacilliformis GroEL showed a dramatic increase in tubule formation across time 
points from six to 96 hours (Figure 3.24).  This angiogenic effect reached a maximum at 72 
hours, where a five-fold increase in angiogenesis as compared to the control was observed.  
Further studies were conducted to determine the effect of incubating HMEC-1 with both live 
B. bacilliformis (MOI of 100:1) and 10 ng/ml of purified B. bacilliformis GroEL.  The results 
of these studies indicate that the presence of B. bacilliformis GroEL continues to induce 
angiogenesis in HMEC-1 cells despite ongoing infection by B. bacilliformis.  As shown in 
Figure 3.25, there is a stable increase in angiogenesis seen after 24 hours of infection which 
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continues throughout the 96 hour monitoring period.  This increase in angiogenesis is seen 
maximally at 48 hours as a two-fold increase relative to mock infected HMEC-1 cells, and 
continues through the remaining time points.  In order to ensure that the angiogenesis seen 
was induced by B. bacilliformis GroEL and not by a minor contaminant of the GroEL protein 
preparation, a series of control experiments was carried out in which HMEC-1 cells were 
incubated with E. coli anti-GroEL antibodies in the presence of live B. bacilliformis, B. 
bacilliformis GroEL, or E. coli GroEL  (Figures 3.26-3.29).  The results indicate that anti-
GroEL antibodies significantly reduce the angiogenic effect seen with purified B. 
bacilliformis GroEL; furthermore, they show that neither E. coli GroEL nor anti-GroEL 
antibodies themselves affect angiogenesis in HMEC-1 cells. 
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Figure 3.24 – HMEC-1 Tubule-formation in the presence of purified B. bacilliformis GroEL. 
Ten ng of purified B. bacilliformis GroEL was added to HMEC-1 cells that had been grown 
for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in M199 media containing 
5% FBS.  Photomicrographs were taken at the time points noted above and each frame was 
analyzed for the presence of blood vessel nodules.   The 0 time points for experimental and 
control samples were each normalized to 100; subsequent time point values are expressed as 
a percent of the initial time point.
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Figure 3.25 – HMEC-1 Tubule-formation in the presence of Live B. bacilliformis and GroEL. 
Purified B. bacilliformis GroEL was added to HMEC-1 cells that had B. bacilliformis at an 
MOI of 100:1 and 10 ng of purified GroEL were added to HMEC-1 cells that had been 
grown for 36 hours in EGM-2 on Matrigel followed by 12 hours’ growth in a low serum 
M199 medium containing 5% FBS.   Photomicrographs were taken at the time points noted 
above and each frame was analyzed for the presence of blood vessel nodules.  The 0 time 
points for experimental and control samples were each normalized to 100; subsequent time 
point values are expressed as a percentage of the initial time point.
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Figure 3.26 – HMEC-1 Tubule-formation in the presence of E. coli GroEL Antibodies. 
Rabbit-based E. coli Anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 cells 
that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 hours in a low serum 
M199 medium containing 5% FBS.  Photomicrographs were taken at the time points noted 
above and each frame was analyzed for the presence of blood vessel nodules.  The 0 time 
points for experimental and control samples were each normalized to 100; subsequent time 
point values are expressed as a percent of the initial time point. 
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Figure 3.27 – HMEC-1 Tubule-formation in the presence of Live. B. bacilliformis and E. coli 
Anti-GroEL Antibodies. 
Live B. bacilliformis and anti-GroEL antibodies (diluted 1:5000) were added to HMEC-1 
cells that had been grown for 36 hours in EGM-2 on Matrigel followed by growth for 12 
hours in a low serum M199 medium containing 5% FBS.  Photomicrographs were taken at 
the time points noted above and each frame was analyzed for the presence of blood vessel 
nodules.  The 0 time points for experimental and control samples were each normalized to 
100; subsequent time point values are expressed as a percent of the initial time point. 
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Figure 3.28 – HMEC-1 Tubule-formation in the presence of B. bacilliformis GroEL and E. 
coli GroEL antibodies. 
Purified B. bacilliformis GroEL (10 ng) in the presence of E. coli anti-GroEL antibodies 
(diluted 1:5000) were added to HMEC-1 cells that had been grown for 36 hours in EGM-2 on 
Matrigel followed by 12 hours’ growth in a low serum, M199 with 5% FBS, media.  
Photomicrographs were taken at the time points noted above and each frame was analyzed 
for the presence of blood vessel nodules.  These were then used as a comparison from Time 
Point 0 to determine the up- or down-regulation of HMEC-1 tubule formation. 
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Figure 3.29 – HMEC-1 Tubule-formation in the presence of purified E. coli GroEL and E. 
coli Anti-GroEL antibodies. 
Purified E. coli GroEL (10 ng) and Anti-GroEL antibodies (diluted 1:5000) were added to 
HMEC-1 cells that had been grown for 36 hours in EGM-2 on Matrigel followed by 12 
hours’ growth in a low serum M199 medium containing 5% FBS.  Photomicrographs were 
taken at the time points noted above and each frame was analyzed for the presence of blood 
vessel nodules.  The 0 time points for experimental and control samples were each 
normalized to 100; subsequent time point values are expressed as a percent of the initial time 
point. 
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ELISA Analysis of HMEC-1 cells in the Presence of Purified B. bacilliformis GroEL.   
 ELISA analysis was carried out to determine the production of various cytokines by 
HMEC-1 after incubation with 10 ng GroEL in a tubule-forming environment.  Overall, 
cytokine production of IL-2 and IL-6 showed a general increase relative to the control, while 
IL-8, IL-17 and IL-18 showed little to no change.  Specifically, IL-2 induction was seen after 
24 hours, with a seven-fold increase in IL-2 production over that of the mock incubated 
HMEC-1 (Figure 3.30).  Unlike IL-2, IL-6 production showed an overall increase at all 
measured time points, with the greatest increase (10-fold) noted at six hours (Figure 3.31).  
Production of IL-8 showed a slight decrease relative to the control at all measured time 
points, but none of statistical significance (Figure 3.32).  IL-17 cytokine production (Figure 
3.33) exhibited almost no change from control values. Production of IL-18 showed a slight 
increase at 12 hours post incubation while other time points showed little change (Figure 
3.34).
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Figure 3.30 – ELISA Analysis of IL-2 production in the presence of B. bacilliformis GroEL. 
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; then the media was replaced 
with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was added.  
ELISA was carried out per the manufacturer’s instructions using a single control and two 
experimental media.  After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.31 – ELISA Analysis of IL-6 production in the presence of B. bacilliformis GroEL. 
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the media was then replaced 
with M199 containing 5% FBS and  10 ng of purified B. bacilliformis GroEL was added.  
ELISA was carried out per the manufacturer’s instructions using a single control and two 
experimental media. After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.32 – ELISA Analysis of IL-8 production in the presence of B. bacilliformis GroEL. 
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then 
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was 
added.  ELISA was carried out per the manufacturer’s instructions using a single control and 
two experimental media. After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.33 – ELISA Analysis of IL-17 production in the presence of B. bacilliformis GroEL. 
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then was 
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was 
added.  ELISA was carried out per the manufacturer’s instructions using a single control and 
two experimental media.  After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm.  
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Figure 3.34 – ELISA Analysis of IL-18 production in the presence of B. bacilliformis GroEL. 
HMEC-1 cells were grown on Matrigel for 24 hours in EGM-2; the medium was then 
replaced with M199 containing 5% FBS and 10 ng of purified B. bacilliformis GroEL was 
added.  ELISA was carried out per the manufacturer’s instructions using a single control and 
two experimental media. After the ELISA reaction was complete, the 96-well plate was read 
using a SPECTRAmax plate reader set at 450 nm. 
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Motif analysis of Bartonella bacilliformis KC584 GroEL.   
 DNA and protein sequence analyses were conducted on B. bacilliformis KC583 
GroEL (Accession YP989430) in order to search for any unique motifs that may be present 
in this protein.  DNA sequence analysis using Vector NTI AlignX (Invitrogen) was 
conducted to compare the GroEL open reading frame deduced from the published B. 
bacilliformis KC583 with those of other bacterial species, as well as those coding for GroEL 
proteins and homologues implicated in disease and immunosuppression (Table 3.1).  B. 
bacilliformis GroEL DNA shares high sequence identity to the GroEL open reading frames 
of  B. henselae (85.0%), B. quintana str Toulouse (84.7%) and a lower 45.5% identity to that 
of B. tribocorum GroEL,  with a similar degree of identity to homologues of other Bartonella 
species and other members of the !-2 Proteobacteria family (data not shown). Comparison of 
the gene encoding B. bacilliformis GroEL to bacterial DNA sequence(s) from other genera 
shows high individual identity, with the highest being B. abortus (72.5%), followed by E. 
coli K12 and M. loti, with 65.8% and 65.7% identity, respectively.  The degree of identity 
between DNA sequences coding for B. bacilliformis GroEL and GroEL proteins implicated 
in disease states from 34% to 63.1%, with Human HSP70 and C. trachomatis GroEL 
exhibiting the lowest and highest level of identity, respectively.  Finally, a comparison of B. 
bacilliformis GroEL DNA sequences of eukaryotic GroEL homologues exhibited little or no 
sequence identity above random background, with the possible exception of Mouse HSP60.  
 Comparison of the predicted amino acid sequences of the GroEL open reading frames 
reveals a high degree of identity, as well as functional similarity.  Within the genus 
Bartonella, the identity exceeded 90% for all species tested.   When protein homology was 
determined between B. bacilliformis and other common bacterial GroELs there was an 88.4% 
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similarity between all sequences noted with the highest similarity to B. abortus (92.5%).  As 
with the DNA sequence comparisons, amino acid identity and functional similarity between 
B. bacilliformis and disease implicated GroEL species are lower (ranging from 20.2% to 
79.6%) and the comparison with two of the three immunosuppressive GroEL proteins reveals 
no significant identity or similarity.  The very low identity within this grouping is not 
unexpected as these proteins are derived from eukaryotic sources.   
 Motif analysis (MotifScan) indicates that the B. bacilliformis GroEL amino acid 
sequence contains an unusual sequence of amino acids at position 466-492. This sequence, 
termed the staphylocoagulase binding motif, is found in several strains of Staphylococcus 
aureus (Figure 3.35) and is known to be able to form complexes with prothrombin 
(Kawabata et al., 1985). Interestingly, the GroEL proteins from B. henselae and B. quintana 
also contain a similar staphylocoagulase motif site, with each differing from the B. 
bacilliformis protein at five positions (Figure 3.35).  Motif-based searches of other human, !-
2-proteobacterial and infective bacterial GroEL proteins do not reveal other organisms that 
share this unique staphylocoagulase-binding site. 
 In order to determine the hydrophobicity and antigenicity of the B. bacilliformis 
GroEL protein, a series of Kyte/Doolittle and Hopp/Woods plots were prepared based on the 
published B. bacilliformis KC583 GroEL DNA sequence.  Examination of the Kyte/Doolittle 
hydrophobicity plot indicates that B. bacilliformis GroEL is hydrophilic overall, which is 
expected of a cytosolic/extracellular protein (Figure 3.36).  The Hopp/Woods antigenicity 
plot of B. bacilliformis GroEL indicates that there are several acceptable epitope sites for 
antibody production;  the highest scores are observed for sites between amino acids 350-435, 
a region located at a distance from the Staphylocoagulase-binding site motif.  Further 
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Kyte/Doolittle hydrophobicity analysis reveals that amino acids between 468 and 485 are 
weakly scored as being buried inside the GroEL globular protein structure, while amino acids 
486-500 are predicted to be on the outer surface of the protein (Figure 3.37).  A detailed 
Hopp/Woods antigenicity analysis of amino acids 460-500 indicates a mix of weak epitope 
sites.  This analysis shows amino acids 467-475 to be predicted epitope sites, whereas 475-
495 are unlikely to be epitopes.    
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Table 3.1 - B. bacilliformis GroEL DNA and Protein Sequence Homology to Bacterial 
GroELs/Eukaryotic HSP Homologues.   
DNA and protein sequence homology analysis was completed via AlignX (Vector NTI) 
between common bacterial GroEL proteins, GroEL-implicated disease factors and GroEL 
homologues with known immunosuppressant roles in disease. 
 
 
DNA 
Sequence 
Protein Sequence 
  Identity Identity Similarity 
Bartonella GroEL Homologues     
B. henselae 85.0% 91.6% 95.1% 
B. quintana str Toulouse 84.7% 91.4% 95.1% 
B. tribocorum  45.5% 90.9% 95.1% 
GroEL Homologues of Other Bacteria    
M. loti 65.7% 78.3% 87.9% 
R. Prowazekii 64.5% 64.9% 78.4% 
E. coli K12 65.8% 65.8% 78.3% 
R. typhi 64.9% 64.9% 78.4% 
H. pylori 60.7% 61.6% 75.1% 
M. pneumonia 54.1% 44.3% 60.7% 
B. abortis 72.5% 85.5% 92.5% 
GroEL-Implicated Disease Factor     
C. trachomatis 63.1% 61.9% 75.2% 
P. gingivalis 61.7% 65.1% 77.9% 
Human HSP60 57.9% 51.7% 68.2% 
Human HSP70 34.0% 11.4% 20.2% 
GroEL-Homologues with Known 
Immunosupressant Roles     
Rat HSP60 19.0% 7.3% 12.3% 
Human HSP10 10.0% 3.1% 5.0% 
Mouse HSP60 57.4% 51.7% 68.2% 
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Figure 3.35  – Analysis of a possible staphylocoagulase motif site in B. bacilliformis GroEL.   
AlignX (Invitrogen) was used to conduct a protein sequence-based alignment of the known 
GroEL sequences for various Bartonella species, including B. henselae (BH), B. quintana 
Toulouse (BQT) and B. bacilliformis (BB).  This view of amino acids 451-500, shows the 
predicted staphylocoagulase binding site of B. bacilliformis in red, with the unique amino 
acid residues as compared to the other Bartonella species noted in blue.  The remainder of 
the protein sequence alignment can be found in Appendix I.
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Figure 3.36 – Hydrophilicity and antigenicity plots for B. bacilliformis GroEL.  Panel A & B 
above represent the hydrophilicity (A) and antigenicity (B) of the B. bacilliformis GroEL 
protein as conducted via MacVector 9.5.  The B. bacilliformis GroEL protein sequence was 
used to complete both the Kyte/Doolittle (hydrophilicity) and Hopp/Woods (antigenicity) 
plots using an analysis window of 7. 
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Figure 3.37 – Hydrophilicity & antigenicity plots for aa 460-500 of B. bacilliformis GroEL. 
Panels A and B above represent the hydrophilicity(A) and antigenicity (B) of the 
approximate location of the established Staphylocoagulase binding-site motif of B. 
bacilliformis GroEL protein as conducted via MacVector 9.5.  The B. bacilliformis GroEL 
protein sequence from amino acid 460-500 was used to complete both the Kyte/Doolittle 
(Hydrophilicity) and Hopp/Woods (Antigenicity) plots using an analysis window of 7. 
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Discussion 
 
Carrion’s disease, the infection caused by B. bacilliformis, is marked in the latter 
phase by the formation of verruga, which are known to be proliferative lesions brought about 
by cutaneous uncontrolled angiogenesis.  These lesions form after the migration of B. 
bacilliformis from host RBCs to the endothelial cells lining blood vessels and the subsequent 
invasion of these cells.  Several studies have reported results implicating B. bacilliformis 
supernatants and possible secreted factors in verruga formation, although none have yet 
presented a cohesive model for how this could occur (Garcia et al., 1992; Minnick et al., 
2003; Smitherman et al., 2005).  In this study we attempt to identify the role played by B. 
bacilliformis and the highly antigenic BB65 protein, which has been previously determined 
to be a potential virulence factor and has been tentatively identified as a GroEL homologue 
(Garcia et al., 1990; Knobloch, 1988; Knobloch et al., 1990). 
Inoculation of HMEC-1 cells with live B. bacilliformis resulted in a significant, 
though transient, increase in cell number (relative to the mock infected control) at 6 and  
12 hours post infection.  These results are very similar to what has been noted previously by 
Liberto et al. (2004) in their studies of B. quintana.  These investigators reported that 
between 8 and 24 hours post infection of HMEC-1 cells with B. quintana, p38 map kinase 
and JNK/SAPK signaling is inhibited, resulting in the induction of anti-apoptotic factors and 
an increase in cell proliferation due to the decrease in host cell apoptosis (Liberto et al., 
2004).  Our data suggest that this effect may also be in play during B. bacilliformis infection.  
The transient nature of the cell proliferation observed in our studies may be due to the 
production of cells that are unable to attach properly and therefore become free-floating; 
since HMEC-1 require polarity to live, these free-floating cells would subsequently die.  
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Also, it should be noted that we only observed proliferation in the presence of live B. 
bacilliformis, but not with formalin-killed bacteria. This could indicate that not only are live 
bacteria required but also that they are producing a factor(s) that is inducing proliferation in 
HMEC-1cells.  Research with B. henselae suggests that the presence of the bacteria in co-
culture with HUVEC cells is all that is required for the cells to proliferate as long as the 
bacteria are alive; direct cell-to-bacteria contact is not required.  B. quintana have been 
shown to increase the production of the anti-apoptotic factor Bcl-2 at approximately 10 hours 
post infection.  The resulting cell survival would have a positive effect on B. quintana 
infection as well, since it would provide a larger number of host cells able to support 
bacterial growth (Liberto et al., 2004).   
Cytokine Production in the Presence of Bartonella bacilliformis 
 
 In order to assess the effect of B. bacilliformis infection on the cytokine profile of 
HMEC-1 cells these host cells were infected with both live and formalin-killed B. 
bacilliformis and monitored for alterations in the cytokine production.  Infection with live B. 
bacilliformis resulted in little or no change in IL-2, IL-6, or TNF alpha cytokine production.  
IL-17 production, on the other hand, was increased by three fold during the time course.  
This increase in IL-17 production could indicate the initiation of an angiogenesis cascade 
that, due to the lack of proper environmental signals, was not completed.  Interestingly, we 
did not observe an increase in IL-8 or IL-18 production from the HMEC-1 cells during 
incubation with B. bacilliformis.  This observation contrasts with that of Resto-Ruiz, et al. 
(2002), who reported an increase in IL-8 production by HMEC-1 cells following 6 hours of 
incubation with B. henselae.   
 Our data suggest that formalin-killed B. bacilliformis is generally able to induce a 
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higher cytokine response than live B. bacilliformis, exhibiting an increase in IL-6, IL-8, IL-
17 and IL-18 evident between 36 and 48 hours of incubation.   This may be due to in 
increased persistence of the killed bacteria in the extracellular environment.   
 Incubation of HMEC-1 cells with isolated membranes of B. bacilliformis generated 
results that correlate more closely with those reported for other Bartonella species than the 
results we observed with live bacteria.  Incubation with fractionated inner or outer 
membranes produced an increase of IL-6 production at the 6- and 36-hour time points.  This 
increase has also been seen with B. henselae during macrophage infection, and with B. 
quintana infection of HUVECs (Capo et al., 2003; Musso et al., 2001). Also, we note a 
decrease in the overall production of TNF alpha in the presence of B. bacilliformis outer 
membranes, seen maximally at 36 hours. This could indicate that, much like B. quintana, the 
LPS of B. bacilliformis is a poor inducer of inflammatory responses normally observed with 
other Gram-negative bacteria (Liberto et al., 2003). 
The addition of membrane components also had a demonstrable effect on the number 
of HMEC-1 cells in culture.  Inner membranes caused a slight (approximately 1.5 fold) 
increase in cell number relative to the mock infected control after both 6 and 36 hours of 
incubation.  Conversely, outer membranes produced a four-fold decrease in cell number after 
36 hours.  These results raise the possibility that B. bacilliformis outer membranes contain a 
factor(s) that negatively affects cell proliferation or viability. 
B. bacilliformis Infection and Angiogenesis 
 Our results indicate that B. bacilliformis not only affects cell number, but also 
promotes changes in the blood vessels that are the hallmark of angiogenesis.  Live B. 
bacilliformis was found to have a significant effect on the stability of tubules formed by 
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endothelial cells, causing a 30-fold decrease in pre-formed tubules (relative to mock infected 
controls) over a 96 hour time period.  These data would appear to suggest that live B. 
bacilliformis causes a decrease in angiogenesis, a finding that would conflict with the clinical 
observations of increased angiogenesis during B. bacilliformis induced verruga peruana 
formation. The degradation of tubules could be advantageous at early stages of infection as it 
would increase the localized environment of red blood cells, thus allowing for a higher 
concentration of hemin in the localized environment and providing at an additional 
nutritional source for the infecting bacteria. Previous work by Verma et al. (2000) has shown 
that B. bacilliformis is able to induce cytoskeletal rearrangement and therefore disrupts cell-
to-cell contacts. Their research also suggests that endothelial cell motility is decreased by B. 
bacilliformis infection.  This decrease in motility could therefore interfere with the 
endothelial cells’ ability to form tubules, causing them to be unable to take part in further 
angiogenesis (Verma et al., 2001; Verma et al., 2000; Verma et al., 2002).  The degradative 
effect on preexisting tubules, or the effect of infection itself, may also establish conditions 
that promote a response by the cells that ultimately leads to new blood vessel formation.  It is 
interesting to note that the expression of genes coding for two subunits of hypoxia induced 
growth factor (HIF), a protein that has been shown to promote angiogenesis, are significantly 
upregulated following B. bacilliformis infection (Chapter II).   Taken together, these 
processes could result in the poorly formed blood vessels characteristic of verruga peruana. 
Crosstalk analysis and angiogenesis 
 Our work with cell-signaling involved studies with both endothelial and epithelial cell 
lines  (HUVEC and HEp-2, respectively) using the Corning TransWell% System.  This 
system allows for the movement of proteins, but not bacteria, from the infected to uninfected 
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chamber, thus facilitating the analysis of cell signaling molecules. Our data suggests that 
components produced by infected endothelial or epithelial cells are able to decrease the 
numbers of established tubules formed by uninfected HUVEC within approximately 24 hours 
of exposure.  These data suggest that the infection by B. bacilliformis can result in an 
alteration of the angiogenic profile of cells which are uninfected, and raise the possibility that 
cell-signaling events are occurring between infected and uninfected cells.  This would not be 
surprising as work with endothelial cells has suggested that the induction of cytokines and 
the inflammatory response of cells can result in vascular injury of uninfected endothelial 
cells over time (Waltenberger et al., 1999).  Several other studies with B. henselae have 
suggested that macrophages are called into sites of infection and act as effector cells on both 
infected and uninfected endothelial cells to induce angiogenesis (Dehio, 1999; Dehio, 2003; 
McCord et al., 2005; Resto-Ruiz et al., 2002).   The results of our cell-signaling and cytokine 
studies raise the possibility that the cytokines which are produced are allowing for the 
infiltration of macrophages into the B. bacilliformis-infected area and that these effector cells 
might also be altering the angiogenic profile of endothelial cells in the localized environment.    
The Role of GroEL in Angiogenesis 
 The search for angiogenic and other virulence factors produced by B. bacilliformis 
has been ongoing for several years.  Research in this area was initiated by Garcia et al. 
(1990), who reported that B. bacilliformis produces a factor between 12 and 14 kilodaltons 
that is able to stimulate tissue plasminogen activator (t-PA), a thrombolytic protein 
implicated in angiogenesis.  Using immunoprecipitation, Knobloch et al. (1990) identified 24 
antigens produced by B. bacilliformis, including Bb65, a highly immunogenic protein that is 
now believed to be a homologue of GroEL. 
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Classically GroEL, a molecular chaperone, is not considered a virulence factor in most 
bacteria.  Subsequent work, however, led to the proposal that GroEL may enhance the 
virulence of numerous bacteria, including H. pylori (Phadnis et al, 1996), M. tuberculosis 
(Ranford et al., 2002), and L. pneumophila (Garduno et al., 1998).  Recently, B. bacilliformis 
has been added to the list of bacteria that may use GroEL as a virulence factor.  In 2003, 
Minnick and coworkers reported the identification of a mitogenic and/or angiogenic factor 
produced by B. bacilliformis (Minnick et al., 2003).  The factor was found to be unaffected 
by polymyxin B, indicating that it is not related to LPS, and was also shown to be heat and 
trypsin sensitive, suggesting a proteinaceous nature.  Further investigation by Minnick et al. 
(2003) led to the proposal that this angiogenic factor is GroEL, based primarily on their 
findings that a) a GroEL over-producing strain of B. bacilliformis enhances endothelial cell 
growth by 6-20 fold and b) cell proliferation is inhibited by anti-GroEL antibodies.  Our 
results with purified B. bacilliformis GroEL are in agreement with Minnick’s observations.  
Although we did not observe a direct proliferative effect on cell proliferation, we found that 
addition of GroEL to endothelial cells stimulates the formation of the tubules that are 
characteristic of angiogenesis.  Moreover, this effect is abolished by the presence of anti-
GroEL antibodies, again implicating GroEL directly in the angiogenesis process.  Unlike our 
previous observations, where the addition of live B. bacilliformis led to tubule degradation, 
exposure of cells to the bacteria in the presence of purified GroEL, actually increases 
angiogenesis. This suggests that not only does GroEL play a role in angiogenesis but it is 
actually protective against the effects of live B. bacilliformis infection on the angiogenic 
process.  The angiogenic effect was not observed with E. coli GroEL, suggesting that it is 
due to amino acids unique to the B. bacilliformis homologue.   
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 DNA and protein analysis of B. bacilliformis GroEL suggests a high homology to 
other Bartonella species GroEL, as would be expected since bacterial GroEL proteins are 
highly conserved.  Interestingly, motif analysis reveals suggests a staphylocoagulase binding 
site between amino acids at positions 466-496.  Hydrophobicity and antigenicity plots 
suggest that this unique motif site is present on the outer surface of the B. bacilliformis 
GroEL and is therefore expose the localized environment.  The staphylocoagulase binding 
site may play a role in the binding of prothrombin to the surface of the B. bacilliformis 
GroEL.   Given the repetitive nature of the GroEL subunits which make up the GroEL 
structure, a maximum of 14 staphylocoagulase sites could be exposed for prothrombin 
binding.  This may produce in vivo a B. bacilliformis GroEL that is covered with 
prothrombin in the interstitial environment.  Studies have shown the role of prothrombin to 
be vast.   Prothrombin has been reported to interact directly with !5$3 integrin, one of a set 
of cell surface receptors that have been implicated in adherence and invasion by pathogenic 
bacteria.  Prothrombin was shown to bind to the !5$3 integrin through the tripeptide RGD, a 
motif that is recognized by integrins. The binding of prothrombin to the integrin is reported 
to support increased adhesion of stimulated endothelial cells and smooth muscle, both in 
suspension and cell monolayers.  This activity is mediated by the protein kinase C and 
calpain signaling pathways, as inhibition of those molecules prevented increased adhesion.  
The authors of this study suggest that the maintenance of vascular homeostasis may be 
related to the presence of prothrombin in limited quantities (Byzova et al., 1998).  Further 
studies indicate that the binding and activate of !5$3 integrin to higher concentrations of 
localized prothrombin may result in a proliferation and focal adhesion formation effect on 
smooth muscle cells due to the activation of JUN kinase-1 (Byzova et al., 1998; Stouffer et 
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al., 2003).  Thrombin has also been shown to interact with the PAF-1 receptor to induce 
endothelial cell tube formation in vitro and to increase bFGF-induced angiogenesis in vivo 
(Rhim et al., 1998).  Taken together, the extracellular localized increase of prothrombin due 
to its binding of B. bacilliformis GroEL could lead to the activation of integrin signaling 
pathways which in turn could activate the angiogenesis cascade.   In the case of B. 
bacilliformis infected endothelial cells, however, the activation and angiogenic cycle of these 
cells may be compromised by the volatile nature of extracellular protein degradation and a 
general limitation on prothrombin availability.  These limits could then manifest themselves 
as the poorly formed and highly porous vessels seen in patients exhibiting verruga peruana.  
 To date there is no evidence for a staphylocoagulase binding site in GroEL 
homologues from organisms other than Bartonella.  The binding site seen in other Bartonella 
GroEL proteins differs by five amino acids from that of B. bacilliformis.  Further studies will 
need to be conducted to determine whether the staphylocoagulase motif plays a role in 
stimulating either the cell proliferation or angiogenesis. 
 Tests of B. bacilliformis purified GroEL for its ability to induce a change in the 
cytokine profile in HMEC-1 cells revealed an IL-2 and IL-6 increase between six and 24 
hours of incubation with a maximal increase for IL-2 and IL-6 of five fold at 24 hours.  The 
secretion of these cytokines may be the host cells’ initial response to invasion and would 
bring about the infiltration of macrophages and other immune cells in order to begin fighting 
off the Bartonella infection.  These cytokines are also known to prime endothelial cells to 
begin the angiogenesis cascade as other environmental signals become present.  Interestingly, 
there was an overall decrease in IL-8 production, the hallmark of angiogenesis, which may 
indicate that IL-8 production is not necessary for the induction of angiogenesis in the 
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formation of verruga peruana.  This could be an interesting differentiation between the 
infective profile of B. bacilliformis versus that of B. henselae, which has been shown to 
increase IL-8 production in HUVEC cells (McCord et al., 2007).  It is not uncommon for 
various bacterial GroEL proteins to induce cytokine changes; incubation of E. coli GroEL 
with monocytes shows increased IL-1$ and IL-6 production even under circumstances when 
the E. coli GroEL has been partially degraded (Tabona et al., 1998).  Work by Galdiero et al. 
(1997) shows the increased production by monocytes of GM-CSF, IL-6, E-selectin, ICAM-1 
and VCAM-1 in the presence of E. coli HSP60.  This increase in ICAM-1 and VCAM-1 on 
the outer surface of monocytes allows for migration by the cells into various regions and 
increases the likelihood of cell-to-cell contact (Galdiero et al., 1997).  If this characteristic is 
also shared by B. bacilliformis GroEL, then it could also prime endothelial cells for migration 
resulting in the production of tubules.   
 In conclusion, the localized environment of B. bacilliformis infected endothelial or 
epithelial cells is likely to contain a mix of signals.  We have shown cytokine induction under 
conditions of exposure to bacteria or to GroEL that would be expected not only to aid in the 
activation and priming of endothelial cells toward angiogenesis, but also to induce the 
infiltration of effector macrophages.  This in turn should produce a barrage of cytokines 
including IL-8, the primary angiogenesis signal with probable VEGF involvement.  This 
along with the tubule-destructive nature of live B. bacilliformis should result in endothelial 
cell proliferation and reduced endothelial cell migration, leading to poorly-formed and 
degrading tubules.  However, the addition of localized high concentrations of secreted B. 
bacilliformis GroEL with its unique staphylocoagulase binding site, may activate !5$3 
integrins, resulting in a boost to the angiogenic signaling in the localized environment.  This 
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may be the true hallmark of B. bacilliformis induced verruga peruana formation.  The 
infective cycle, which would result in host cell proliferation, infiltration of hemin and other 
nutrients, would support the continued growth, invasion and immune evasion of B. 
bacilliformis and give rise to the formation of verruga peruana in those with Carrion’s 
disease. 
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Concluding Remarks:  A model for the formation of Verruga Peruana 
 
 The interaction of any bacteria with its host results in a variety of changes for both 
organisms.  The purpose of this project was to determine what role B. bacilliformis plays in 
the formation of verruga peruana during Carrion’s disease.  The data presented in Chapter II 
and Chapter III provide the basis for our model of verruga peruana formation.  According to 
this model, once B. bacilliformis exits the RBCs it will migrate to and infect the endothelial 
cells lining the subcutaneous capillary beds.  The invasion of B. bacilliformis into the 
endothelial cells and surrounding areas occurs within 30 minutes to 2 hours post-infection 
followed by a rapid proliferation of endothelial cells at 6 hours post-infection.  These new 
endothelial cells provide an excellent location for the surrounding B. bacilliformis to hide 
from the migrating effector macrophages.  As infection progresses, active macrophages in the 
area are able to kill some interstitial B. bacilliformis, resulting the presence of B. 
bacilliformis membranes and whole dead B. bacilliformis in the localized environment.  We 
have found that the presence of these bacterial components and whole dead bacteria induces 
the production of IL-6, IL-8, IL-17 and IL-18 cytokines from neighboring endothelial cells. 
While the release of IL-6 can result in the increased migration of effector macrophages, the 
other cytokines present are proangiogenic and able to prime endothelial cells into the 
angiogenesis cascade.  Also, during this time, infected cells increase transcription of 
proangiogenic factors such as VEGF and hypoxia factors HIF1! and HIF2!.  These factors 
further prime endothelial cells to begin angiogenesis and increase localized tubule formation.  
We have noted the degradation of pre-formed tubules by the presence of live B. bacilliformis 
as infection continues, which could allow for greater numbers of host RBCs, hemin and 
serum components to enter the infected interstitial spaces.  Each of these components could 
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contribute to bacterial growth and survival.  Finally, our data show that infected endothelial 
cells begin to transcribe greater quantities of HIF3!, which may aid in localized tubule 
degradation.   The persistent infection of B. bacilliformis may result in an increased localized 
concentration of its unique, secreted GroEL.  This GroEL has been shown to stabilize and 
maintain tubule formation, and in some instances increase angiogenesis.  As infection moves 
from hours to days, the localized environment would be flooded with proangiogenic 
cytokines and proteins, which along with the presence of a prothrombin-coated GroEL may 
continue to push angiogenesis forward, resulting in the formation of incomplete, damaged 
tubules.  These would be unable to support proper blood flow, allowing the migration of host 
RBCs into the area of infection and the formation of verruga. 
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AP.1 - Bartonella quintana - virB Operon Sequence       
 
        1 TTTAAACCCA AAAATGACAG AGACTATATC CAGAAATATT 
      41 ATTTTTATCG TTATCGTGCT GCTGTTAACA GCACTTGTTG 
      81 TATCAAATCC CTCTTATGCT GCGAATAGTG CTAGTAGTCT 
     121 GGGAAACGTT GATAGTGTTT TACAGAATAT TGTTACGATG 
     161 ATGACGGGGA CAACAGCAAA GCTGATTGCA ATTATATGTG 
     201 TTGCAGCTGT GGGCATTGGT TGGATGTCCG GCTTTATTGA 
     241 TTTACGCAAA GCCGCTTATT GTATTCTCGG CATTGGGATT 
     281 GTTTTTGGTG CCCCCACTCT TGTTAGTACA TTAATGGGCT 
     321 CATCATAAAT GAATGAAGAT ACTCTTTTTC TTGCCTGTAC 
     361 GCGACCAGCT ACGTTTGCCG GTGTCACAAT GGAAGGAATG 
     401 GCCCTTAATG TCATGGCGAC ATCCATTCTC TTTATTTTGA 
     441 CCAGCAACTT TACAATGATT GGTCTTGGCA TTGGATTGCA 
     481 CTTTGTTTTG CGTGAAGTGA CAAAATACGA CCACAACCAG 
     521 TTTCGCGTAT TATTTGCTTG GCTCAACACA AGAGGAAAAC 
     561 AAAAAAACCT CACCAGATGG GGAGGAGGAT CTACATCTCC 
     601 CCTACGCCTT ATCCGTACTT ATAAGGAACT GAACAGATGT 
     641 CAATTATGAA ACGGGAGTCT TTACCTGAAG AATATATTCC 
     681 TTACATACGC CACGTCAACC AACACGTCAT TGCATTAAAT 
     721 TCACGCTGCT TAATGACTGT AATGGCTGTT GAGGGGGTGA 
     761 ATTTTGATAC TGCAGATATC AATCACTTAA ATTCCTTACA 
     801 CAACCAGTTA AACACTCTCT TGAGAAATAT CGCGGATGAA 
     841 CGTGTTGCTT TATATTCTCA CATCATTCGT CGGCGCGAAA 
     881 CGATCTATCC AGAGAGTCGT TTTTTTTCAT CTTTTGCAGC 
     921 AACACTAGAT GAAAATACAA AAAGAAAATG GTTTCGCAAG 
     961 AGCTGTATAG AAATGATCTC CTTCGTTTCA CTGCTGTGGA 
    1001 ATCCAACATC GGGTAAGACT GAGCAACTCG CTTCATTTTT 
    1041 TCAGCGCTTA ACAAAAGCGA AGAAAACACA ATCTGAACCA 
    1081 GACATGGAAG CCATTCGTAA AATTGAAGAG TTAAGCCAAG 
    1121 ATCTTATACA AGGGTTGGAG AGCTATGAAG CGCGCCTCTT 
    1161 GTCAGTCTAT GCACATGAGG GCATTTTGTT TTCCGAACAA 
    1201 AGTGAATTTC TACACCAGTT ATGGGAGGAA GGCGTGAGCG 
    1241 GATTCCTCTC ACATTTGGTA CCCATTCCTT CAACGATTTA 
    1281 CTCAGACCGT GTCATTTTTG GCAAAGAAAT GATCGAAATT 
    1321 CGTCATGAAA GCAATGAACG CTTTGTTGGC ATGTTTGGCT 
    1361 GGAAAGAATA TCCCTCTAAA ACACGCCCAG GTATGACAGA 
    1401 TGGTTTACTC ACAGCACCGT TTGAATTTAT CTTAACACAA 
    1441 TCCTTTGTCT TTAAGAGTAA AGCAGCTGCC AGGGTCATTA 
    1481 TGGGCCGCAA ACAAAATCAG ATGATTAATG CAGCGGATCG 
    1521 TGCTAGCTCG CAAATTGATG CACTTGATGA AGCGCTTGAT 
    1561 GATTTAGAAT CAAACCGTTT TGTTTTGGGC GAACATCATC 
    1601 TCTCTCTAGC CGTTTTTGCT GATCAACCAA AAACATTGGT 
    1641 TGAATACCTC TCAAAAGCGC GCGCTCACTT AACCAATGGT 
    1681 GGAGCGGTTA TCGCCAGAGA AGATCTAGGA TTAGAAGCTG 
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    1721 CATGGTGGGC GCAACTGCCT GGAAATTTCA GCTATCGTGC 
    1761 GCGATCTGGA GCCATTACCA GCAGAAATTT TGCAGCGTTA 
    1801 TCGCCCTTCC ATTCCTTCCC CATTGGCAAA CTTGAAGGCA 
    1841 ATGTTTGGGG AGCGGCTGTG GCATTGCTGA AAACACAAGC 
    1881 TGGTTCACCT TATTATTTTA ATTTTCATTA TGGTGACCTT 
    1921 GGCAACACTT TTGTTTGCGG TCCATCAGGA TCTGGTAAAA 
    1961 CTGTGATTGT TAATTTCCTT CTCGCACAAT TACAAAAACA 
    2001 TAACCCGACA ATGGTCTTTT TTGACAAAGA TCAAGGCGCA 
    2041 GAGATTTTTG TGCGTGCTGG AGGTGGAAAA TATAAGCCTT 
    2081 TGAAAAACGG ACAGCCCACG GGCATTGCTC CATTAAAGGG 
    2121 CATGGAATAC ACTGAAAAAA ACAAAATCTT TCTTCGCAGT 
    2161 TGGGTCTTGA AGCTGGTGAC AACTGAAGGG CAAACAGTGA 
    2201 CAGAACAAGA GCGACAAGAT ATCGCCAAAG CCATAAATTC 
    2241 CTTGGAAAGT CTTCCACATG CGCAACGCTC TCTTGGTGCC 
    2281 CTTCAATTGT TTTTTGATAA CACATCAAAA GAAGGAATTG 
    2321 CTATACGGTT ACAACGCTGG ATCAAAGGCA ATGACTTAGG 
    2361 CTGGGTTTTT GACAACGATC AAGATGATCT CAATTTAGAC 
    2401 TCACAATTCA TTGGTTATGA CATGACCGAT TTCTTAGACA 
    2441 ATGAAGAAAT TCGGCGCCCC TTGATGATGT ATCTGTTTAA 
    2481 CCGCATTCTC GATCTTATTG ATGGGCGGCG CATTATTATT 
    2521 GTCATTGATG AATTCTGGAA AGCGCTTGAA GATGATTCCT 
    2561 TTAAAGCTTT GCGCAAGCTC GCCTTAAGAC GATCCGTAAA 
    2601 AAAATGGTAT GATGCTCTTT GCTACGCAAA GCCCAAAGAT 
    2641 GCTTTGAACT CTACAATCGC ACACACGATT ATTGAGCAAT 
    2681 GCCCTACCCA AATATTTTTT CCAAATCAAA AAGCAAATTA 
    2721 CAAAGATTAT GTTGAAGATT TTAAACTGAC TGAGCGTGAA 
    2761 TTTGAACTGA TACAGTCAGA ATTAAGCAGA GAATCTCGTC 
    2801 GTTTTCTCAT AAAACAGGGA CAAAATTCGG TCGTTGCAGA 
    2841 ACTCAATTTA CGTGGAATGA ACGATGAGAT CGCCATCTTA 
    2881 AGCGGTACGA CCAAAAACAT CGAACTGGTG AACCAAATTA 
    2921 TCAACGATTA TGGAGCAGAT CCCGATACAT GGCTGCCTAT 
    2961 ATTTCACCAA AGGAGAGAAA ATCAATGAAA AAATATGGTT 
    3001 TAGTCACACT TTTATCTTTA TCTTGCGTCT CTCATACAAT 
    3041 AGCAGAAACT GCATTACTTG CTGATGAATA TTACAAAAGA 
    3081 GCATTAGAAA ACACGCAAAA ATTAGATGCT GCAAAATCAG 
    3121 AAACAGCGGA ATCTATTTAT GCATCTGCAA ATGAAATTAC 
    3161 TAATAAAATT AAGGAAATAA ACGAGAAACT TAGAAAGGCT 
    3201 CAGGCAGCTG AAAAAACCAA ACCTGAAGAA TTTCAGGCTC 
    3241 TTCAAATAGA GCTGTCTCTT CTTCAAGCAC AGCTGCAAGC 
    3281 AGATACTTTA AAAATTCAAT TCCTGTCTAT GATTCAAGCG 
    3321 AAAAATACGA AAACAAAAGA AGACATCCGT GAAGAGCAAA 
    3361 CACAAAAAAA GCATAAAGAT CTTCAAGAAA AATTAAAAGA 
    3401 AAAACTTGGG AATTCTGATG TCCGACTTTA GTTTTTCCCC 
    3441 GTAGTTTTTC CCCGTTTGAG AGCATTTCTG GATATATTTT 
    3481 AAATCCACTC GAAAATGCAA TGAATACGAC AGTGAGTGGG 
    3521 TTGTCTTCTG CTATTTCAGC ACCCTTAAAT CTTGCCTCGA 
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    3561 TCATTTTTAT CTTTCTGTAT GGCTATAATG TTATGACTGG 
    3601 TCGTGTCTCC CTTTCGATGC ATAGCCTTCT CAACAATGTT 
    3641 GTGAAAATCG TTGTTGTGAC GGCAATGGCA ACGAATGCGG 
    3681 ATACATTTAA TACCTATGTC AAAGATATTT TCTTTGGTGA 
    3721 TTTAGCAAAC GCTATTGGGA ATGCACTCAA CAGCAACCCC 
    3761 GCTAGCGCAA ATGTTTTTGA TTATATTCTG TTAAAGACAA 
    3801 GTGCCCGTTA TCAAGAAGTT TTAGCAGCTG CTTGGTTTCT 
    3841 TGAAAAAATC ATGGTTGGTC TTCTTGGATC TTTAATGATT 
    3881 ATGGCCGTTA TTGTCTTTTG TATAGGTGGT TTTATCGTAC 
    3921 AAATGTTTGC ACAAGTTGCA CTTGTAATGA TTATAGGTCT 
    3961 TGGTCCCCTC TTCATCAGCC TCTATTTGTT CAATGCAACC 
    4001 AGAAAATTCA CCGATGCATG GATTACAACG CTGATTAATT 
    4041 TTACCATTTT GCAAGTTTTA GTGATCATGC TTGGAACGAT 
    4081 CATGTGCAAA ATTATCCTGC ATGTTCTCAA TGGCACCTAT 
    4121 GATTCAATCT ATTTCCTTTT CCCACCTGTT GTCGTTATCT 
    4161 CGATAGTGGG AGCTATTCTC TTCCGCGCAC TTCCTGGCAT 
    4201 TGCCTCTGCA CTTTCTAGTG GAGGACCATA CTTTAACGCT 
    4241 GGTATCTCTT CAGGAGGACA AATTTTTACA ATGCTTTCCA 
    4281 GTGGCGCGAA AACGGGCAGA AACGCAGCCA AAAGCGCAGC 
    4321 ATCAACTCTC TCTGGTACAG CAGGTGCCGC AGCCAAAGTT 
    4361 GCAAAAATTG GAGATAGAGG CCGTGGTCGA TTTTAATGTC 
    4401 AGATACCTCT TAAAAAGAAC GAGGGTTCTT GTTTTTGCAT 
    4441 TGCGCGCGCT AGAGAGCGCG CAATGTACAT ATTGCGTGAA 
    4481 ACAGTTGAGA TCTTTGATTT CATAAGACCA ATCAAAATGT 
    4521 TTCATCGCAC GCTTTTGTGA AATTGTTCAA AGCAAGAGCC 
    4561 CCACACCTCA CCTCTATGGG GTCATGCGGT TATGTGTTGT 
    4601 ATTTTAAAGT ATTTGTGTGA GTTCAAAAAA TGAAACGAAA 
    4641 AATAACTTTT TTTATGATCC TGATGATTGC CCTTACGGGT 
    4681 TGTGCTTCTC TTAGTGGGCC CAAAAAACCA CCACGATGTA 
    4721 ATGGCCAGTA TACGCGCGCT TTAAATAGAG ATAAGTGGGA 
    4761 TTGGGACAAT AAAAACATCA TCATACAAAA AAAAATCGTA 
    4801 AAACCTGTTA CAACCCCCAT CATCCTCAAC ACGCTGGAAA 
    4841 GTGAAAAAGC AACAGCTGAC GTGACGCTTC ATCCAGCTTC 
    4881 ATTGGATTCT ATAAATCATG AAAAATTCTC TGATCAAAAT 
    4921 ACGGAAATCG CTCGTGAAAA GTGATGCATT TGATGAATAT 
    4961 GTAAAAGAAG CACGCTCATT TGATATTGAT CGCATGCATA 
    5001 GCCTACAACA GCGAATGAGA ATTGCCATGA CTTTGACAGT 
    5041 GCTTTTTGGC TTGATGACAA TCGCCTTGGC TTTGGCTGTA 
    5081 GCAGCATTAA CACCCTTAAA AACAGTAGAG CCCTTTGTTA 
    5121 TCCGCGTTGA TAATTCAACA GGTATTATTG AGACAGTAAG 
    5161 TGCCTTAAAA GAAACGCCAA ACAATTATGA TGAAGCAATA 
    5201 ACACGTTATT TTGCTGGCAA ATATGTTCGT GCGCGCGAAG 
    5241 GTTTTCAATT ATCAGAGGCG GAATACAATT TTCGCTTGAT 
    5281 TTCTCTTTTA TCTTCACCAG AAGAACAAAA CCGTTTTGCA 
    5321 AAATGGTATT CGGGCAACAA TCCAGAAAGT CCGCAAAATA 
    5361 TCTATCACAA CATGACTGCT AAGGTCACAA TCAAGTCAAT 
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    5401 CTCCTTTTTA AGCAAAGATC TTATTCAAGT GCGTTACTAT 
    5441 AAAACGATCA GAGAATTGAA TGGAAAAGAA AATATTTCCC 
    5481 ATTGGGTCTC GATCCTCAAT TTTTCCTACA TTAATGCACA 
    5521 CATTTCAACA GAAGACCGAC TAATCAACCC GCTTGGTTTT 
    5561 CAAGTGTCAG AATATCGATC TGATCCAGAG GTGATAAAAT 
    5601 GATGAGATTT TCAAAAATAA TCTTTTTAGC TTTCCTTTTT 
    5641 GCAATAAGCT GCCTGACAGT CCCGTTATTT GCTGAAACAG 
    5681 CTCCTGTAAG TGCGCGCAAA GACAATCGCA TCAGATTTGT 
    5721 CAATTATGAC CCATACAATG TCACACAAAT CATTGGATCT 
    5761 ATTCGTTCTT CTGTTCAGCT TGAATTTGCC GATGATGAAG 
    5801 AAGTGACCTA TGTGGGCATT GGCAATTCTG TTGCTTGGCA 
    5841 AGTTGCACCA GCTGGACATT TTGTATTTCT CAAACCGCGC 
    5881 GAAGTTCAAC CTGTGACCAA TTTACAAATT GTCACAAGCC 
    5921 GTCAAGACGG GACAAAACGG TCCTATCAGT TTGAACTCAA 
    5961 GTTCGTGAAG GCGACGTTTC ACCGCAGATA CTATTTCCTC 
    6001 GTAAGTTTCG TTATCCAAAA GAACTTTGCG CAGAAATTAG 
    6041 CCAAAGCAGC AGAAGCTGCA CAGCGTGAAG AAAATTTTGT 
    6081 CAATGATGTT TTTAACATCC ATGAAAATTT TGGACCACGC 
    6121 AATTGGGCTT ATGAAGCGCA AGGTTCATCC CTCATTGAAC 
    6161 CTGCTTCTGT CTATGACAAC GGTAAAACAA CAACCTTTAC 
    6201 ATTTTTGGGC AATACCGAAA TCCCTGCCAT TTATCTCGTA 
    6241 TCGCTTGATG GGCAAGAATC TCTCGTTCCA AAATCAATTA 
    6281 AAGGAAACAA GGTTATTGTT CATGCCATAG CTGCGCAATT 
    6321 TACTTTGCGC CGCGGGAATG ACGTGCTGTG CATCTTTAAT 
    6361 AAAAGATTTG TACCTGAAGG GATTAACCCT GAGACCGGTA 
    6401 CGACATCACC ATCTGTACAA CGTAGAGTGA ACATAGGAAA 
    6441 TGGTCATGAA GGATGAAATG GATGAAAACA ACATAAATGA 
    6481 TCGCAGTACA ATAAAAGACG GTCAAGGAAA AAAACTGCAT 
    6521 TCCAATACAA GTAAAGCAGT TGCTCTTCTC GTTCTTTTGG 
    6561 GTGTTTGTGG TTATTTAGCG TATTCAACGC TTATCACAAA 
    6601 CAAAAAACAG CCGGTTGAAC TTCCAAAAGA GGCGATTATT 
    6641 AAGCAAACAG AGCGTTTCCG CCCTGCACAG CCCAAGCCTG 
    6681 TACTCCTCGA GCCAACTGAA AAAAATAATC CGTCCTGTTG 
    6721 CCCAAGGTCC TTTGAATTGC CAACGCCCAA AATAAACCTG 
    6761 TTGAAAACAA ATGCTGATGA TTCACTCTTA GAAGCAGCAC 
    6801 AAACAGAATG CTCCTGTCTT GCCTATGCCA GCCCACAAAA 
    6841 AAGCCAAGCA ATGCAGAAAA AAATAACGAC ACTTCACCGA 
    6881 ACCAACTCGA AAGAAAACCT GATGAAACAG CACAACGCTT 
    6921 TAATCATCTT CTCAAACCGA CAAACCTTGA AGGTATTCAT 
    6961 GCTTCAACAC TTACTAATCG AAATGCCAGC CCACAAAAAA 
    7001 GCCAAGCAAA TGCAGAAAAA AATAACGACA CTTGACCGAA 
    7041 CCAACTCGAA AGAAAACCTG ATGAAACAGC ACAACGCTTT 
    7081 AATCATCTTC TCAAACCGAC AAACCTTGAA GGTATTCATG 
    7121 CTTCAACACT TACTAATCGA AACTACATCA TCGCAAGGTG 
    7161 CTTCCATTCC ATGTATTTTA GAAACGGCAA TCAGCAGTGA 
    7201 CCAACAGGGA TTTACCAGTT GTATCGTTTC TAGAGATATC 
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    7241 TTGGTCAGAC AATGGTCGCG TTTGTCCTTC TTGACAAGGG 
    7281 CACACAAATC GTTGGCGAAT ACCCGTTCCG GATTAAAAAA 
    7321 GGGGCAAAAT CGTCTTTTTG TGTTATGGAA TAGAGCCAAA 
    7361 ACCCAAGTGG GTATTATAAC ATTAGCCTCC CCGGCAACGG 
    7401 ATGCCTTAGG GCGTTCTGGT GTTGATGGAG ATGTTGATAA 
    7441 TCATTGGTTT GAGCGGATTG GATCTGCGCT TCTTGTATCG 
    7481 ATTGTCAGAG ATGCAACCAA TTATGCGAGA AACCGGTTGC 
    7521 CAAAAGATCA AGATAAGAAC AGTTCTGACA CAATCTCTTC 
    7561 GGGACCAAAT ATTGCAAATA TTGTCGTGGA AAATTACGCC 
    7601 AACATTCCTC CCACACTAAC AAAAAAACCA AGGGGAAAAT 
    7641 GGTCAATGTT TTTTGTTGCC CCGCGATTTA GAATTTTTTC 
    7681 CAGTGTTTAT AAATTGAAAG TGATCGAAGA CAAAAAACAG 
    7721 ATTGTCAATC GATCCATTTC AAGAAACTTT TATAAAAATT 
    7761 CTGCGGTGAT TTTGAAATGA ACCAAAACCT GCATAAATTG 
    7801 AGCAATGAAA CTGTCGCGAT TGTTTTAACA AAACTTGAAC 
    7841 CCATCAGTGC CTTTCTGAAA GATAAGAGCC TTTTTGAAAT 
    7881 TGTCATCAAT AGTCCCTATC AAGTGATGAC AGAAGGTATT 
    7921 GAGGGATGGA AACCAATAGA AGCACCAGCT CTTTCGTTTG 
    7961 ATGAGCTTAT GGGAATTGCT AAAGTTGTCG CTTCCTATTC 
    8001 TAAGCAAAAG ATATCCGACA AAAATCCAAT ATTATCGGCT 
    8041 ACCCTACCGG GGAATGAACG TATTCAAATT GTCATTCCTC 
    8081 CTGCAGTGGA AAAAGACACA ATCAGCATGA CAATTCGCAA 
    8121 ACCATCATCG CGGAATTTTT CACTCGAAGA GCTGGCAAAT 
    8161 AAAGGTCTCT TTTCTGTGTG TGAACAAGTG TCATTTACGC 
    8201 CATTGAATGA TTATCAATCG CGTTTTAGTG AACTCAAACA 
    8241 CATTGAGCAT AGCTTGGCAA CCGCTTATTC TAATAAGGAT 
    8281 TTTGTCTCCT TTTTAAATCA AGCTGTAAAA TGCCAAAAAA 
    8321 ATATTTTAAT TGCAGGGAAA ACGGGTTCTG GTAAAACACC 
    8361 GCTATCAAAG GCATTAATCG CTAAAATTCC CGATAATGAG 
    8401 CGTATTATCA CCATTGAAGA TACACCAGAA TTGGTCGTAC 
    8441 CACAGCCCAA TTATGTCTCT ATGATCTATT CAAAAGATGG 
    8481 TCAAGGCTTA GCCTCTGTTG GTCCAAAAGA ATTGCTTGAA 
    8521 TCTGCTTTGC GCATGCGTCC TGATCGCATT CTTCTACAAG 
    8561 AGCTTCGAGA TGGTACAGCC TTTTATTATA TCCGCAATAT 
    8601 CAATTCAGGA CATCCAGGTT CAATTACCAC GGTTCATGCA 
    8641 TCAACAGCAC TCGCTGCATT TGAGCAAATG ACCCTCTTGG 
    8681 TCAAAGAAAG TGAAGGCGGA GGTGATTTAG AGCGTGATAT 
    8721 TCGAGGGCTG TTGATTTAGA GCGTGATGAT ATTCGAGGGC 
    8761 TGTTGATTTC AATGATTGAT ATCATTGTTC AATGCAAACG 
    8801 GGTTGAAGGA AAATTTAAGG GTCACAGAAA TTTATTATGA 
    8841 CCCGTTTAAA CAACGACACT TGGAGGATCT ACCGGATAAT 
    8881 CGGGGCCACC GCGGTGGAGC TCCAGCTTTT TG 
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AP.2 - Bartonella clarridgeiae - virB Operon Sequence       
 
        1 ATGACAGACA CTATATCCAG GAACATCATT TTTATCATCA 
      41 TCATGCTGCT GTTAACAGCG CTCGTTGTAT CAGACCCTTC 
      81 TTATGCTGCT GCTGCTACGG GTAGTGCCAG TAGTCTGGGA 
     121 AACGTTGATA ATGTTTTACA AAATATTGTT ACGATGATGA 
     161 CAGGAACAAC AGCAAAGCTG ATTGCAACAA TATGTGTTGC 
     201 AGCTGTGGGC ATTGGTTGGA TGTCCGGCTT TATTGATTTA 
     241 CGCAAAGCCG CTTATTGTAT TCTCGGCATT GGGATTGTTT 
     281 TTGGTGCCCC CACTCTTGTT AGTACATTAA TGGGCTCATC 
     321 ATAAATGAAT GAAGATACTC TTTTTCTTGC CTGTACGCGA 
     361 CCAGCTACGT TTGCCGGTGT CACAATGGAA GGAATGGCCC 
     401 TTAATGTCAT GGCGACATCC ATTCTCTTTA TTTTGACCAG 
     441 CAACTTTACA ATGATTGGTC TTGGCATTGG ATTGCACTTT 
     481 GTTTTGCGTG AAGTGACAAA ATACGACCAC AACCAGTTTC 
     521 GCGTATTATT TGCTTGGCTC AACACAAGAG GAAAACAAAA 
     561 AAACCTCACC AGATGGGGAG GAGGATCTAC ATCTCCCCTA 
     601 CGCCTTATCC GGTACTTATA AGGAACTGAA CAGGGGAAAC 
     641 AGATGTCAAT TATGAAAACG GGAGTCTTTA CCTGAAGAAT 
     681 ATATTCCTTA CATACGCCAC GTCAACCAAC ACGTCATTGC 
     721 ATTAAATTCA CGCTGCTTAA TGACTGTAAT GCGCGTGTTG 
     761 AGGGGGTGAA TTTTGATACT GCAGATATCA ATCACTTAAA 
     801 TTCCTTACAC AACCAGTTAA ACACTCTCTT GAGAAATATC 
     841 GCGGATGAAC GTGTTGCTTT ATATTCTCAC ATCATTCGTC 
     881 GGCGCGAAAC GATCTATCCA GAGAGTCGTT TTTTTTCATC 
     921 TTTTGCAGCA ACACTAGATG AAAAATACAA AAAGAAAATG 
     961 GTTTCGCAAG AGCTGTATAG AAATGATCTC TTCGTTTCAC 
    1001 TGCTGTGGAA TCCAACATCG GGTAAGACTG AGCAACTCGC 
    1041 TTCATTTTTT CAGCGCTTAA CAAAAGCGAA GAAAACACAA 
    1081 TCTGAACCAG ACATGGAAGC CATTCGTAAA ATTGAAGAGT 
    1121 TAAGCCAAGA TCTTATACAA GGGTTGGAGA GCTATGAAGC 
    1161 GCGCCTCTTG TCAGTCTATG CACATGAGGG CATTTTGTTT 
    1201 TCCGAACAAA GTGAATTTCT ACACCAGTTA GTGGGAGGAA 
    1241 GGCGTGAGCG GATTCCTCTC ACATTTGGTA CCATTGCCTC 
    1281 AACGATTTAC TCAGACCGTG TCATTTTTGG CAAAGAAATG 
    1321 ATCGAAATTC GTCATGAAAG CAATGAACGC TTTGTTGGCA 
    1361 TGTTTGGCTG GAAAGAATAT CCCTCTAAAA CACGCCCAGG 
    1401 TATGACAGAT GGTTTACTCA CAGCACCGTT TGAATTTATC 
    1441 TTAACACAAA CGTGTGGTCG ACGGCCCGGG CTGGTCTGCC 
    1481 AGGGTCATTA TGGGCCGCAA ACAAAATCAG ATGATTAATG 
    1521 CAGCGGATCG TGCTAGCTCG CAAATTGATG CACTTGATGA 
    1561 AGCGCTTGAT GATTTAGAAT CAAACCGTTT TGTTTTGGGC 
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    1601 GAACATCATC TCTCTCTAGC CGTTTTTGCT GATCAACCAA 
    1641 AAACATTGGT TGAATACCTC TCAAAAGCGC GCGCTCACTT 
    1681 AACCAATGGT GGAGCGGTTA TCGCCAGAGA AGATCTAGGA 
    1721 TTAGAAGCTG CATGGTGGGC GCAACTGCCT GGAAATTTCA 
    1761 GCTATCGTGC GCGATCTGGA GCCATTACCA GCAGAAATTT 
    1801 TGCAGCGTTA TCGCCCTTCC ATTCCTTCCC CATTGGCAAA 
    1841 CTTGAAGGCA ATGTTTGGGG AGCGGCTGTG GCATTGCTGA 
    1881 AAACACAAGC TGGTTCACCT TATTATTTTA ATTTTCATTA 
    1921 TGGTGACCTT GGCAACACTT TTGTTTGCGG TCCATCAGGA 
    1961 TCTGGTAAAA CTGTGATTGT TAATTTCCTT CTCGCACAAT 
    2001 TACAAAAACA TAACCCGACA ATGGTCTTTT TTGACAAAGA 
    2041 TCAAGGCGCA GAGATTTTTG TGCGTGCTGG AGGTGGAAAA 
    2081 TATAAGCCTT TGAAAAACGG ACAGCCCACG GGCATTGCTC 
    2121 CATTAAAGGG CATGGAATAC ACTGAAAAAA ACAAAATCTT 
    2161 TCTTCGCAGT TGGGTCTTGA AGCTGGTGAC AACTGAAGGG 
    2201 CAAACAGTGA CAGAACAAGA GCGACAAGAT ATCGCCCAAA 
    2241 GCCCATAAAT TTCCCTTGGG AAAAGTTTTT TCCACCATGC 
    2281 GCAAACGCTC TCTTGGTGCC CCTTCAATTG TTTTTTTGAT 
    2321 ACCACATCAA AAGAAGGAAT TGCTATACGG TTACAACGCT 
    2361 GGATCAAAGG CAATGACTTA GGCTGGGTTT TTGACAACGA 
    2401 TCAAGATGAT CTCAATTTAG ACTCACAATT CATTGGTTAT 
    2441 GACATGACCG ATTTCTTAGA CAATGAAGAA ATTCGGCGCC 
    2481 CCTTGATGAT GTATCTGTTT AACCGCATTC TCGATCTTAT 
    2521 TGATGGGCGG CGCATTATTA TTGTCATTGA TGAATTCTGG 
    2561 AAAGCGCTTG AAGATGATTC CTTTAAAGCT TTTGCGCAAG 
    2601 ATCGCCTTAA GACGATCCGT AAACAAAATG GTATGATGCT 
    2641 CTTTGCTACG CAAAGCCCCA AAGATGCTTT GAACTCTACA 
    2681 ATCGCACACA CGATTATTGA GCAATGCCCT ACCCAAATAT 
    2721 TTTTTCCAAA TCAAAAAGCA AATTACAAAG ATTATGTTGA 
    2761 AGATTTTAAA CTGACTGAGC GTGAATTTGA ACTGATACAG 
    2801 TCAGAATTAA GCAGAGAATC TCGTCGTTTT CTCATAAAAC 
    2841 AGGGACAAAA TTCGGTCGTT GCAGAACTCA ATTTACGTGG 
    2881 AATGAACGAT GAGATCGCCA TCTTAAGCGG TACGACCAAA 
    2921 AACATCGAAC TGGTGAACCA AATTATCAAC GATTATGGAG 
    2961 CAGACCCAGA CATATGGCTG CCTATATTTC ATCAAAGGAG 
    3001 AGAAAATCAA TGAAAAAATA TAGCTTAGTC ACATTGTTAT 
    3041 CTTTATTTTG CATCTCTCAT GCAAAAGCAC AAACAGCACC 
    3081 CCTTGCTGAT GAATATTATA AAAAAGCCTT AGAAAACAAG 
    3121 CAACAATTAG ACGTTGCAAA ATCACAAACA GCTGAGTCTA 
    3161 TTTATGAATC TGCAACACAA ACTGCAAATA AAATTAAGGA 
    3201 CATAAACGAT CAACTTAAAA CTCTTAAAGC AGATACAAAG 
    3241 ACTAAACCTG AACAATTGCA AACCCTGCAA ATAGAGCTCT 
    3281 CTCTTCTCCA AGCGCAGTTG CAAGCGGATA CTTTAAAAGT 
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    3321 TCAGTCTCTT GCTATGATTC AAGCAAAAGA TACAAAAACA 
    3361 AAAGAAGAAC TGCGTGAAGA GCAAACACAA CAAAATCATA 
    3401 AAAAAATTGA AGAAAAATTA AAAGAAAAAC TTGGAAAATC 
    3441 TGATGTCCGA CTTTAGTTTT TCCCCGTTTG AGAGCATTTC 
    3481 TGGATATATT TTAAAACCAC TCAAAAATGC AATGAACACA 
    3521 ACAGTGAGTG GGTTGTCTTC TGCTATTTCA GCACCCTTAA 
    3561 ATCTTGCCTC GATCATTTTT ATCTTTCTGT ATGGCTATAA 
    3601 TGTTATGACC GGTCGCGTCG CCCTTTCGAT GAATAGCCTT 
    3641 CTCAACAATG TTGTAAAAAT CGTCATTGTG ACGACAATGG 
    3681 CAACCAACGC GGATACATTT AATACCTATG TCAAAAATAT 
    3721 TTTCTTTGGC GATTTAGCAA ACGCTATTGG GAATGCACTC 
    3761 AACAGCAACC CCGCTAGCGC AAATGTTTTT GATTATATTC 
    3801 TGTTAAAGAC AAGTGCCCGC TATCAAGAAG TTTTAGCAGC 
    3841 GGCTTGGTTC CTTGAAAAAA TCATGGTTGG TCTTCTTGGA 
    3881 TCTTTAATGA TTATGGCCGT TATTGTCTTT TGTATAGGTG 
    3921 GTTTTATCGT ACAAATGTTT GCACAAGTTG CACTTGTAAT 
    3961 GATTATAGGT CTTGGACCCC TCTTCATCAG CCTCTATTTG 
    4001 TTCAATGCAA CCAGAAAATT CACCGATGCA TGGATTACAA 
    4041 CACTGATCAA TTTTACCATT TTGCAAGTTT TAGTGATCAT 
    4081 GCTTGGAACG ATCATGTGCA AAATTATCCT GCATGTTCTC 
    4121 AATGGAACAT ATGAGTCAAT CTATTTCCTG TTCCCACCTG 
    4161 TCGTCGTTAT CTCCATAGTA GGAGCTATTC TCTTCCGCGC 
    4201 ACTTCCTGGC ATTGCCTCTG CACTCTCCAG TGGAGGACCA 
    4241 TACTTTAACG CTGGTATATC TTCAGGAGGA CAAATTTTCA 
    4281 CAATGCTCTC CAGCGGCGCG AAAACGGGAA GAAACGCAGC 
    4321 AAAAAGCGCA GCATCAACAC TCTCTGGTAC AGCAGGAACC 
    4361 GCAACCAAAG CGGCAAAAAT AGGAGAGAAA GGCCGTGGTC 
    4401 GATTTTAAAT GAAACGAAAA ATAACTTTTG TTATGATCCT 
    4441 GATAATTGCC CTTACTGGCT GTGCTTCTCT TAGTGGCCCC 
    4481 AAAAAACCAC CACGATGTAA TGGCAAAGAT ACGCGCGCTT 
    4521 TAAATAGAGA TAAGTGGGAT TGGGACAATA AAAACATCAT 
    4561 CCTACAAGAA AAAAGTGTAA AACCTGTTAC CACCCCCATC 
    4601 ATCCTCAACA CGCTGGAAAG TGAAAAAGCA ACAGCTAACA 
    4641 TCACCATATA CGCAAATTAA TTTAAGCCAT TCAGTCGTGA 
    4681 ACCACACCGT GATAAAACTC TGGAGGTTAC GCGTGAAAAC 
    4721 TGAATGTCCG ACTTTAGTTT TTCTCCGTTT GAGAGCATTT 
    4761 CTGGATATAT TTTAGAACCA CTCATGAAAA ATTCTCTGAT 
    4801 CAAAATACGG AAATCGCTCG TGAAAAGTGA TGCATTTGAT 
    4841 GAATATGTAA AAGAAGCACG CTCATTTGAT ATTGATCGCA 
    4881 TGCATAGCCT ACAACAGCGA ATGAGAATTG CCATGACTTT 
    4921 GACAGTGCTT TTTGGCTTGA TGACAATCGC CTTGGCTTTG 
    4961 GCTGTAGCAG CATTAACACC CTTAAAAACA GTAGAGCCCT 
    5001 TTGTTATCCG CGTTGATAAT TCAACAGGTA TTATTGAGAC 
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    5041 AGTAAGTGCC TTAAAAGAAA CGCCAAACAA TTATGATGAA 
    5081 GCAATAACAC GTTATTTTGC TGGCAAATAT GTTCGTGCGC 
    5121 GCGAAGGTTT TCAATTATCA GAGGCGGAAT ACAATTTTCG 
    5161 CTTGATTTCT CTTTTATCTT CACCAGAAGA ACAAAACCGT 
    5201 TTTGCAAAAT GGTATTCGGG CAACAATCCA GAAAGTCCGC 
    5241 AAAATATCTA TCACAACATG ACTGCTAAGG TCACAATCAA 
    5281 GTCAATCTCC TTTTTAAGCA AAGATCTTAT TCAAGTGCGT 
    5321 TACTATAAAA CGATCAGAGA ATTGAATGGA AAAGAAAATA 
    5361 TTTCCCATTG GGTCTCGATC CTCAATTTTT CCTACATTAA 
    5401 TGCACACATT TCAACAGAAG ACCGACTAAT CAACCCGCTT 
    5441 GGTTTTCAAG TGTCAGAATA TCGATCTGAT CCAGAGGTGA 
    5481 TAAAATGAAT GATGAGGATT TTAAAAACAC TCTTTTTAGC 
    5521 TTTCATAGCT GCAATAAGTT GCTATACGAC CCCCTCATTT 
    5561 GCTGAAACAG CACCTGTGAG TGCACGCAAA GACAATCGCA 
    5601 TCAGATTTGT CAATTATGAC CCCTATAATG TGACAAAAAT 
    5641 CATTGGCTCC ATTCGTTCTT CTGTTCAACT TGAATTTGCC 
    5681 GATGATGAAG AAGTAACCTA TGTAGGGATT GGCAATTCCG 
    5721 TTGCTTGGCA AGTTGCACCG GCTGGCCACT TTGTATTTCT 
    5761 AAAACCACGC GAAGTTCAAC CTGTTACCAA TTTACAAATT 
    5801 GTTACAAGCC GCCAAGACGG CACAAAACGC TCTTATCAAT 
    5841 TTGAACTACA AGTGCGTGAA GGGGATGTTT CAGCGGGCAA 
    5881 TGATACATAT TTTCTGGTAA AGTTTCGTTA TCCAGAAGAT 
    5921 GAAGCCTTGC GTAAAAAATT AGCCGAAGCA GCGAAAGCGG 
    5961 CACAACGTGA AGAAAATCCA AAGCAGCAGA AGCTGCACAG 
    6001 CGTGAAGAAA ATTTTGTCAA TGATGTTTTT AACATCCATG 
    6041 AAAATTTTGG ACCACGCAAT TGGGCTTATG AAGCGCAAGG 
    6081 TTCATCCCTC ATTGAACCTG CTTCTGTCTA TGACAACGGT 
    6121 AAAACAACAA CCCTTTACAT TTTTGGGGCA ATACCGAAAT 
    6161 CCCTGCCATT TATTCTGGTA TCGCTTGATG GGCAAGATTC 
    6201 TCTCGTTCCA AAATCAATTA AAGGAACCAG GTTATTGTTC 
    6241 ATGCCATAGC TGCGCAATTT ACTTTGCGCC GCGGGAATGA 
    6281 CGTGCTGTGC ATCTTTAATA AAAGATTTGT ACCTGAAGGG 
    6321 ATTAACCCTG AGACCGGTAC GACATCACCA TCTGTACAAC 
    6361 GTAGAGTGAA CATAGGAAAT GGTCATGAAG GATGAAATAG 
    6401 ATGAAAACAA CATAAATGAT CGCAGTACAA TAAAAGACGG 
    6441 TCAAGGAAAA AAACTGCATT CCAATACAAG TAAAGCAGTT 
    6481 GCTCTTCTCG TTCTTTTGGG TGTTTGTGGT TATTTAGCGT 
    6521 ATTCAACGCT TATCACAAAC AAAAAACAGC CGGTTGAACT 
    6561 TCCAAAAGAG GCGATTATTA AGCAAACAGA GCGTTTCCGC 
    6601 CCTGCACAGC CCAAGCCTGT ACTCCTCGAG CCAACTGAAA 
    6641 AAAATAACCT CCTGTTGCCC AAGGTTGAAT TGCCAACGCC 
    6681 CAAAAGAAAC CAAACAAATG CTGATGATTC ACTCTTAGAA 
    6721 GCAGCACAAC GTGCTCCTGT CTTAGCCTAT GCCAGCCCAC 
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    6761 AAAAAAGCCA AGCAAATGCA GAAAAAAATA ACGACACTTC 
    6801 ACCGAACCAA CTCGAAAGAA AACCTGATGA AACAGCACAA 
    6841 CGCTTTAATC ATCTTCTCAA ACCGACAAAC CTTGAAGGTA 
    6881 TTCATGCTTC AACACTTACT AATCGAAACT ACATCATCGC 
    6921 AATGGGTGCT TCCATTCCAT GTATTTTAGA AACGGCAATC 
    6961 AGCAGTGACC AACAGGGATT TACCAGTTGT ATCGTTTCTA 
    7001 GAGATACCAG CCCGGGCCGT CGACCACGCG TATGAACCAA 
    7041 AACCTGCATA AATTGAGCAA TGAAACTGTC GCGATTGTTT 
    7081 TAACAAAACT TGAACCTATC AGTACCTTTC TGAAAGATGA 
    7121 GAGTCTTTTT GAAATTGTCA TCAATCGTCC CTATCAAGTG 
    7161 ATGACAGAAG GAATTGAGGG ATGGAAAACA ATAGAAGCAC 
    7201 CAGCTCTCTC ATTTAATGAG CTTATGGGAA TTGCTAAAGT 
    7241 TGTCGCGTCC TATTCTAAGC AAAATATATC AGAAAAAAAT 
    7281 CCAATATTAT CAGCCACCCT ACCAGGCAAT GAGCGTATTC 
    7321 AAATTGTCAT TCCACCTGCA GTAGAAAAAG ACACAATCAG 
    7361 TATGACAATT CGCAAACCAT CATCGCGGAG TTTTTCACTC 
    7401 GAAGAGCTGG CAAATAAAGG TCTCTTTTCA GTGTGTGAAC 
    7441 AAGTCTCATT CACGCCATTG AATGATTATC AATCGCGTTT 
    7481 TAGTGAACTC AAACACATTG AGCATAACTT AGCCAATGCT 
    7521 TATTCAAATA AGGATTTTGT CTCCTTTTTA AATCAGGCTG 
    7561 TAAAATGCCA AAAAAATATT TTGATTGCAG GAAAAACCGG 
    7601 TTCGGGTAAA ACAACGCTAT CAAAGGCATT AATCGCAAAA 
    7641 ATTCCCGATG ATGAGCGTAT TATCACCATT GAAGATACAC 
    7681 CAGAATTGGT CGTACCACAG CCTAATTATG TCTCTATGAT 
    7721 CTATTCAAAA GATGGTCAAG GCTTAGCCTC TGTTGGTCCA 
    7761 AAAGAATTGC TTGAATCTGC TTTACGCATG CGTCCTGATC 
    7801 GCATTCTTTT ACAAGAGCTT CGAGATGGTA CAGCCTTTTA 
    7841 TTATATCCGC AATGTCAATT CAGGACATCC AGGTTCAATT 
    7881 ACCACGGTTC ATGCATCAAC AGCACTTGCT GCCTTTGAGC 
    7921 AAATGACCCT TTTGGTCAAA GAAAGTGAAG GAGGAGGAGA 
    7961 TTTAGAGCGT GATATTCGAG GGCTGTTGAT TT 
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AP.3 – Alignment of various Bartonella GroEL Proteins. 
The program AlignX (Invitrogen) was used to prepare a protein sequence alignment for B. 
henselae (BH), B. quintana str. Tolouse (BQT) and B. bacilliformis (BB).  The predicted B. 
bacilliformis Staphylocoagulase binding-motif has been underlined and the amino acids 
which differ between B. bacilliformis, B. henselae and B. quintana are red. 
 
     1                                                   50 
 BH_GroEL  MAAKEVKFGR EARERLLRGV DILANAVKVT LGPKGRNVVI DKSFGAPRIT 
BQT_GroEL  MAAKEVKFGR EARERLLRGV DILANAVKVT LGPKGRNVVI DKSFGAPRIT 
 BB_GroEL  MAAKEVKFGR DARERLLRGV DILADAVKVT LGPKGRNVVI DKSFGAPRIT 
 
           51                                                 100 
 BH_GroEL  KDGVSVAKEI ELEDKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV 
BQT_GroEL  KDGVSVAKEI ELEDKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV 
 BB_GroEL  KDGVSVAKEI ELENKFENMG AQMLREVASK TNDIAGDGTT TATVLGQAIV 
 
           101                                                150 
 BH_GroEL  QEGVKAVAAG MNPMDLKRGI DAAVDEVVAN LFKKAKKIQT SAEIAQVGTI 
BQT_GroEL  QEGVKAVAAG MNPMDLKRGI DAAVEEVVGN LFKKAKKIQT SAEIAQVGTI 
 BB_GroEL  QEGVKAVAAS MNPMDLKRGI DAAVEAVVAD LFKKAKKIQT SEEIAQVATI 
 
           151                                                200 
 BH_GroEL  SANGAAEIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL 
BQT_GroEL  SANGAAEIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL 
 BB_GroEL  SANGAEDIGK MIADAMEKVG NEGVITVEEA KTAETELEVV EGMQFDRGYL 
 
           201                                                250 
 BH_GroEL  SPYFVTNAEK MVADLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII 
BQT_GroEL  SPYFVTNADK MVADLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII 
 BB_GroEL  SPYFVTNSEK MMVDLDDPYI LIHEKKLSNL QSLLPVLEAV VQSGKPLLII 
 
           251                                                300 
 BH_GroEL  AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAILTSGQV 
BQT_GroEL  AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAILTSGQV 
 BB_GroEL  AEDVEGEALA TLVVNKLRGG LKIAAVKAPG FGDRRKAMLE DIAVLTSGQV 
 
           301                                                350 
 BH_GroEL  ISEDVGIKLE NVTLDMLGRA KKVNISKENT TIIDGAGQKS EINARVNQIK 
BQT_GroEL  ISEDVGIKLE NVTLDMLGRA KKVNISKENT TIIDGAGKKA EINARVNQIK 
 BB_GroEL  ISEDVGIKLE NVTLEMLGRA KKVHVSKETT TIVDGAGQKS EINARVSQIK 
 
           351                                                400 
 BH_GroEL  VQIEETTSDY DREKLQERLA KLAGGVAVIR VGGATEVEVK EKKDRVDDAL 
BQT_GroEL  VQIEETTSDY DREKLQERLA KLAGGVAVIR VGGATEVEVK EKKDRVDDAL 
 BB_GroEL  AQIEETTSDY DREKLQERLA KLAGGVAVIR VGGSTEVEVK EKKDRVDDAL 
 
           401                                                450 
 BH_GroEL  NATRAAVEEG IVAGGGTALL RAANALTVKG SNPDQEAGIN IVRRALQAPA 
BQT_GroEL  NATRAAVEEG IVAGGGTALL RAANALAIKG SNPDQEAGIN IVRRALQAPA 
 BB_GroEL  NATRAAVEEG IVPGGGTALL RAAKALSIKG KNPDQEAGIG IIRRALQAPA 
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           451                                                500 
 BH_GroEL  RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGEFGDLIA LGIVDPVKVV 
BQT_GroEL  RQIATNAGEE AAIIVGKVLE NNADTFGYNT ATGQFGDLIA LGIVDPVKVV 
 BB_GroEL  RQIAHNAGEE AAVIVGKVLE NCSDTFGYNT ATAQFGDLIS FGIVDPVKVV 
 
           501                                             547 
 BH_GroEL  RSALQNAASI ASLLITTEAM VAEVPKKDTP VPPMPGGGMG GMGGMDF 
BQT_GroEL  RSALQNAASI ASLLITTEAM VAEVPKKDTP MPPMPGGGMG GMGGMDF 
 
